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Schizophrenia and bipolar disorder share many symptoms but are difficult to separate on
the basis of treatment response or prognosis. This had led some to question their validity as disease
entities. The evidence concerning their validity is introduced in chapter 1 of this thesis and chapter
2 discusses the evidence for structural and neuropsychology abnormalities in both disorders, and
specifically whether these form a basis by which they can be separated. Particular attention is given
to magnetic resonance imaging (MRI) studies in affected individuals and in unaffected family
members. Chapter 3 is a systematic review and meta-analysis of structural MRI studies of bipolar
disorder, comparing affected patients with both healthy controls and with schizophrenic subjects.
Some evidence is found for regions which may separate patients with bipolar disorder from
controls and from patients with schizophrenia.
Chapter 4 outlines the methods for the main neuropsychological and MRI study of families
affected by schizophrenia, bipolar disorder or both. The clinical and neuropsychological results are
given in chapter 5 and the MRI results in chapter 6. This study finds some evidence that certain
neuropsychological impairments are specific to a family history of schizophrenia. Certain
reductions in grey matter, particularly in prefrontal areas, appear to be relatively specific to a
genetic liability for schizophrenia. Other regions, particularly the anterior thalamus, may be
affected in all patients and relatives. Furthermore these grey matter findings are associated with
complimentary white matter density reductions.
Chapter 7 discusses some of the outstanding issues in terms of the separation of
schizophrenia and bipolar disorder, and discusses the future of neuropsychological and brain
imaging research in this area.
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Preface
For over 100 years the diagnostic categories of manic-depressive illness, bipolar
disorder, and schizophrenia have been used as a basis for diagnosis, targeted treatments
and to convey meaning to both patients and clinicians about the likely course and
outcome in an individual patient. These categories have also been adopted for
psychiatric research in spite of their imperfect reliability and validity.
However, the lack of a validation for the schizophrenia/affective illness
dichotomy does not in itself mean that the model is wrong. Indeed, many diseases in
other parts of medicine were recognised by clinicians as discrete syndromes long before
aetiological validation was eventually forthcoming.
This thesis considers only the two 'functional psychoses' for which the clinical




The original ideas were developed in collaboration with Professor E.C.
Johnstone who was also my MD advisor throughout the project. Additional advice was
also provided by Dr Stephen Lawrie and Professor David Owens prior to the application
to the Medical Research Council for funding and during the study's execution.
Thanks are also due to Professor Ronan O'Carroll for his help with the
development of the neuropsychological test battery and the training of two research
assistants who implemented them. Also thanks to Dr Lesley Harrison and Miss Karen
Forrester who performed all neuropsychological assessments.
Thanks to Dominic Job, Bill Moorhead and Heather Sibley (nee Whalley) for
teaching me how to use SPM99 and the techniques of Voxel based Morphometry.
Thanks are also due for the regular back-up and storage of data.
Thank you to Professor Joanna Wardlaw who reported the clinical scans and who
arranged for further clinical scanning with respect to one of the participants. Thank you
to Professor Gillian Raab, Statistician at Napier University, for her help with the use of
multilevel modelling as implemented within the SAS computer program.
Thanks to all of the study participants and their families, without whom the study
would not have been possible. Thanks also to the many psychiatrists, nurses, general
practitioners, radiologists, radiographers and medical records officers for their
cooperation and help throughout.
Thank you to Dr J Cavanagh for his guidance with the systematic review and to
Dr K Ullyat and D Gerber for helping to locate and critically appraise identified
abstracts and papers.
Thank you to the external examiners (Professor E Bullmore and Professor S
Lewis) for reading this thesis.
Finally, thanks also to the Medical Research Council for awarding me a 3 year
Clinical Training Fellowship in which to conduct the study, and also to the Veda and
Theodore Stanley foundation for their financial assistance in respect of the scans.
v
Chapter 1: The Validity of the Concepts of Schizophrenia and Bipolar
Disorder, a Historical Perspective 7
1.1 Classification of functional psychosis in the classical period 8
1.2 The medieval period and Renaissance 10
1.3 Classification in the eighteenth and nineteenth centuries 11
1.4 Twentieth century approaches to classification 14
1.5 The reincarnation of bipolar disorder 19
1.6 The International Classification of Diseases 21
1.7 The American classification 24
1.8 Issues relating to disease in general 31
1.8.1 The medical model of disease 31
1.8.2 The biological disadvantage of disease 36
1.8.3 Alternative models of disease 37
1.8.4 Diseases as concepts 39
1.8.5 The spectrum of disease 41
1.9 Diagnostic validity applied to schizophrenia and bipolar disorder 42
1.10 Genetic considerations 43
1.11 Multivariate methods to derive or confirm categories 47
1.11.1 Discriminant function analysis 47
1.11.2 Cluster and latent class analysis 51
1.12 Conclusions 55
Chapter 2: Neuropsychology and Brain Structure in Schizophrenia and
Bipolar Disorder 57
2.1 Neuropsychology 58
2.1.1 Methodological considerations 58
2.1.2 Premorbid intelligence 61
2.1.3 Current intelligence 63
2.1.4 Memory 65
2.1.5 Executive function 67
2.1.6 Attention and psychomotor performance 70
2.2 Neuropathology 72
2.2.1 Methodological considerations 73
2.2.2 Brain dimensions 75
2.2.3 Frontal lobes 76
2.2.4 Temporal lobes 77
2.2.5 Subcortical structures 78
2.3 Pneumoencephalography 79
2.3.1 Methodological considerations 79
2.3.2 Findings in affected patients 80
2.4 Computed tomography 81
2.4.1 Methodological considerations 81
2.4.2 Findings in affected patients 83
2.5 Structural magnetic resonance imaging 85
1
2.5.1 Spin-echo sequence 87
2.5.2 Gradient-echo 88
2.5.3 Measurement of tissue signal 89
2.5.4 Image acquisition 89
2.5.5 Image Analysis 91
2.5.6 Patient and control selection 92
2.6 Structural MRI findings in affected patients 95
2.6.1 Whole brain 95
2.6.2 Ventricles and CSF 97
2.6.3 Frontal lobes 100
2.6.4 Temporal cortex 101
2.6.5 Amygdala 104
2.6.6 Hippocampus and parahippocampus 105
2.6.7 Thalamus 106
2.6.8 Basal ganglia and nucleus accumbens 107
2.6.9 Insula 108
2.7 Structural MRI findings in relatives 109
2.7.1 Monozygotic twin studies 109
2.7.2 Findings in the extended family 113
2.7.3 Studies of obligate carriers 117
2.7.4 Studies of familial and sporadic psychosis 119
2.7.5 High risk studies 120
2.8 The molecular genetics of schizophrenia and bipolar disorder 126
2.8.1 Evidence for single gene loci 126
2.8.2 Imaging gene effects in psychosis 129
2.9 Conclusions 131
2.10 Hypotheses and aims 132
2.11 Power calculation 134




3.2.1 Study ascertainment 139
3.2.2 Search strategy 140
3.2.3 Study quality assessment 142
3.2.4 Data extraction and analysis 142
3.3 Results 146
3.3.1 Included studies 147
3.3.2 Excluded Studies 160
3.3.3 Meta-analysis of region of interest studies 161
3.3.4 Sensitivity analyses 167
3.4 Discussion 178
3.4.1 Main Findings 178
2
3.4.2 Strengths and Limitations 182
3.4.2.1 Publication bias 182
3.4.3 Future studies 184
Chapter 4: Clinical, Neuropsychological and Imaging Methods 186
4.1 Patient identification and recruitment 187
4.2 Recruitment of well relatives 188
4.3 The Present State Examination (PSE) 188
4.4 Case note assessment 189
4.4.1 The OPCCI 189
4.4.2 The OPCRIT computer program 189
4.5 Recruitment of healthy controls 190
4.5.1 Method of identification 190
4.5.2 Control screening procedure 190
4.6 Demographic data set collected on all subjects and controls 191
4.6.1 Personal and paternal socio-economic status 191
4.6.2 Alcohol, substance and cigarette History 192
4.6.3 Height, weight and handedness 192
4.6.4 Educational history 193
4.6.5 Marital status 193
4.6.6 Current medication 193
4.7 Measurement of genetic loading for psychosis 194
4.7.1 Method of calculation 195
4.8 Baseline clinical data set collected on all subjects and controls 200
4.8.1 The Positive and Negative Symptom Scale 200
4.8.2 The Young Mania Rating Scale 203
4.8.3 The Hamilton Depression Rating Scale 204
4.9 Neuropsychological battery 205
4.10 Current and premorbid functioning 206
4.10.1 The Wechsler Abbreviated Scale of Intelligence 206
4.10.2 The National Adult Reading Test 207
4.11 Executive functioning 208
4.11.1 The Stockings of Cambridge Test 208
4.11.2 The Hayling Sentence Completion Test 209
4.11.3 Verbal fluency 209
4.12 Sustained attention 210
4.12.1 Digit Symbol Substitution Test 210
4.13 Perceptual and motor speed 211
4.13.1 The Simple and Choice Reaction Time 211
4.14 Learning and memory 212
4.14.1 The Extended Rivemead Behavioural Memory Test 212
4.15 Statistical analysis of neuropsychology data 215
4.15.1 Outlier detection and assessment of normality 216
4.15.2 Multivariate analyses 217
3
4.15.3 Between-group comparisons 218
4.16 Image acquisition 219
4.17 Voxel based morphometry 220
4.17.1 Conversion from Dicom® to Analyze® Format & Origin Setting 220




4.17.6 Statistical analysis 225
4.17.7 Gaussian random fields 226
4.17.8 Planned image analyses 229
Chapter 5: Clinical & Neuropsychological Results 232
5.2 Flow of patients through the study 233
5.3 Comparison of data from the Present State Examination 236
5.5 Comparison of demographic data 237
5.5.1 Age and gender 237
5.5.2 Marital status 238
5.5.3 Personal and paternal socio-economic atatus 239
5.5.5 Weight and height measurement 245
5.5.6 Handedness 245
5.5.7 Educational history 246
5.5.8 Current medication 248
5.6 Comparison of clinical data collected on all subjects 250
5.6.1 Clinical rating scales 250
5.6.2 Measurement of genetic liability 254
5.7 Neuropsychological results 256
5.7.1 Intellectual function 256
5.7.1.1 NART FSIQ 257
5.7.1.2 WASI FSIQ 260
5.7.1.3 WASI performance IQ 262
5.7.1.4 WASI verbal IQ 265
5.7.1.5 Premorbid versus current IQ difference 268
5.8 Memory 271
5.8.1 Extended Rivermead Behavioural Memory Test 271
5.9 Attention and psychomotor performance 276
5.10 Executive function 282
5.11 Medication and substance effects on neuropsychological function.294
5.12 Relationship of neuropsychology to genetic liability 296
5.12.1 Genetic liability to schizophrenia and general intelligence 296
5.12.2 Genetic liability to schizophrenia and memory 298
5.12.3 Genetic liability to bipolar disorder and general intelligence 298
5.12.4 Genetic liability to bipolar disorder and memory 299
5.13 Discussion 300
4
5.13.1 Measurement of genetic liability 303
5.13.2 Neuropsychological findings 304
5.13.3 General intellectual ability (IQ) 304
5.13.4 Memory 305
5.13.5 Executive function 306
5.13.6 Attention and psychomotor performance 308
5.13.6 Relationship to genetic liability 309
5.14 Strengths and limitations 310
Chapter 6: Imaging Results 316
6.1 Summary of patient groups and contrasts performed 317
6.2 Images acquired 323
6.3 Characteristics of patients receiving an MRI scan 324
6.4 Differences between patients and controls 326
6.5 Pairwise differences between patients with psychosis 331
6.6 Masked contrasts 332
6.7 Differences between patients and unaffected relatives 336
6.8 Differences between unaffected relatives and controls 338
6.9 Thalamic densities across groups 341
6.9 White matter analysis 344
6.9.1 Contrasts between patients and controls 346
6.9.2 Contrasts between unaffected relatives and controls 353
6.10 Discussion 354
6.10.1 Main findings: prefrontal cortex 354
6.10.2 Main findings: thalamus 356
6.10.3 Other findings 362
6.11 Methodological limitations 364
6.12 Summary 368
Chapter 7: Brain Mapping and the Future of Attempts to Separate
'Functional' Psychotic Disorders 372
7.1 Introduction 373
7.2 Causation and psychosis 374
7.3 Issues of study design and analysis in imaging research 377
7.5 Imaging analysis 384





Chapter 1: The Validity of the Concepts of
Schizophrenia and Bipolar Disorder, a Historical
Perspective
1.1 Classification of functional psychosis in the classical period
Skulls dated to around the time of Neolithic man have been found with bore
holes drilled in order, it is thought, to allow the release of evil spirits. It is likely that
shamen who practiced trepanning may have been attempting to relieve the mental or
physical ills of their patients. Paintings have also been found on cave walls of human
figures, adorned will deer antlers who may have been the prototype doctors or
psychiatrists. Some of these paintings, found in the south of France, date to as early as
15 000 BC. Mental illness is often referred to in the writings of the Old and New
Testament. King Saul is said to have been 'beset with paranoia' and Nebuchadnezzar
troubled by persistent melancholia. Descriptions of mental disorder also appear in the
Hindu Ayurveda (cl400 BC), and have been interpreted by some as similes of dementia
or delirium (Romm 1994).
Clear references to mental illness, and probably psychotic illness, precede the
bible. Insanity was referred to in Homer's Iliad when Podaleirios 'diagnosed' mental
insanity in Ajax by examining his Tightening eyes'. Hippocrates (c460-377 BC)
classified mental disorders into three categories: mania, melancholia and phrenitis
(probably febrile delirium) on the basis of their conspicuous symptomatology (Simon
1973). Paranoia was also used as a descriptive term later incorporated under the term
insanity. However, these descriptive classes of observation incorporated clearly
heterogeneous cases. Mania was used to describe an agitated form of melancholia and a
relatively quiet form of insanity. Aristotle (c384-322 BC), a student of Plato, was
perhaps the first to attempt to classify human emotions (desire, fear, envy and joy)
(Romm 1994). However, he questioned Hippocrates's categorical classification and saw
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no clear distinction between health and illness (Roccatagliata 1986). In spite of much
attention, none of the early Greek philosophers published a separate text on insanity.
Mania was however a popular 'diagnosis' amongst Greek physicians who thought it was
particularly common amongst young men who drank to excess (Romm 1994). Mania
was punctuated by silliness, rage and fear and was treated by placing the sufferer in a
room with windows 'high enough to discourage jumping'.
A basic classification emerges in the writings of the Cappadocian physician
Arataeus (clOO AD). In the second century AD, Arataeus described mania and
melancholia occurring in the same individual and in doing so, anticipated Falret and
Baillarger by more than 1800 years (Roccatagliata 1986). Arataeus also suggested that
melancholia and mania had the same aetiology, namely disturbances of the brain and
some other organs. Marneros and Angst (2000) clearly identify Arataeus as the first
descriptor of "manic-depressive' illness, although not all authors would agree
(Ackerknecht 1959;Fischer-Homberger 1968). Arataeus was also one of the first to use
prognosis as a basis for the classification of illness.
Roman philosophers also considered conditions which retrospectively were
probably psychotic illness. Celsus (c30 AD) wrote about melancholia and mania and
advocated that they be treated by ducking the sufferer under water so that the evil
demons that caused the affliction would run away (Romm 1994). Galen (130-210 AD)
also used the terms mania and melancholia and claimed to localise mania's cause in the
blood and stomach although a scientific basis for such a claim was clearly absent.
The medieval era (c500 AD to c 1450 AD) appears to have been a time when
rational enquiry about the nature of insanity was abandoned in favour of demonology
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and superstition. The diagnosis and treatment of insanity was dictated by the church.
Although some 'madmen' were thought to be gifted or chosen by god for rewards to be
bestowed after death, many were tortured or subject to cruel and inhumane treatments.
During the same period however, the Muslim world had a more humane attitude to the
insane. Lunatics were housed in asylums and treated with baths, soothing music and
visits from prostitutes. Recorded examples of such asylums have been found in
Baghdad, Damascus, Cairo and Fez. Little is known of their approach to classification
(Alexander and Selesnick 1966).
1.2 The medieval period and Renaissance
During much of the Renaissance (cl350-cl650) scientific enquiry into the
aetiology and classification of mental disorder was also sparse. Descriptions of the
insane being drowned at sea have been found in the early Renaissance period and
witchcraft was a common aetiological theory of madness which pervaded at the time
(Sprenger and Kramer 1486).
Paracelsus (1493-1541) was one of the few Renaissance thinkers who viewed
lunatics as sick people and attempted to provide a possible classification. He believed
that mental disorders could be classified as mania, vesania (true insanity), chorea lasciva
(St Vitus Dance) and suffocatio intellectus (hysteria). Mania was a disorder of reason,
not of the senses as in true insanity. Vesania was subdivided into many further classes
including the melancholia, the insania (disease in which the affected were born mad or
defective) and obsessional disorders.
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Felix Plater (1536-1614), a Swiss Renaissance physician, decided to classify
mental conditions by whether they were inherited, congenital or acquired. Plater
advanced four diagnoses for those who were deemed insane: imbecility, consternation,
alienation and defatigatio (Lorr et al. 1963). Imbecility included those with bizarre
psychotic states. Consternation included various disorders including stupor and delirium.
Alienation was a diverse group of disorders including St Vitus Dance, melancholia,
mania, alcoholism and hypochondriasis. Defatigatio was identified by the presence of
insomnia and was attributed to god or the devil.
Interest towards the end of the Renaissance was directed towards the brain.
Vieussens (1641-1716), Descartes (1596-1650) and Willis (1621-1675) all proposed
theories which made a link between brain structure and mental functions. Stahl (1660-
1734) observed that powerful physiological reactions often accompanied emotional
states and that brain disorder may also lead to psychological symptoms. He proposed a
distinction between organic and functional mental disorders which became a classifying
criterion in many diagnostic nosologies (Lorr et al. 1963).
1.3 Classification in the eighteenth and nineteenth centuries
Influenced by Linnaeus's botanical classification of plants, the eighteenth
century and 'age of enlightenment' were a time where many nosologies of disease were
advanced (Mack et al. 1994). Francois de Sauvages (1706-1767) wrote the Nosologic
Methodique (Veith, 1957), based directly on Linnaeus's botanical model. He
distinguished a class of Folies under which he distinguished four orders, errors of
reason, bizarreries, deliria and anomalies. Mania and melancholia was subsumed under
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disorders of reason. People whom we would now refer to as schizophrenic would
probably have been classified under the bizarreries (Lorr et al. 1963).
William Cullen (1712-1790) in Edinburgh provided an extensive list of mental
illnesses which were catalogued by symptoms, signs and treatments and also introduced
the term neurosis (Berrios and Beer 1995). Esquirol (1772-1840) in France was of the
first to used statistical methods to address the problems of aetiology and classification.
He rediscovered the difference between illusions and hallucinations and separated
psychotics into those who were preoccupied with a single thought or set of thoughts
(monomania) from people with melancholia (Lorr et al. 1963). Also in France, Georget
(1795-1828) asserted that there was only one psychosis, which was due to a single brain
disease. His ideas may have anticipated those of Griesinger by many years, although this
point is a matter of some debate (Lorr et al 1963).
Jean-Paul Falret (1794-1870), a student of Esquirol and a Parisian psychiatrist at
the Salpetriere, is credited by some as the father of the modem concept of bipolar
disorder. In 1851 he published a statement in which he described a mental disorder
called 'folie circulaire' characterised by a continuous cycle of depression, mania and
intervening periods of varying length. Three years later Jules Baillarger (1809-1890)
published his concept of 'folie a double forme' in which he described recurrent periods
of melancholia and mania (Baillarger 1854). Falret differed from Baillarger in that he
considered the intervening period as part of the illness whereas Baillarger considered it
apparently unimportant.
The concepts of 'folie circulaire' and 'folie a double forme' found widespread
acceptance in both France and also in German speaking nations. Karl Kahlbaum
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introduced both terms into mainstream German psychiatry in his famous book 'The
grouping and classification of mental disorders' in which he also introduces the term
'Katatonia' (1874) a prototype of the current concept of catatonic schizophrenia (Berrios
1995).
In German and English speaking psychiatry, it is Wilhelm Griesinger's (1817-
1868) name that is most often associated with the term 'unitary psychosis' or
'Einheitspsychose' (Berrios and Beer 1995). This general view asserts that there is only
one psychosis and that differences between patients are variously due to the pathoplastic
effects of personality, life events or observer bias. Wilhelm Griesinger (1817-1868)
graduated at a time when questions were starting to be asked about the biological
substrate of illness, and the techniques of chemistry, physiology and microscopy were
just being developed to answer them. He famously asserted that mental disease was
brain disease. His views were so influential he has sometimes been called the father of
biological psychiatry.
Many people shared Griesinger's views about the unitary nature of psychosis.
Kant (1724-1804) believed that madness resulted from impairment of the brain and that
classification should reflect only which faculty of the mind was involved. Zeller (1804-
1877) and Neumen (1814-1884) also believed that insanity had a unitary cause and
Benedict Morel's (1809-1873) concept of degeneration theory has also been interpreted
in this context. It is interesting that in his later years, Wilhelm Griesinger came to doubt
his unitary classification of psychosis. In 1861 he wrote 'from our observations there are
two groups of insanities: firstly the affective ones and secondly the primary disturbances
of perception and will' (Berrios and Beer 1995).
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1.4 Twentieth century approaches to classification
Although many attempts to classify mental disorders, and in particular psychotic
illness, predate Kraepelin (1856-1926). Kraepelin was the first to propose a systematic
nosology which has come into widespread acceptance (Shorter 1997). Kraepelin, in the
Platonic tradition, hoped to discover natural disease entities and hypothesised that
patients with the same course of illness might suffer from the same disease and, like
Sydenham before him, he classified on the basis that common characteristics would co-
occur across patients with the same disease.
On the basis of meticulous clinical observation, Kraepelin proposed that
psychotic illness could be divided into those with recurrent episodes of mania or
melancholia with intervening periods of remission and good outcome and those with a
chronic persistent illness who showed a tendency to deteriorate over time. He referred to
the former disease as manic-depressive insanity and the latter as dementia praecox and
emphasised that auditory hallucinations and lack of volition were relatively more
common in dementia praecox. He later subdivided dementia praecox into Hebephrenia,
Katatonia and Dementia Paranoides (Shorter 1997). He expected that researchers would
in future find definite anatomical correlates or specific risk factors which would
eventually confirm his classification.
It is sometimes not appreciated that Kraepelin came to doubt his own
classification. In 1920 he said:
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"No experienced psychiatrist will deny that there are an alarmingly large
number of cases in which it seems impossible, in spite of the most careful
observation, to make a firm diagnosis. It is becoming increasingly clear that
we cannot distinguish satisfactorily between these two illnesses and this
brings home the suspicion that our formulation of the problem may be
incorrect" (Kraepelin 1920).
His system was however widely adopted and continues to influence many modern
classifications. His unification of bipolar and unipolar illness into one category caused
strong opposition in Germany, especially by Carl Wernicke (1848-1905) who
distinguished five separate types of unipolar melancholia, 'folie circulaire', 'folie a
double forme' as well as recurrent unipolar mania. Wernicke's opinions were the basis
for future work by Kleist (1911; 1926) in Frankfurt and Leonard (1957) in Berlin. Kleist
and Leonard both regarded recurrent unipolar melancholia, recurrent unipolar mania and
manic depressive insanity as separate disorders. Leonard (1979) added a further category
of cycloid psychosis which he described as a recurrent non-affective illness of good
prognosis which in which delusions or hallucinations are present. Wernicke's, Kleist's
and Leonard's ideas never gained widespread acceptance. This may have been due in
part to their relative complexity.
It was generally acknowledged that some people who displayed psychotic
features fell between the descriptions of dementia praecox (schizophrenia) and manic-
depressive psychosis. In 1933 a further diagnostic category termed 'Schizoaffective
Psychosis' (Kasanin 1933) was introduced to account for those cases in which the signs
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of schizophrenia and manic-depressive psychosis were found in equal measure. Gabriel
Langfeldt (1939) separated schizophrenia into three varieties: process, reactive and
atypical. In the process variety, the course was usually deteriorating and patents would
show blunting of affect and loss of will. In reactive schizophrenia, the outcome was
much more favourable and the symptoms displayed were almost equivalent to that
described in schizoaffective psychosis. The atypical group comprised patients who were
difficult to fit into the other two categories. Typically patients would suffer from vague,
shifting delusions and hallucinations which lacked a bizarre and alien quality. In a 7-10
year follow up of patients with the atypical subtype, 1 out of 13 patients followed up had
completely recovered. Langfeldt (1939; 1969) coined the term schizophreniform
psychosis to refer to the group of patients with 'atypical schizophrenia'.
Eugen Bleuler (1898-1927), like Kraepelin, assumed that the cause of
schizophrenia lay in the substance of the brain but was more influenced by the
psychological theories of his time. Bleuler proposed that that the fundamental features of
schizophrenia were not poor outcome but the presence of five core symptoms (Bleuler
1911; 1924).
Bleuler referred to his concept as schizophrenia, and for him symptoms such as
hallucinations and delusions were regarded as of only secondary importance. It is clear
that Bleuler's concept is considerable broader than that of Kraepelin, and the degree of
interpretation involved in deciding whether the fundamental symptoms are present or
absent is great. His ideas primarily concerned schizophrenia (dementia praecox), he did
little to explicitly alter the concept of manic-depressive insanity.
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Bleuler's concept of schizophrenia became very popular in North America
whereas in Europe Kraepelin's concept of dementia praecox remained dominant.
Consistent with this transatlantic difference in thinking, diagnostic practices diverged
widely. Schizophrenia, being a relatively broad concept in North America, was a
common diagnosis which was used in people we would not now regard as suffering
from psychotic symptoms. In Europe, Schizophrenia was a relatively narrower concept
and patients with psychotic symptoms were much more likely to receive a diagnosis of
manic-depression than schizophrenia. This was clearly demonstrated in the US-UK
Diagnostic Project (Cooper et al. 1972).
Using identical interviewing methods and diagnostic criteria, psychiatrists in the
US and in the UK made detailed studies of consecutive admissions to mental hospitals in
the two countries (Cooper et al. 1972). These comparisons showed that, while that the
symptoms displayed by patients in the two countries were virtually identical, the
proportion of people diagnosed with schizophrenia was far greater in New York and the
proportion of people diagnosed with affective disorders greater in London. This
appeared to be due to the fact that US psychiatrists had a much broader concept of
schizophrenia than UK psychiatrists, and that the diagnosis embraced many patients who
would have received a diagnosis of depression, manic-depression or even neurosis in the
UK. A later study (The International Pilot Study of Schizophrenia, WHO 1973) also
confirmed that psychiatrists in Washington and Moscow had much broader concepts of
schizophrenia than psychiatrists in the other centres (Columbia, Czechoslovakia,
Denmark, India, Nigeria, Taiwan and the UK).
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Jaspers (1883-1969) made no attempt to devise a diagnostic classification of his
own, but was interested in the assumptions made by those who had. He pointed out that
by assuming each disease had its own distinct cause, symptoms, course, outcome and
pathology that the same classification would result regardless of which criteria were
used (Jaspers 1963). He also pointed out that no entities found within the field of
psychiatry had been found had ever fulfilled these exacting criteria. Many non-
psychiatric conditions (e.g. TB, lung cancer) would also fail these criteria in spite of
detailed knowledge of their pathology. Jasper's believed instead that disease entities
were concepts which could be endlessly refined.
Kurt Schneider (1887-1967) made further refinements to the diagnosis of
schizophrenia by introducing symptoms 'first rank features' which, in the absence of
organic brain disease, were pathognomic of schizophrenia (Schneider 1959). Many of
these 'first rank features' may be interpreted as a failure to distinguish ideas or impulses
which arise from within an individual from those which are imposed from outside.
Schneider did not regard them as having any special theoretical significance. Instead he
regarded them simply as convenient diagnostic aids and accepted that not all people who
suffered from schizophrenia would show the symptoms. Modern diagnostic criteria
incorporate his fist rank features to varying degrees. Although some studies of people
with manic-depressive psychosis would show that they also display first rank symptoms,
perhaps Schneider's greatest contribution was to the establishment of core symptoms
whose presence or absence could be agreed upon with greater reliability than had
previously been realised.
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Twentieth century unitarian thinkers are considerably less common than in the
19th century. This probably reflects the increasing interest in Kraepelin's binary
classification and the search for disease entities. Bonhoeffer (1909) believed that the
brain was endowed with only a few stereotyped responses to disease. Although he
divided psychosis into organic and functional, his writings emphasise the importance of
careful description over the search for specific causes. Karl Menninger (1963) and other
writers of a psychodynamic persuasion believed that mental illness was a continuum
from health to disease, and that each person was unique. Crow (1987) and Kendell's
(1980) work has also been interpreted in a Unitarian context. Crow (1987) expressed the
view that schizophrenia and manic-depressive psychosis were parts on a continuum of
psychosis to which he has variously attributed to genetic causes or viruses. Kendell
(1980) made an unfruitful search for discontinuities within the symptoms and outcome
of functional psychoses and also within the various subtypes of depression that existed at
one time. His work is cited by some as support for a unitary concept of psychosis.
1.5 The reincarnation of bipolar disorder
Kraepelin's classification of affective disorders assumed that there was only one
endogenous affective psychosis, namely manic-depressive insanity. Although this
formulation was criticised widely, its detractors failed to convince practicing clinicians
(Angst and Marneros 2001). In 1966 two large scale studies were published which
separated manic-depressive insanity into bipolar and unipolar disorders. The first
(Angst 1966) study examined 326 patients treated at the University Hospital of Zurich
between 1959 and 1963, 638 parents, 1236 siblings, 111 half siblings, 425 children and
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189 husbands and wives. Angst (1973) and others applied diagnoses, which were
apparently non-operationalised, to the subjects themselves and their probands.
Information was obtained from several sources including case records, relatives and
employment records. Groups of patients and their relatives were compared in terms of
gender, family history, age of onset, precipitating factors and comorbid medical and
psychiatric conditions. The study is published only once in English (Angst 1973 and
personal communication) although the conclusions were re-published in an article by
Angst and Marneros (2001), shown in the following table.
Table 1.5: Conclusions from Angst's 1966 study
1.
Genetic and environmental factors have
independent and interactive effects on the
aetiology of endogenous depression
2.
Endogenous unipolar depression has a female
preponderance whereas in bipolar disorder,
the sexes are equally represented
3.
Manic-depressive insanity is not
homogeneous. The unipolar form differs
from bipolar disorder in several important
respects (genetics, gender, course, premorbid
personality)
4.
Depression of late onset seems to 'belong to
unipolar depression having only a weak
relationship to bipolar disorder
A second study (Perris 1966) concerned 138 bipolar and 139 unipolar depressive
probands treated on one or more occasions at the Sidsjon Mental Hospital in Sundsvall
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during the period 1950-1963. Like Angst (1966) the risk of illness in close relatives,
precipitating factors and course were examined. In addition, assessments were also made
of childhood environment, celibacy rate, body build, personality, perception (flicker
fusion and colour), the EEG, therapy and mortality. Like Angst (1966) the study
concludes that unipolar and bipolar disorders are separate in terms of heredity, celibacy
rate, personality, flicker threshold, EEG profile, ECT response, course and mortality.
Later studies generally confirmed their findings and more recently, and for similar
reasons, bipolar disorder has been further subdivided into recurrent mania and
depressive or mixed episodes (Bipolar I Disorder) and recurrent depression with
episodes of hypomania (Bipolar II disorder).
1.6 The International Classification of Diseases
At the Congress of Mental Medicine held in Antwerp in 1885 a commission was
appointed under the chairmanship of a Dr Morel from Ghent to consider whether
existing classifications could be combined and a typology of mental disorders derived
upon which the majority of psychiatrists could agree. The resulting classification, a
forerunner of the International Classification of Diseases, consisted of 11 categories
devised on the basis of majority verdict within the committee itself. The classification
included melancholia, periodic insanity (folie a double forme by another name),
progressive systematic insanity and insane neurosis amongst others. Whilst Morel and
his colleagues were engaged in this ultimately fruitless process others were engaged in
the same task. Even when the various conflicting classifications were eventually
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published, many organisations insisted on using their own (e.g. The New York State
Commission on Lunacy used their own classification as late as 1968).
Probably because of the obvious importance of mortality statistics to
governments a International List of Causes of Death was produced which gained
progressively widespread acceptance. The list was produced by the International
Statistical Institute who in 1899 recommended that it should be taken over by a more
weighty governmental body. In 1948 the 6th revision of the list was published as the
International Statistical Classification of Diseases, Injuries and Causes of Death by the
World Health Organisation (WHO). Section V of this publication entitled 'Mental,
Psychoneurotic and Personality Disorders' consisted of 10 categories of psychosis and
nine of psychoneurosis. Most were subdivided further. Although the classification was
recommended for use by all member states of the WHO, it did not come into widespread
use and in the US it was completely ignored.
Within psychiatry there was widespread disenchantment with international
classification, despite the fact that most psychiatrists recognised the need for one. There
was a growing recognition of the low reliability of clinical diagnosis and recognition
that, whatever classification was used, a large number of patients seemed to fall between
categories. A report by Stengel (1959) commissioned by the WHO concluded that the
main reason for the current impasse lay in the aetiological implications of diagnostic
terms, upon which there was widespread disagreement. Many categories carried explicit
assumptions (e.g. psychogenic psychosis, reactive depression) whilst others were less
obvious but nonetheless implied (involutional melancholia). Stengel recommended that
all diagnoses should therefore be explicitly shorn of their aetiological underpinnings and
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regarded simply as 'operational definitions' for certain types of abnormal behaviour.
This conclusion was reached simultaneously by another psychiatrist Carl Hempel,
although his recommendations were based upon considerations of low reliability.
The seventh edition of the International Classification contained a mental
disorders section identical to that of the 6th. The 8th edition was entirely self-sufficient
consisting of categories for all types of psychiatric disturbance and, in contrast to the
preceding editions, were based on extensive international collaboration. Two separate
glossaries were produced in the US and UK which contained authoritative diagnostic
criteria by which the classification could be applied. The classification was referred to
extensively in the literature but contained no operational definitions for specific mental
disorders, failed to define 'mental disorder', failed to follow a consistent textual form
throughout and some disorders continued to include aetiological underpinnings.
The 9th edition of the International Classification of Diseases was introduced in
1975 and although only minor modifications were made to the form of the previous
edition, the scope was expanded dramatically to reflect the expanding boundaries of
psychiatric practice. The category of involutional melancholia was also dropped but the
categories of neurotic depression and reactive psychosis remained. Manic-depression
and schizophrenia remained as separate categories although patients with both
symptoms of affective disorder and schizophrenia were classified as having
schizophrenia.
The 10th edition of the International Classification finally made the shift to
operational definitions of mental disorder. Like its predecessors, it has a hierarchy of
classification in which organic disorders take precedence over other categories when two
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or more separate criteria are met by the same patient. Affective disorders and
schizophrenia are at the same level. A diagnosis of schizophrenia may not be made if a
full manic or depressive syndrome is present, unless the schizophrenic symptoms clearly
predated the affective disturbance. In the 10th edition (revised), the distinction between
psychosis and neurosis was dropped and mood disorders were all subsumed under one
category, mood disorder. 'Manic-depressive psychosis' was also replaced with the term
'bipolar disorder'.
1.7 The American classification
By the early 1940s American Psychiatry had three competing official nosologies,
none of them in line with the International Classification. It was obvious that this made
communication between clinicians or researchers unnecessarily difficult and so in 1944
the American Psychiatric Association's Special Committee on Reorganisation was
formed. William Menninger and a group of like-minded psychiatrists, fearful that
psychosocial and psychodynamic concerns would be ignored, formed the Group for the
Advancement of Psychiatry (GAP). The Diagnostic and Statistical Manual of the
American Medical Association (DSM-I) was finally published in 1952 and its content
was probably disproportionately influenced by GAP. DSM I was never accepted by the
American Medical Association and there were difficulties in translating its categories
into those of the International Classification. DSM-II was finally published in 1968
dropping several terms, such as 'schizophrenic reaction', in an attempt to distance
classification from aetiological theory. However, DSM-II was not a major
transformation over DSM-I and the majority of American Psychiatrists continue to value
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psychodynamic and social theories over ones based on description, statistics and
neurobiology.
DSM-III and DSM-IIIR reflect a major shift in psychiatric thinking within the
US. Interest in psychodynamic theory was in rapid decline and the forthcoming ICD-9
prompted large revisions to the previous version. DSM-III and IIIR attempt to be
atheoretical although concepts such as melancholic depression persisted. The manuals
were based on a greater consideration of empirical patient data and the criteria for each
disorder were spelled out in much greater detail than before. The move to
operationalised diagnostic criteria in DSM-IIIR reflects a growing move to make
psychiatric diagnoses more reliable. The concept of schizophrenia presented in DSM-III
and IIIR is considerably narrower than that of its predecessors, reflecting the findings of
the US/UK diagnostic project and the International Pilot study. Manic-depression is
removed altogether and replaced with bipolar disorder. It is also further subdivided into
type I, recurrent depression with mania, and bipolar II, recurring depression and
hypomania.
DSM-IV borrowed extensively from ICD-10 and incorporated several new ideas
over its predecessor. However, issues regarding the validity of psychiatric diagnoses are
as pertinent today as they were centuries ago. Although two classifications now exist,
each with high inter-rater reliability, there is still some disagreement about the correct
nosology of mental disorders. The differences between the current classifications are
illustrated in the following tables. Diagnoses in medicine as a whole appear to be more
widely accepted and generate less debate amongst practising clinicians (with occasional
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exceptions). The models on which these disease entities are based may also inform the
debate surrounding the validity of mental disorder.
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1.8 Issues relating to disease in general
1.8.1 The medical model of disease
Early models of disease were usually based on the premise that diseases had a
real existence outside the observer and were waiting to be discovered. This approach
had shown early promise in the classification of species. Its application to medicine also
had considerable initial success. Sydenham (1696) conceptualised disease as a collection
of symptoms with a characteristic prognosis, but with the invention of the microscope by
Leeuwenhoek and the study of post mortem tissue led to the discovery that many human
illnesses seemed to be associated with an underlying bodily pathology and with the
presence of identifiable microscopic pathogens. This shifted the predominant model of
disease to one based on pathological rather than symptomatic criteria. Kreapelin's
description of Dementia Praecox was consistent with Sydenham's syndromal model of
disease, although he also believed that a defining pathological lesion would eventually
be discovered by which the diagnosis would be confirmed.
This pathological model of disease continues to pervade both 'physical' and
'psychological' medicine. In the former, physical diseases are associated with pathology
of the soma, whereas in the latter they were associated with disordered function or
psychopathology. The term 'psychopathology' carries with it an implied psychological
lesion contingent on the fact that, for most functional psychiatric illnesses, no obvious
structural abnormality had been found. The ontological separation of mind and body
(Descartes 1649) remained the dominant view in philosophy and medicine for many
years. However, the concept of mental disease has received severe criticism from several
quarters. A particularly vociferous critic, Thomas Szasz (1960; 1991) wrote:
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If mental illnesses are diseases of the CNS, they are diseases of the brain not
the mind. If they are the names of (mis)behaviour, they are forms of
behaviour, not diseases. Psychiatrists have persuaded the scientific
community, the courts, the media and the general public that the conditions
they call mental disorders are diseases, that is, phenomena independent of
motivation or will. The literal language of psychiatry allows motivated
actions [kleptomania, pyromania, transvestism] to be called 'diseases'. (Szasz
1991)
Szasz assumes that diseases must be bodily disorders occurring as the result of a
recognisable change in bodily structure. He asserts that because psychiatric disorders are
defined by symptoms and behaviours, and because psychiatric diagnoses are subject to
the social and political opinions of the time, they cannot be diseases. Szasz assumes
robustness to physical (somatic) disease which doesn't stand up to closer scrutiny. Some
physical diseases (e.g. migraine) continue to be defined on the basis of symptoms.
Others (hypertension, diabetes) appear to be defined on the basis of an arbitrary criterion
or are without a unifying single pathology.
The concept of illness itself is also a relatively insubstantial concept but is often
defined as the subjective awareness of distress. People who are ill then exhibit 'illness
behaviour' such as seeking help from a doctor. Although illness is often the reason that
patients present to their doctors, this behaviour is subject to their perception of what the
doctor is likely to offer. Patients may complain of illness to a doctor on the assumption
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that this may be a more effective strategy than going to visit a priest for example. In this
way diseases may be formed by doctors to explain what doctors treat rather than to
define a natural entity which they have 'discovered'.
Finally, the notion that somatic illnesses affect the soma whereas mental illnesses
affect the mind has also become progressively more unsafe. Although it has been known
for a century that mercury poisoning could cause madness, the appreciation that mental
illness might, in general, be the manifestation of brain disease has taken considerably
longer. Modem neuroscientific techniques have demonstrated links between brain
structure and mental illness. However, the finding of a brain abnormality does not in
itself redefine a mental illness as a disease. By the medical model stated above, it would
have to be a cause in each sufferer. Currently the evidence falls somewhat short of this
criterion.
In spite of some limitations, the somatic model of disease continues to pervade
(somatic) practice. It could be argued that an appreciation of what is meant by illness
and disease is unimportant to clinical practice either because the issues are either self
explanatory or because they are not of practical significance. However, the status-quo is
sometimes disturbed when illnesses purporting to be diseases arise (e.g. neurasthenia,
chronic fatigue syndrome). These situations stimulate lively debate amongst doctors,
patients and even politicians. Usually the arguments appear polarised, either you believe
chronic fatigue syndrome (CFS) is a physical disease which doctors should diagnose or
you believe it is non-disease with no recognisable pathology and no real existence.
Proponents of the concept are usually eager to search for causes and to describe possible
pathologies.
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To illustrate the lack of agreement amongst doctors about what constitutes a
disease, two studies from the British Medical Journal are relevant (Campbell et al.
1979;Smith 2002). In the original 1979 study non-medical academics (the reference
group), medical academics, general practitioners and secondary school students were
asked which items from a list of 38 conditions, they considered to be diseases.
Depression ranked 14th from bottom with around 40% of non-medical academics
believing it to be a disease, schizophrenia was rated somewhat higher at position 20
from bottom with around 60% of non-medical academics believing it to be a real
disease. The role of the doctor in diagnosis and treatment correlated strongly with the
perception of the condition as a disease. Interestingly, whether the condition was defined
in terms of an external cause, structure, function or syndrome was an important
consideration for infectious diseases only.
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Figure 1.8.1: Percentage of respondents classifying a condition as a
disease. Figure originally appeared in BMJ (Smith 2002; Campbell et al
1979) and appears here with the permission of The BMJ Publishing Group
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The second study (Smith 2002) asked clinicians to rate which conditions from a list of
200 they regarded as non-diseases. Chronic fatigue syndrome (27th), adjustment reaction
(38th) and ADHD (46th) all ranked relatively highly but few respondents regarded
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depression or hallucinations (schizophrenia was not listed) as non-diseases. Many high
ranking non-diseases shared a common aesthetic discomfort that could be attributed to
the spectrum of normal variation. It is interesting that many more people now regard
affective disorders and probably also schizophrenia as legitimate diseases in spite of the
fact that criteria for a traditional medico-pathological cause are not fulfilled.
1.8.2 The biological disadvantage of disease
Scadding, a chest physician, has written extensively on the subject of disease. He
noticed that patients with respiratory disease exhibited a limited number of stereotyped
symptoms none of which were diagnostic of a specific condition. Scadding stated that
the definitions used for individual diseases had in common the following factual
implications in spite of their logical heterogeneity:
A disease is the sum of the abnormal phenomena displayed by a group of
living organisms in association with a characteristic or set of characteristics
by which they differ from the norm of their species in such a way as to place
them at a biological disadvantage (Scadding 1959;1967;1988)
Scadding pointed out that he was not attempting to define disease in general and that all
attempts to do so were 'doomed to failure' (Mindham et al. 1992). However, he
suggests that if a condition were manifest so that the sufferer was not placed at a
biological disadvantage (i.e. reduced lifespan or fertility), then this would be outwith the
remit of medicine.
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Scadding and Kendell wrote specifically about the problems of applying a
'biological disadvantage criterion' to psychiatry (Kendell 1975;Scadding 1990).
Biological disadvantage (i.e. reduced fertility or survival) might not be easy to apply to
neurotic illness if the term disease is to define the legitimate territory of medicine.
Schizophrenia and affective disorders limit the social and occupational function of
sufferers and mortality and fertility are both adversely affected. However, depressive
symptoms occurring after loss events are sufficiently common to cast doubt on whether
the sufferers are indeed biologically disadvantaged compared to the general population.
Such a deviation might be seen as an understandable reaction and not abnormal by any
statistical definition. Homosexuality might also be regarded in this framework as a
disease since is associated with the biological disadvantage of reduced fecundity.
Diseases such as sickle cell anaemia also point to the environmental dependence of
Scadding's definition since some diseases, like sickle cell disease, may be advantageous
in some environs (e.g. areas where malaria is endemic).
1.8.3 Alternative models of disease
Attempts to clarify the concept of disease have been offered from many quarters.
Many more models of mental disorder exist outside medicine although these have not
traditionally been the concern of doctors and do not suggest a natural disease
classification.
Disease is often interpreted as implying qualitative imperfection or departure
from what is normal. Unfortunately there have been too many definitions of 'normal' to
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make this definition any less ambiguous. Consider the following statistical rule: if a
physical or psychological measurement lies outside the range defined by the mean, plus
or minus two standard deviations, then that individual is diseased. Under such a rule, 5%
of all individuals would be classified as diseased on a single measurement and the
number classified as diseased would rise with each test performed. People of high
stature or intelligence would also be so classified as diseased. Imperfection might also
be interpreted as socially undesirable. This definition would lead to large cultural
variations in disease definition although some would argue that imperfection is already
the model adopted for disease in general, explains why some diseases become non-
diseases (e.g. homosexuality) and why the insane are revered in some cultures but not
others.
Disease might also be conceived of as 'what doctors treat'. Kraupl-Taylor (1971)
attempted to define disease as having a statistical abnormality by the standards of the
population, therapeutic concern by the patient and by those in his social environment
and medical concern. This definition has attracted very heavy criticism (Kendell
1975;Scadding 1990) because of its obvious tautology. However, its legacy exists in
both modern classification schemes as a clinical significance criterion.
Patients diagnosed as suffering from a disease are usually then offered a medical
treatment. Some have suggested that the disease label itself is nothing but a disguised
prescription (Linder 1965) or plan of action. In the BMJ survey of non-diseases
(Campbell et al. 1979) non-medical academics were significantly more likely to regard a
condition as a disease when the doctor had a role in its management. Conditions such as
chronic fatigue syndrome, club foot or multiple personality disorder are regarded by a
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proportion of clinicians as diseases. Those who regard the patient as ill will usually
regard treatment or further investigation as necessary. However, debate surrounding the
publication of the BMJ's most recent non-disease articles (Smith 2002) and the
involvement of doctors in the normal process of childbirth suggest that this is an
inconsistently applied criteria and that some doctors would pragmatically treat
conditions they did not regard as diseases (e.g. big ears/nose, unsightly mole, anxiety
about penis size) on the basis that their intervention would do more good than harm.
Table 1.8.3: Definitions of disease
Model Summary of assumptions
Medical-pathological definition
(Sydenham 1696;Szasz 1960)
Assumes diseases are associated with a
necessary cause (e.g. bacterial infection of




Assumes that sufferers from a disease
possess a common characteristic such as to
place them at a biological disadvantage
compared to a normal population
Plan of action
(Linder 1965)
Assumes disease labels are justifications
for treatments and further investigations.
Syndrome with characteristic symptoms
and outcome
(Kendell 1975)
Assumes diseases represent circumscribed
concepts distinguished from others by a




Assumes diseases are quantitative or




Assumes diseases are man-made
abstractions with no independent
existence.
1.8.4 Diseases as concepts
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The disease model is based on the Platonic or Realist notion that diseases have a
real existence independent of the observer. Even those criteria which define diseases by
less stringent criteria, short of a necessary cause, may make assumptions that diseases
are real phenomena and consequently search endlessly for an elusive lesion or
characteristic pathology.
An alternative view of disease was proposed by Aristotle (384-322 BC) and
Hippocrates (460-377 BC) both of whom believed that diseases were man-made
abstractions with no independent existence of their own and justified only by their
utility. Their view of disease has been named Hippocratic, biographical, Nominalist or
empirical. Kendell suggests that the dominant views of psychiatrists in this country are
empirical in nature. Psychiatrists, in general, probably do not believe that schizophrenia
or depression have a real existence of their own, but are simply names given to
recognisable syndromes on the basis that their identification has some utility (Kendell
1975).
It is difficult to be critical of the 'concept model' since it seems to have obvious
face validity. Critics might claim that malaria was 'discovered' since the Plasmodium
organism is believed to be the necessary cause of every single case. Isolation of an
infective agent might therefore be taken as evidence that the associated disease is a real
disease entity. However, the cause of TB, to take one example, might be regarded as
multi-factorial (e.g. poverty, host immunosuppression) in that classification by infective
organism defines a disorder at a point where medical intervention is likely to yield the
greatest benefit.
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1.8.5 The spectrum of disease
The search for a unifying concept of disease may be an ultimately fruitless
unscientific quest. Advances in the aetiology of mental disorders will probably not be
achieved by a better definition of what is meant by 'disease'. The meaning of the term
disease is a slippery concept which relies as much on pragmatic issues as it does on
scientific considerations.
The utility of a classification based on characteristic tissue pathology has been
shown for centuries. The pathology enables relatively reliable and objective assessments
to be made, even when the definition of disease is based on an arbitrary criterion. Other
definitions may be achieved using indirect assessments of tissue structure such as x-rays
or other radiological investigations. These also provide a relatively reliable and objective
means of disease identification, although because the diseased organ is not visualised
directly, the diseases thus identified are probably less robust than those identified
directly by their pathology. Still less reliable are indirect and direct measures of patient
function (e.g. symptoms, neuropsychology, and neurophysiology). These measures are
affected by patient effort, the effects of medication, personality, intelligence and social
background to a greater or lesser extent. Functional imaging studies are assumed to be
more reliable than patients' self report because the experimental paradigm controls for
factors which confound patient interviews or self report.
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Figure 1.8.5: The hierarchy of disease
At each stage the term characteristic is used to imply that the measurement or finding
should usually be found in the disorder and be useful in distinguishing it from other
disorders with similar presentations. For a characteristic to be useful it must separate
diseased and non-diseased individuals so that the substantial majority can be allocated to
one category or another with few intermediate or equivocal cases.
1.9 Diagnostic validity applied to schizophrenia and bipolar disorder
Psychiatric disorder differs from the disease concept used in the majority of
physical medicine in that it is usually defined on the basis of symptoms and signs rather
than on the presence of a lesion or other demonstrable abnormality. Often the term
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disorder is usually preferred over disease (Rather 1959) presumably because classifiers
feel that to designate psychiatric 'conditions' as disease is somewhat premature without
a more detailed knowledge of their physical pathology. However, the definition of what
is meant by disorder is not without many of the same semantic difficulties.
Schizophrenia and bipolar disorder are both defined on the basis of their
symptoms. It is uncertain as to whether they constitute separate disease entities since the
aetiology of these disorders is uncertain and the predictive value of each diagnosis in
terms of treatment response and prognosis is not particularly strong. This uncertainty is
reflected in both DSM-IV and ICD 10 with the use of the term disorder instead of
disease.
The diagnostic validity of schizophrenia and bipolar disorder has been tested
using several criteria. The remainer of this chapter will discuss the genetic evidence
before considering those studies which have used multivariate statistics to examine their
separation on clinical or other grounds. The following chapter will review the
neuroimaging and neuropsychological literature.
1.10 Genetic considerations
A family history of psychosis has long been established as one of the strongest
risk factors for the development of the disorder in unaffected probands (Mitchell et al.
1993;Cannon and Jones 1996). Although the heritability estimates for schizophrenia and
bipolar disorder suggest one or more major environmental influences, in practice it has
been difficult to establish what these are. Obstetric complications, cannabis, winter birth
and maternal influenza are all replicated risk factors. However, the population fraction
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of schizophrenia and bipolar disorder for which these environmental factors appear
responsible suggests that there may be many more environmental risk factors still to be
found (Jones and Cannon 1998;Murray et al. 2003).
The model of genetic liability applied most often in medicine is typically that of
Mendelian transmission (autosomal dominant, recessive and sex linked). Schizophrenia
and bipolar disorder have been extensively investigated from this standpoint. However,
several problems with this model emerged early on. Firstly, the pattern of affected
family members within families frequently did not follow a typical Mendelian pattern. In
order to accommodate this, genetic models have been used which allow the assumption
of complete penetrance to be relaxed, allowing genes to be expressed in only a
proportion of people who carry them. This model is typically used in molecular genetic
studies where researchers look for linkage between a given region of DNA and a
psychiatric disorder or alternatively, start with a candidate gene in mind and search for
families in which the disorder and candidate gene co-occur.
Many molecular genetic studies of both schizophrenia and bipolar disorder have
been completed. However, it is commonplace for initial claims of genetic linkage to be
unconfirmed by future genetic studies and even in those studies where linkage has been
replicated; it is common for there to be at least some negative studies. This suggests
either the phenotype is itself sub-optimally defined, that the genes themselves are
specific to certain populations, that there are instead many genes for psychosis or that
the studies finding negative results have insufficient statistical power. In any case,
substantial evidence that there are one or more genes of major effect in either
schizophrenia or bipolar disorder is still lacking. Furthermore, most studies that have
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tried to establish whether schizophrenia and bipolar disorder breed true have failed to
find evidence that this is so (see table 1.10). This suggests that, either the disorders are
themselves sub-optimally defined and/or there must be at least some genes which pre¬
dispose to both disorders.
Table 1.10: Studies examining whether schizophrenia and bipolar disorder
'breed true'
Study Summary
Rudin (1916) Showed that the risk of an unaffected sibling of a schizophrenic
proband developing a non-schizophrenic (usually affective)
psychosis was (10.3%). Also showed that the risk of a unaffected
sibling developing schizophrenia was higher if the affected
sibling had a non-schizophrenic (usually affective) psychosis
(8.2%) than if the affected sibling was schizophrenic (6.2%)
Odegaard (1972) Showed that 19%of the ill relatives of probands with manic-
depression were diagnosed as schizophrenic. Showed also that




Found a risk of 8.6% for affective illness in the first degree
relatives of schizophrenic probands
Tsuang et al (1980) Relatives of people with schizophrenia were more likely to
receive a diagnosis if affective disorder (7.7%) than controls
(5.0%). An increased risk of schizophrenia was also found in the
relatives of people with a previous diagnosis of'mania' (3%) or
depression (1.6%) compared to controls (0.6%). Relative
diagnoses were based on personal or 'approximate' interviews.
Kendleret al (1986) The risk of schizophrenia in the relatives of people with
psychotic affective disorder was increased (4.3%) compared to
normal controls (0.2%).The morbid risk ofbipolar disorder was
higher in the relatives of patients with schizophrenia (1.2%),
schizophreniform disorder (1.3%) and schizoaffective disorder
(3.8%) compared to surgical control probands (0.3%).
Kendler et al
(1993a;1993b)
The risk of schizophrenia was increased in psychotic affective
disorder (2.8%) but not in non-psychotic affective disorders
(0.6%) compared to controls (0.5%) using operational criteria
applied at personal interview.
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Study Summary
Sham et al (1994) The morbid risk of bipolar disorder in the first degree relatives of
schizophrenic probands was approximately 2.1% (95%CI 0 to
4.5). Diagnoses were made by maternal interviews. The morbid
risk of schizophrenia in the first degree relatives of bipolar
probands was approximately 4.3% (95%CI 0 to 10.3). Diagnoses
were made by maternal interviews and no control group was
assessed.
Henn et al (1995) Families with one or more schizophrenic siblings found that
8.3% had a family history of affective disorder only.
Erlenmeyer-Kimling
et al (1997)
Relatives of schizophrenia subjects were more likely to develop
either broadly defined affective disorder (6%) or Bipolar I
Disorder (2.4%) compared to controls (0%). None of the
unaffected relatives or controls developed Bipolar II Disorder.
The lifetime risk of schizoaffective psychosis in families affected
by affective disorder was increased (6%) compared to controls
(0.7%). If a more stringent definition of schizophrenia was
adopted, none of the unaffected relatives or controls satisfied this
definition.
Valles et al (2000) Relatives of patients with bipolar disorder had an increased risk
of schizophrenia. RR=4.9 (95%CI 1.3 to 18.8). The presence of
more than one affected family member also increased the risk but
the presence psychotic symptoms conferred no additional
liability to schizophrenia in relatives.
Molecular studies which were not primarily designed to test this specific
hypothesis have also cast some light on the on the issue. St Clair et al (1990) showed
that in a family with a balanced 1:11 translocation, those with the translocation suffered
from several diagnoses including schizophrenia and affective illnesses. In several studies
of regions from chromosome 22, linkage has also been shown to both schizophrenia and
bipolar disorder from the same loci (Saleem et al. 2001;Kelsoe et al. 2001;Berrettini
2000).
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It would appear therefore that schizophrenia and bipolar disorder do not breed
true and that the mode of genetic inheritance is either polygenetic, although the presence
of one or more major genes in some population remains a possibility. This latter
assertion has also been confirmed using structural equation models in which the likely
model of genetic transmission has been chosen on the basis of which one best fits the
observed data. In each of the studies which have addressed this particular issue, the
presence of multiple loci of quantitative effect has been suggested (O'Rourke et al.
1982;Risch and Baron 1984;McGue et al. 1985).
1.11 Multivariate methods to derive or confirm categories
1.11.1 Discriminant function analysis
Discriminant function analysis (DFA, Fisher 1936) is used to determine which
variables discriminate between two or more naturally occurring groups. For example, a
researcher may want to investigate which variables discriminate between schizophrenia
and manic-depression. Discriminant function analysis could be used to determine which
variables are the best predictors of a person belonging to a given diagnostic group.
Although the technique is able to ascertain which combination of variables fits the data
best, if the model is 'fitted' on the dataset on which it is also used to predict, then the
model is likely to show greater predictive value than is likely to be bome out in practice.
For this reason, DFA should be combined with techniques which predict the group
membership of an observation without using that observation to fit the discriminant
function itself. This process is known as Jacknifing.
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There are few established rules for how the success of a discriminant function
analysis should be measured. The performance of the predicted categories can be
compared against the known clinical diagnosis and error rates for each prediction (i.e.
sensitivity and specificity) can be calculated. Alternatively, Moran (1966) and Kendell
(1968) have both suggested that a bimodal distribution of scores on a discriminant
function, obtained on an unselected population and cross validated on a second should
be an accepted criterion of validity for diagnostic categories. However, this approach
could be criticized for being somewhat tautological since the model derived will be the
one which discriminates best between two populations and will tend to be at least
bimodal.
Using DFA Kendell and Gourley (1970) tried to establish bimodality on a
discriminant function within a sample of 250 admissions to the Netheme Hospital in
Surrey, studied as part of the US/UK Diagnostic project (Cooper et al. 1972). With
unselected functional psychoses and also in 105 patients with schizoaffective admitted to
one of three London Hospitals during a similar period. They attempted, but failed to
show that the relationship between a discriminant function and outcome was non-linear
(i.e. not unimodal). The details of their methods are unclear and would not allow
replication.
Cloninger et al (1985) applied DFA to two random and equal samples (m=250
each) of psychiatric outpatients. Two samples were used, one to extract a discriminant
rule and the other for its validation. On the basis of a symptom score derived from
patient interviews a linear discriminant rule was derived on the first sample of patients.
The authors report than in this first sample 83.7% of the schizophrenic patients were
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correctly allocated using this rule and only 4.4% of non-schizophrenic patients were
wrongly allocated (specificity 95%). In applying the rule to the second sample,
sensitivity was similar at 96%, but specificity diminished slightly to 77.5%. Sensitivity
and specificity were not reported separately for bipolar disorder. These results suggest
that although patients with schizophrenia may be separated from the majority of people
with other psychotic illnesses, as significant number of people without schizophrenia are
falsely allocated to the schizophrenic group. In essence this study supports the
substantial but imperfect separation of schizophrenia from other psychoses on the basis
of symptoms. Unlike Kendell et al (1970), the study uses a valid technique and is well
reported.
Later studies have also examined symptoms and their linear combination as a
discriminator between traditional diagnostic boundaries. Brief Psychiatric Rating Scale
scores were used to classify a sample of 207 inpatients (schizophrenia, bipolar disorder,
unipolar depression) admitted to inpatients psychiatric care in an 8 month period (Hopko
et al. 2001). 68% of schizophrenic subjects, 60% of bipolars and 74% of unipolar
depressive subjects were correctly allocated according to the analysis. However, no
validation was conducted on a separate data set and there is some evidence that the
discriminant analysis was 'overfitted'. Given these limitations, the ability of BPRS items
to discriminate between schizophrenic and affective psychoses appears particularly
disappointing.
Since personality, drug misuse and life events may all confound the presenting
symptoms of psychotic illness, others have used DFA to attempt of validate clinical
syndromes on the basis of objectively measured biological indices. Such an analysis
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assumes that the biological variables measured are more closely related to the
fundamental biology of the disorder. Few such analyses have been undertaken. Although
some success has been achieved in separating schizophrenic patients from controls (e.g.
dermatoglyphic abnormalities, Akabaliev et al. 2001) and other non-psychotic illnesses
(e.g. autism, Bolte et al. 2002), fewer studies have compared schizophrenia with
affective disorder. A study comparing 20 schizophrenic patients with an equal number of
bipolar patients and healthy volunteers examined the ability of reaction time parameters
to discriminate between the three groups. According to the discriminant function
obtained, 78.3% of the entire sample was allocated to the correct group compared to the
33% expected by chance. 100% of the healthy control group was correctly classified
compared to 80% of the schizophrenic group and 55% of the patients in the bipolar
group (Fleck et al. 2001). Of the 20% of schizophrenics misclassified by the analysis,
15% were falsely allocated to the bipolar group and 5% to controls. Patients with bipolar
disorder were mis-allocated more equally between the schizophrenic and healthy control
groups (25% vs. 20%). The study did not validate the results in a second sample or use
the method of Jacknifing to estimate the actual classification rate. An earlier study also
attempted to discriminate between schizophrenia, bipolar disorder and healthy controls
using tests of information processing (Tarn et al. 1998). The study used a combination of
5 psychophysiological and neuropsychological tests and correctly classified 76% of the
schizophrenic and bipolar samples.
The results of most published DFAs are probably more optimistic than would be
borne out in practice. However, the results of both symptom and experimental studies
appear to support the fact that schizophrenia can be consistently but imperfectly
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discriminated from healthy controls and affective psychotic illness. Patients with bipolar
disorder however, appear to be less well discriminated from schizophrenia, unipolar
disorder and healthy controls. It may be the case that the disorders are imperfectly
defined or that the biological indices which most efficiently separate the disorders have
yet to be discovered. Alternatively the possibility that there are no 'disease entities' just
continuous variation remains a possibility which remains to be excluded. The fact that
schizophrenia can usually be discriminated from other disorders and healthy controls is
however evidence against continuous variation.
1.11.2 Cluster and latent class analysis
Latent class analysis (LCA) and cluster analysis (Titterington et al. 1985;Gordon
1999) are a rather loose collection of statistical methods that can be used to assign cases
to groups or classes (clusters). Group members are assigned so that they share certain
properties with other members of their class and are differentiated from those in other
groupings. Both LCA and cluster analysis have been used in an attempt to empirically
separate the broadly defined psychosis into sub-categories. Studies have then compared
the clinical diagnosis with the categories derived by LCA or cluster analysis in order to
see if there is a match.
One of the first studies to apply cluster analysis to the problem of psychiatric
classification was conducted by Lorr et al (1963) on a sample of patients from several
hospitals, although the clinical characteristics of the patients are poorly described. The
cluster analysis separated the sample in 6 clusters none of which closely resemble
current or past diagnostic syndromes. The method of cluster analysis is not stated and
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the patients do not appear to have been subject to standardized assessments according to
operationally defined criteria. As a result, it is extremely difficult to draw any firm
conclusions from the study. Subsequent studies have explicitly stated their method of
patient ascertainment and have used structured schedules to determine diagnostic status
according to pre-specified criteria. Most studies (Everitt et al. 1971;Kendler et al.
1998;Jorgensen and Jensen 1990;Manton et al. 1994) identified one or more clusters
with a high proportion of schizophrenic members. One which failed to find a
'schizophrenic cluster' was based on a sample of patients with cycloid psychoses
(Mojtabai 2000). A second used psychophysiological and dermatoglyphic variables as
parameters by which to derive clusters (Sponheim et al. 2001). Clusters containing a
high proportion of patients with bipolar disorder (Everitt et al. 1971) were found in only
one study. Other studies found clusters which contained patients with mania and another
psychotic disorder, usually schizophrenia (Jorgensen and Jensen 1990;Manton et al.
1994;Kendler et al. 1998). Its is interesting to note that the only study using biological
variables determined in an experiment failed to derive clusters corresponding to
traditional psychiatric disorders (Sponheim et al. 2001).
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The diagnoses of schizophrenia and bipolar disorder have emerged over many
centuries of observation. During this time, others have advanced their own theories
which have been accepted or rejected usually on grounds of clinical consensus or
sometimes because of their inherent simplicity. Few studies have been conducted which
attempt to confirm or refute these diagnostic categories on scientific grounds. However,
the basis on which to derive valid diagnostic categories is far from clear. In medicine as
a whole, categories have emerged based on the pathological appearance of diseased
tissue; although no characteristic tissue pathology has yet been found for any psychiatric
disorder. Studies have instead concentrated on whether psychiatric disorders breed true
or used computer intensive multivariate methods to derive or confirm diagnoses on the
basis of their symptoms and history. Family studies have in general showed that the type
of psychosis does not breed true, although more restrictive definitions of schizophrenia
have showed a tendency to run in families. Cluster and latent class analysis have also
shown a tendency to derive the category of schizophrenia but are less successful at
confirming the presence of delineated affective syndromes and may be influenced by the
diagnostic bias of the observer. Furthermore, such studies use a variety of different
techniques and have failed to show consistency over time. The process of attempting to
confirm diagnostic categories using discriminant function analysis has shown mixed
results and there now seems little continuing research effort using this technique.
It could be argued that a failure to derive or confirm diagnoses on the basis of
symptoms is likely to fail since clearly separate tissue pathologies in the rest of medicine
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may underlie conditions with similar presenting features (e.g. lung cancer and
tuberculosis) and presenting symptoms are likely to be coloured by premorbid
personality, life events and other complicating factors. Under such circumstances,
investigating which biological variables distinguish between bipolar disorder and
schizophrenia might be a more fruitful way of determining whether they can be
separated from one another. Even if such an effort were to fail, an exploratory analysis
of such data might suggest the presence of disease entities amenable to further
investigation.
Biological variables could include any functional or physical substrate which
could be objectively measured, and which has been shown in previous studies to
distinguish patients with psychosis from healthy controls. The majority of contemporary
clinical research has focussed on the fields of neuroimaging and neuropsychology. This
thesis will review the body of neuropsychological, structural and functional
neuroimaging research as it applies to schizophrenia and bipolar disorder.
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Chapter 2: Neuropsychology and Brain Structure in




Numerous neuropsychological studies have been conducted in people with
schizophrenia and depression but, until recently, bipolar disorder has received relatively
little attention. Neuropsychological tests have been grouped by domain of cognitive
function, anatomical associations or by cluster analysis. The first categorization is
probably the most useful as they enable interpretation of tests scores by domain of
function (e.g. memory, IQ, attention, executive function) and they also sometimes
correspond to an anatomical location. However, no test has been isolated to a single
function or anatomical location and current symptoms and medication may always
confound the picture. Nevertheless, testing cognition in schizophrenia and bipolar
disorder is relevant to their validity since neuropsychological functions may be closer to
the fundamental biology of these disorders than symptoms which are probably
influenced by personality and life events to a greater degree.
The role of medication and current psychiatric symptoms on the
neuropsychological performance of subjects has been addressed in several studies. Data
from controlled trials has demonstrated that anticholinergic medication, lithium,
benzodiazepines and antipsychotics may all affect memory and psychomotor
performance. The role of medication in individual test performance is however unclear
as most studies use subjects who are medicated and fail to address its effect as a
confounder. Sharma et al (1999) reviewed several studies examining the effects of
typical and atypical antipsychotic medication on cognition in schizophrenic patients.
Several studies found that conventional antipsychotic drugs worsen attention (e.g. using
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the Continuous Performance Test, CPT) and motor performance acutely, but that the
impairments diminish with chronic exposure and one study found that conventional
antipsychotic drugs ameliorate performance on the CPT. Memory does not appear to be
consistently affected by conventional antipsychotics, although there are studies which
show reductions, improvements and no change. The Wisconsin Cart Sort Test (WCST),
Digit Symbol Substitution Test (DSST) and digit span however appear to relatively
unaffected by conventional antipsychotic treatment. The atypical antipsychotics
(excluding clozapine) appear to have no deleterious effects on cognition in
schizophrenic subject and in some studies improved performance on tests of working
memory. However, it is possible that lower relative dosages of atypicals may exaggerate
their apparent superiority over conventional drugs in terms of cognition. This possibility
has some prima-facie support from a meta-regression which showed dosage effects
explained most of the supremacy of atypical drugs in terms of efficacy and tolerability
(Geddes et al. 2000). However, an advantage for atypicals in terms of extrapyramidal
side effects (EPSE) remained, even after dose was taken into account. It is possible that
this advantage in EPSE could favourably affect cognitive tasks with a motor component
compared to patients on typical drugs. Anticholinergic medication and benzodiazepines
have been shown in several studies to adversely effect memory (Nishiyama et al.
1998;Mizusawa 1998;Verster et al. 2002;McAndrews et al. 2003). However, the
cognitive effect of most antipsychotic medication with a strong affinity for
antimuscarinic receptors is as yet unclear, with the possible exception of clozapine
which has been shown to adversely affect psychomotor speed in randomised controlled
trials, although many other cognitive abilities were apparently spared (Wahlbeck et al.
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2004). The effects of antipsychotic medication on cognition are further clouded by their
positive effects on positive symptoms which may conceal any negative effect of the
antipsychotics themselves.
Psychiatric symptoms themselves may confound tests of cognitive function. In
schizophrenia, negative (but not positive) symptoms were positively associated with
memory impairment in one review (Aleman et al. 1999). However, Liddle et al
(1987;1991) found that in chronic schizophrenic subjects, the syndrome of
disorganisation was associated with poorer performance on certain executive tasks, a
finding which was later replicated in a separate sample (Baxter and Liddle 1998). The
syndrome of psychomotor poverty (which generally corresponds to negative symptoms)
was also associated with a general slowing in mental activity. In bipolar patients
performance IQ, verbal IQ and tests of attention and executive function all appear to be
impaired in symptomatic patients (Quraishi and Frangou 2002) and there is some
evidence that verbal memory impairment is also impaired in euthymic patients (Atre-
Vaidya et al. 1998;Krabbendam et al. 2000). In a recent article by Martinez-Aran et al
(2004) controls were compared with both symptomatic (manic and depressed) and non-
symptomatic bipolar subjects on 19 measures of neuropsychological function. Although
differences were found between controls and bipolar subjects on 16 of the 19 tests used,
there were few significant differences between manic, depressed and euthymic
subgroups. Depressed patients scored lower than euthymic patients on a test of verbal
fluency and on a test of attention. The effect of current symptoms appears more likely to
confound cognitive performance than that of concurrent medication in both
schizophrenia and bipolar disorder. However, patients with ongoing positive symptoms
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are often those with worse functional outcomes and likely to receive higher doses of
medication. Some studies examining the role of symptoms in unmedicated people with
sub-syndromal illness have not found a relationship with cognition (Byrne et al. 2003).
However, almost all domains of cognitive impairment could usefully be re-examined in
either asymptomatic subjects or by accounting for them in the statistical analysis.
2.1.2 Premorbid intelligence
Premorbid intelligence concerns the general intellectual ability of a subject
before they have begun to manifest signs of illness. Because of practical considerations,
premorbid IQ is generally inferred from tests administered in people once the matter of
whether they will become ill has already been resolved. The most commonly used index
of premorbid function is the National Adult reading Test or NART (Nelson 1982). The
NART uses knowledge about the correct pronunciation of irregular nouns to infer an
individual's premorbid intelligence. This is based on two assumptions, that individuals
acquire few new words in the course of their adult life and secondly that such abilities
are relatively robust to pathological processes which affect other cognitive functions.
Studies of patients with neurological illness have suggested that the NART is a valid and
reliable method of measuring IQ (Gladsjo et al. 1999;Watt and O'Carroll 1999).
However, few studies have considered the validity of the NART in psychiatric patients.
In a review by Heinrichs and Zakzanis (1998) NART scores were found to have a large
distribution of effect sizes when schizophrenic subjects and healthy controls were
compared. The authors attribute this finding to reduced reliability in this patient group.
A later study by Russell (2000) compared estimates of premorbid IQ measured using the
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WAIS-R in childhood and compared them to the NART scores obtained in adult life.
The study found that the NART scores obtained once the illness had developed
overestimated premorbid intelligence when compared to the WAIS-R scores obtained
premorbidly. Higher NART scores are also associated with greater educational
opportunity and are of limited value in those whose first language is not English (Filley
and Cullum 1997). Nevertheless, the NART has become the accepted measure of
premorbid IQ in psychiatric research.
Prospective cohort studies of children have shown that IQ is reduced in those
who develop schizophrenia many years later (Jones et al. 1994b;Crow et al. 1995;David
et al. 1997). This finding is confirmed by further studies of adults at high risk of
schizophrenia for genetic reasons, in that it is those subjects with greatest premorbid
impairments that are most likely to become manifestly unwell in the course of the study
(Byrne et al. 1999;2003).
Prospective studies of individuals at high risk of developing bipolar disorder
have yet to be conducted. Therefore differences between bipolar subjects and controls
are generally inferred from the results of the NART, with all the aforementioned
difficulties that entails. Several studies have also been conducted which compare bipolar
subjects with either controls or schizophrenic subjects. Generally these studies show that
bipolar subjects perform as well as healthy controls (Ferrier et al. 1999;Rubinsztein et al.
2000) and better than schizophrenic subjects (Souza et al. 1995;Gilvarry et al.
2000;Seidman et al. 2002b). Two studies have also suggested that premorbid intellectual
deficits may also be present in unaffected relatives of schizophrenic subjects (Gilvarry et
al. 2000) and related to paranoid personality traits (Gilvarry et al. 2001). These results
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suggest that premorbid intellectual deficits may be related to genetic liability to
schizophrenia but not bipolar disorder, although the research base for bipolar disorder is
relatively weak compared to that of schizophrenia.
2.1.3 Current intelligence
There are several commonly used measures of intellectual ability in general use
from which measures of performance, verbal and full scale IQ may be made. The most
common test of intelligence is probably the Wechsler Adult Intelligence Scale (WAIS)
and its revised (WAIS-R) and abbreviated (WASI) forms. The WAIS has several
subtests from which full-scale, performance and verbal IQ scores can be derived. The
difference between WAIS full-scale (current) IQ and NART (premorbid) IQ has also
been used to infer a change in intellectual ability over time.
Numerous studies have found schizophrenic subjects to have lower current IQ
that appropriately matched controls (Heinrichs and Zakzanis 1998). Most interest in this
finding has concentrated on whether this deficit predates the onset of illness or is
acquired as patients become unwell. Data obtained from prospective studies of children
and from high risk studies of adults suggest that the IQ difference is both present before
the illness and worsens as people become unwell (Aylward et al. 1984;Cannon et al.
1999). Unaffected relatives of people with schizophrenia also appear to have a lower
current IQ than matched controls (Cannon et al. 1994;Faraone et al. 1995) suggesting
that at least some of the genetic liability for schizophrenia is expressed as reduced full-
scale IQ. Performance IQ (mean effect size=1.26) also appears to be relatively more
affected than verbal IQ (mean effect size=0.88) (Heinrichs and Zakzanis 1998;0'Carroll
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2000) although it is at least a theoretical possibility that tasks which depend more on
motor function may be relatively more prone to the effects of medication.
Research into the intellectual ability of subjects with bipolar disorder is at a
much earlier stage than that of schizophrenia. A study which compared full-scale IQ in
bipolar subjects in remission found no significant differences between patients and
controls (Coffman et al. 1990). Most other studies involve patients with variable degrees
of affective symptoms. Dalby and Williams (1986) studied 15 bipolar inpatients and 21
controls and found that patients scored significantly lower in terms of full-scale and
performance, but not verbal IQ. The finding was later partially replicated by Morice
(1990) who found that bipolar subjects had lower performance IQ, but were
approximately equal in terms of full-scale and verbal IQ compared to controls.
Robertson and Taylor (1985), using a remand prison population found IQ differences
which found bipolars performed better in terms of verbal IQ than healthy controls. The
balance of this research seems to indicate that full-scale and verbal IQ is probably spared
in bipolar disorder. There is insufficient evidence to draw any conclusions about
performance IQ since studies have not yet adequately addressed whether observed
differences are due to confounding by medication or current psychiatric symptoms. A
verbal-performance IQ deficit of 6 points has also been found in studies of bipolar
patients, although this difference may also be dependent on current clinical state
(Bearden et al. 2001). Unaffected people from families affected by bipolar disorder have
been examined in at least two studies. Both studies found that unaffected individuals had
similar full-scale IQs to normal controls although some evidence was found for a
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performance-verbal IQ deficit in the children of bipolar subjects compared to normal
control children (Decina et al. 1983;Gourovitch et al. 1999).
Several studies have compared schizophrenic and bipolar patients directly using
the full WAIS although in only one study were the bipolar patients described as in
remission. All studies appear to find that bipolar patients perform either equally or better
than schizophrenic patients in terms of full-scale, performance and verbal IQ (Abrams et
al. 1981;Morice 1990;Goldberg et al. 1993;Souza et al. 1995;Mojtabai et al.
2000;Seidman et al. 2002b) and only one study, using acutely manic subjects, found no
difference (Hoff et al. 1990). On the basis of these studies, performance IQ appeared to
discriminate the least between schizophrenic and bipolar patients, although this issue
could be clarified further.
2.1.4 Memory
Although memory was considered by Kraepelin (1919) to be preserved in
schizophrenia and bipolar disorder, numerous studies conducted in the second half of the
twentieth century have demonstrated that this is certainly not the case (Heinrichs and
Zakzanis 1998;Aleman et al. 1999;Bearden et al. 2001).
In an early systematic review and meta-analysis (Heinrichs and Zakzanis 1998)
memory was found to be impaired in schizophrenic subjects compared to controls.
Verbal memory was more impaired than non-verbal, a finding confirmed by a later
review (Aleman et al. 1999) which also found that differences were present irrespective
of whether the recall condition was immediate or delayed. Cued recall and recognition
conditions reduced the differences observed between schizophrenics and controls,
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although the differences remained statistically significant. Working memory was also
impaired compared to controls (Aleman et al. 1999) and subsequent studies suggest that
working memory deficits are also present regardless of whether the stimuli are presented
verbally or visually (Barch et al. 2002;Coleman et al. 2002;Gold et al. 2003;Glahn et al.
2003) and may also be manifest in unaffected relatives (Toulopoulou et al.
2003;Callicott et al. 2003).
Verbal memory has been assessed in several studies of remitted (van Gorp et al.
1998;Ferrier et al. 1999;Krabbendam et al. 2000) or stable symptomatic bipolar subjects
(Coffman et al. 1990;Jones et al. 1994a). Most studies found a robust impairment of
verbal memory in bipolar patients compared to controls (Quraishi and Frangou 2002)
and an early study which correlated impairments to numbers of episodes (van Gorp et al.
1998), has recently been replicated (Cavanagh et al. 2002). Non-verbal memory
impairments (e.g. visio-spatial memory) appear less consistently disturbed compared to
controls with both positive (Atre-Vaidya et al. 1998;Quraishi and Frangou 2002) and
'negative' studies (Coffman et al. 1990;Jones et al. 1994a;Clark et al. 2002).
Unaffected relatives of bipolar subjects also show evidence of memory
impairments compared to healthy controls. Gourovitch (1999) studied 7 MZ twin pairs
discordant for bipolar disorder and 7 healthy concordant MZ twin pairs. Bipolars were
impaired on measures of verbal memory and visiospatial functioning compared to
unaffected co-twins and normal MZ twins. Unaffected co-twins were also impaired on a
verbal list learning task and the overall Wechsler Memory Task Quotient.
Direct comparisons of schizophrenic and bipolar subjects have found mixed
results. Goldberg et al (1993) found that symptomatic bipolar patients were less
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impaired on the Wechsler Memory Scale (WMS) than schizophrenic patients, a finding
which was replicated in a later study using the same scale (Mojtabai et al. 2000).
However, another study (Albus et al. 1996) found no differences between schizophrenic
and psychotic bipolar subjects in terms of verbal memory, but found a significant
impairment in subjects with a history of psychotic symptoms compared to those without.
Non-verbal memory also appears to be more impaired in schizophrenia on several non¬
verbal tasks, including tests of visual reproduction and visual short term memory
(Goldberg et al. 1993;Mojtabai et al. 2000). However, there are also some 'negative'
studies which find no differences in facial recognition (Goldberg et al. 1993) or in WMS
visual reproduction (Verdoux and Liruad 2000). Hence the available evidence suggests
that verbal and non-verbal memory tasks may be impaired in schizophrenia and bipolar
subjects, but that the degree of impairment is greater in schizophrenia. It remains to be
seen how the impairments relate to the presence or absence of psychotic symptoms in
general.
2.1.5 Executive function
Executive function can be assessed by a number of cognitive tests, including
ones that attempt to measure controlled output (e.g. verbal fluency), response inhibition
(e.g. The Hayling Test) and planning (e.g. Tower of London, Stockings of Cambridge).
Some of these tests have been used for over 50 years and evidence has gradually
emerged of the relationship between tests of executive performance and frontal lobe
function from lesion studies and from functional imaging.
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Abnormalities of executive function have been extensively described in
schizophrenic subjects, particularly using the Wisconsin Card Sort Test (WCST, Berg
1948). The WCST measures a subject's ability to match a presented card to a series of
stimulus cards, according to an un-stated rule. A subject's performance can be measured
by the number of categories they complete, or by the number of perseverations they
make. Subjects with schizophrenia make both types of error more often than controls
(Heinrichs and Zakzanis 1998) and performance on the WCST may be related to the
syndromes of psychomotor poverty and disorganisation (Nieuwenstein et al. 2001).
Close relatives of schizophrenic subjects also appear to be impaired on the WCST (Wolf
et al. 2002;Rybakowski and Borkowska 2002;Saoud et al. 2000) although there are some
'negative' studies (Stratta et al. 1997;Laurent et al. 2001).
Performance on tests of response inhibition such as the Hayling Sentence
Completion Test (HSCT, Burgess and Shallice 1996) and Stroop Test (Golden 1978)
have also been shown to be impaired in schizophrenic subjects, their close relatives and
also subjects at high risk of schizophrenia for genetic reasons (Byrne et al. 1999;Yucel et
al. 2002;Rybakowski and Borkowska 2002;Byrne et al. 2003). Tests of spontaneous
production such as the verbal fluency test (e.g. FAS, Spreen and Strauss 1991), also
show a similar pattern of impairment (Chen et al. 2000a;Chen et al. 2000b) as do tests of
planning ability (Morris et al. 1995;Morice and Delahunty 1996;Staal et al. 2000a).
Performance on frontal lobe tests also appear to be reduced in at least some
patients with bipolar disorder (Bearden et al. 2001;Quraishi and Frangou 2002).
Performance on the WCST is reduced in bipolar subjects, both in terms of categories
completed (Morice 1990) and perseverative errors (Coffman et al. 1990;Morice
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1990;McGrath et al. 1997). However, one study suggests found that the differences
between bipolars subjects and controls could be explained by the inclusion of bipolar
patients with psychotic symptoms (Albus et al. 1996).
In a study of remitted bipolar patients, Ferrier et al (1999) demonstrated
decreased verbal fluency in bipolar patients compared to controls. Decreased verbal
fluency has been confirmed in some (Docherty et al. 1996;Atre-Vaidya et al. 1998), but
not all studies (Calev et al. 1989;van Gorp et al. 1998;Hawkins et al. 1997;Gruzelier et
al. 1988) and many studies do not control for general intellectual function or psychiatric
symptoms.
On tests of planning ability, two studies find no difference between bipolar
subjects and controls (Ferrier et al. 1999;Rubinsztein et al. 2000). The first study
initially found significant differences which were lost once the analysis was adjusted for
current depressive symptoms. These studies are balanced by two further studies of
symptomatic bipolar patients in which patients were significantly impaired compared to
controls (Murphy et al. 1999;Sweeney et al. 2000).
There are only a few direct comparisons of executive function in schizophrenic
and bipolar subjects. Docherty et al (1996) found that although bipolars and
schizophrenics were both impaired compared to controls, schizophrenics performed
significantly worse in terms of verbal fluency than the bipolars. Hawkins et al (1997)
and Gruzelier et al (1988) also found significantly greater impairments of verbal fluency
in schizophrenics compared to bipolar subjects. Morice (1990) however, found no
difference between schizophrenic subjects and controls in terms of verbal fluency.
Goldberg et al (1993) in a study of schizophrenic subjects and patients with both
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unipolar and bipolar affective disorders found that the affective disorders group
performed significantly better than schizophrenics on the WCST test. This finding has
been replicated by at least one (Mojtabai et al. 2000), but not all later studies (Young et
al. 1998;Verdoux and Liruad 2000). No studies identified compared schizophrenic and
bipolar subjects on measures of planning ability.
2.1.6 Attention and psychomotor performance
Heinrichs and Zakzanis (1998) reviewed four attentional variables (Digit Span,
Continuous Performance, Stroop, Trail Making) in their meta-analysis of
neuropsychological test scores in schizophrenia. Digit span would generally now be
regarded as a test of working memory and the Stroop test would be regarded as a test of
executive function (probably suppression/control, see Lezak 1995). The trail making test
had an average effect size in schizophrenic subjects compared to controls of 0.95 (part
A) and 1.07 (part B), although the confidence intervals overlapped zero (Heinrichs and
Zakzanis 1998). Subsequent studies have however found that Trail Making Test scores
are lower in schizophrenic subjects than in controls (Grawe and Levander 1995;Liddle
and Morris 1991;Wolwer and Gaebel 2002), and are reduced in the unmedicated close
relatives of affected subjects (Pogue-Geile et al. 1991;Franke et al. 1993).
The Span of Apprehension Test (SPAN, Arsanow et al. 1991), Continuous
Performance Test (CPT, Cornblatt et al. 1988) and their many forms are probably the
most often used standardised tests of attention in schizophrenia research. The tests
involve the identification of a target stimulus from a background of other stimuli. More
than forty studies using the CPT have been conducted in schizophrenic subjects
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(Cornblatt and Keip 1994). Studies using the classic CPT consistently find differences
between schizophrenic subjects and controls (Mirsky et al. 1992), but it tends to be the
task's more challenging versions which find impairments in the healthy relatives of
affected patients (e.g. Nuechterlein 1983;Cornblatt and Keip 1994).
Studies of patients with bipolar disorder reveal that stable bipolar subjects have
significant impairments on the CPT (and its variants) and SPAN which are greater than
controls, but less than that of schizophrenic subjects (Arsanow and MacCrimmon
1981;Docherty et al. 1996;Addington and Addington 1997;Clark et al. 2002). Other
studies, using acutely symptomatic patients, have found that bipolar subjects perform as
poorly as schizophrenic subjects (Strauss et al. 1984) and that those bipolar patients who
perform the worst are more likely to have psychotic symptoms (Albus et al. 1996).
Studies using the Trail Making Test also find that bipolar subjects consistently score
worse than controls (Ferrier et al. 1999;Mojtabai et al. 2000), but although symptomatic
bipolars perform better than symptomatic schizophrenic patients in the acute phase of
illness (Mojtabai et al. 2000;McGrath et al. 1997), the difference was lost after 4 weeks
of medical treatment in one study (McGrath et al. 1997).
The Digit Symbol Substitution Test (DSST, Kaplan et al. 1991) and the Reaction
Time Test (RT, e.g. Lezak 1995) are tests of psychomotor performance which tend also
to correlate highly with measures of attention (Spreen and Strauss 1991). Digit Symbol
test scores appear to be impaired in schizophrenia (Jogems-Kosterman et al.
2001;Brebion et al. 2000) although it is still unclear whether there are abnormalities in
bipolar disorder and whether the test can discriminate between the disorders. Reaction
Time test scores are also reduced in schizophrenic (Krieger et al. 2001;Jogems-
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Kosterman et al. 2001;Ngan and Liddle 2000;Gale and Holzman 2000) and bipolar
subjects (Strauss et al. 1987;Pierson et al. 2000) and there is also an unreplicated study
which finds that reaction time may have the ability to discriminate between
schizophrenic and bipolar subjects when used in alongside the CPT (Fleck et al. 2001).
Fleck et al (2001) studied a sample of 40 patients (20 bipolars with psychotic features,
20 schizophrenics) and 20 non-related healthy controls. Using discriminant function
analysis, the diagnoses of each patient an could be made with 80% accuracy using a
weighted combination of three reaction time variables reflecting psychomotor speed.
Since the study did not confirm their results using the techniques outlined at the end of
chapter 1 (e.g. jacknifing, confirmation with a second sample) the results should be
regarded as preliminary.
2.2 Neuropathology
Neuropathological investigations of schizophrenia began in the hope that an
identifiable lesion would be identified in the brain of affected people. Early studies using
primitive histological techniques (Alzheimer 1897;Wernicke 1900) were often positive
and lacunae or neuronal atrophy was frequently described in the histological specimens
of affected subjects (Bruton et al. 1990). These early studies were conducted when the
need to control for fixation and other artefacts was not appreciated and were
contradicted by later, more methodologically rigorous studies (Lewis 1923;Dunlap
1924). Neuropathological study of schizophrenia was given fresh impetus following
Johnstone's (1976) finding of ventriculomegaly on computed tomography. The notion
that there may be a neuropathological abnormality in schizophrenia was based on many
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strands of evidence. Firstly, people with schizophrenia showed a tendency to have static
or progressive abnormalities in terms of symptoms. Secondly, it was also appreciated
that cognitive impairments were also present. Thirdly, some organic brain syndromes
were known to present with psychotic symptoms and finally, case studies of people with
focal brain lesions also occasionally showed cognitive and behavioural abnormalities
similar to schizophrenic subjects.
Post-mortem studies have been relatively infrequent in bipolar disorder. This is
perhaps because subjects show a tendency to remit over time and neuroimaging studies
have not, until recently, begun to show evidence of brain abnormality. However,
advanced techniques (e.g. immunological techniques, mRNA measurement) have the
potential to reveal subtle degrees of abnormality which may not be apparent to the naked
eye or using conventional staining techniques.
2.2.1 Methodological considerations
Diagnostic validity and heterogeneity, medication effects, selection of controls
and blind assessment are all methodological issues which, in common with all
psychiatric brain research, may limit the validity of study findings. However, in addition
to these general problems, neuropathological studies face other specific methodological
difficulties.
The diagnosis of psychiatric patients whose brains become available for
neuropathological research will rarely have been confirmed in life using operational
criteria, except perhaps in disorders of late life such as Alzheimer's disease or disorders
related to Parkinson's disease. Detailed case notes may not be available after death in
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some cases limiting any further diagnostic clarification. Where case notes are available,
it is sometimes possible to apply modem diagnostic criteria, and schedules exist for this
very purpose (Zalcman and Endicott 1983). However, the tendency for diagnostic
confusion with other disorders is perhaps greater than for studies carried out on live
volunteers. Unsuspected neuropathological abnormalities may be discovered at post¬
mortem, some of which may be related to the cause of death and indeed some may
suggest that the psychotic illness manifested was secondary to an undiagnosed
neurological condition. In either case, the potential of such findings to cloud the micro
and macroscopic picture is significant. Furthermore most patients develop schizophrenia
in their 3rd decade and often do not die until their 7th or 8th. Much may happen over the
intervening 40-50 years including physical treatments, some which have been out of
favour for many years, substance misuse and intercurrent disease.
The decline in autopsy rates internationally has limited the numbers of brains
which can be collected for research. This problem has been compounded in the UK by
several widely publicised scandals regarding the inappropriate acquisition of human
brains without the consent of the individual or their relatives. Prospective identification
of individuals willing to donate their brains to psychiatric research might improve the
rate at which brains may be collected and also improve the quality of diagnostic
information collected. However, to the best of my knowledge, no scheme of this sort has
begun for 'functional' psychiatric illness, although prospective brain collections do exist
for Alzheimer's disease. Unfortunately, in the current political climate, there seems little
prospect of developing new collections.
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The quality of brain tissue obtained is dependent upon many factors. In addition
to the confounding effects of medication, overdoses of prescribed medication and the
use of illicit substances both have the potential to cause significant brain injury. Drug
analysis of blood, urine or hair is possible but is rarely performed. Other peri- and post¬
mortem factors also influence the quality of brain tissue (see figure below) and their
effects may be greater than those of the mental illness under study.
Figure 2.2.1: Factors influencing tissue quality in post-mortem studies
Mode of death
Time from death to refrigeration
Time from refrigeration to fixation or freezing
The duration of fixation
Methods of embedding and fixation
2.2.2 Brain dimensions
Brain weight in schizophrenia has recently seen subject to a systematic review
and meta-analysis (Harrison et al. 2003) in which published and unpublished studies
comparing schizophrenic subjects to normal controls were identified. Seventeen studies
of 540 schizophrenics and 794 comparison subjects were located which recorded whole
brain weight on adult patients to whom operational criteria had been applied. After
controlling for age, sex and series-diagnosis interactions, brain weight in schizophrenic
subjects was found to be approximately 24g lighter than in control subjects. Brain
weight was lower in women than in men and found to decrease in all groups at a rate of
approximately 2.4g per year. The effect size was not related to duration of illness or to
age at death although patients with a later age of onset had significantly lower brain
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weights in an exploratory analysis. There is evidence from this systematic, and other
non-systematic reviews that the methods used in each study varied considerably. The
number of post-mortem studies reporting brain length or width is somewhat more
disappointing (Bruton et al. 1990). The few studies that exist appear to suggest that brain
length is reduced.
In contrast to schizophrenia, no studies could be identified which measure brain
weight in a sample of people with bipolar disorder.
2.2.3 Frontal lobes
Few studies have examined the size or weight of the prefrontal cortices, in either
schizophrenia or bipolar disorder. However, in schizophrenia there is some evidence that
the neuronal morphology of frontal neurones is abnormal. Several studies have found a
decrease in neuronal density in layers II, III and VI of the cortex (Benes et al.
1986; 1991; 1993) and a reduction in neuronal size (Benes and Bird 1987;Rajkowska et
al. 1998). However, there are several contradictory studies and some suggestions that
particular types of neurones may be affected (Selemon et al. 1995;Akbarian et al.
1996;Anderson and Rutledge 1996). Brodmann's areas 4, 10 (lateral) and. 24 (anterior
cingulate) appear to be the most consistently implicated areas.
Most neuropathological studies of the frontal cortex in bipolar disorder have
considered the anterior cingulate cortex specifically, based primarily on the functional
imaging data which also implicates this region and a structural study also finding a
volumetric deficit in the sub-genual prefrontal cortex (Drevets 2001). Drevets and
colleagues (Ongur et al. 1998) subsequently found reductions in BA24 (sub-genual)
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volume and in glial density. A further study of brains from the Stanley foundation found
that glial density and number was reduced in both bipolar and unipolar disorder, but not
in schizophrenics. Reductions were also found in the orbitofrontal cortex. Bouras et al
(2001) also replicated these findings, but found reductions only in the dorsal part of
BA24. His study also found that neuronal density and lamina depth was reduced but did
not replicate reductions in glial density. Cotter (2001) was the first study to fail to
replicate these findings, although non-significant trends in the same direction were
found. Benes et al (2000;2001) also found a reduction in neuronal density in BA24
(rostral, pre-genual part) but no differences in glial density or neuronal size. Molecular
studies of the same region find reductions in growth associated protein (GAP-43),
dendritic microtubule associated protein and synaptophysin all of which point to a
synaptic pathology (Eastwood and Harrison 2001;Bouras et al. 2001). Reductions in
both glial and neuronal density have been found in other parts of the prefrontal cortex,
including BA9 (Rajkowska et al. 1999;Cotter et al. 2002).
2.2.4 Temporal lobes
Several neuropathological studies support the finding of reduced temporal lobe
volume in schizophrenia (Bogerts et al. 1985;1990;Brown et al. 1986;Falkai and Bogerts
1986;1988;Altshuler et al. 1990;Vogeley et al. 1998). Studies find reductions in
neuronal number or density in cortical areas (Akbarian et al. 1993), although the
hippocampal complex and amygdala have been subject to greater study. Studies
consistently find reductions in neuronal cell size, number and density within the
hippocampus (Falkai and Bogerts 1986;Jonsson et al. 1997b) and entorhinal cortex
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(Falkai et al. 1988;Krimer et al. 1997) with only a couple of equivocal or contradictory
studies (Christison et al. 1989;Pakkenberg 1993b). These studies have been extensively
criticised in the neuropathological literature (Harrison 1999) and the most
methodologically rigorous study to examine this region found no differences in neuronal
cell number or density (Heckers et al. 1991a). Disarray of hippocampal neurones in
schizophrenia has also been found in some studies (Kovelman and Scheibel
1984;Conrad et al. 1991) although these studies have implicated separate subflelds of the
hippocampus and have not been consistently replicated (see Harrison 1999 for a review).
In contrast to schizophrenia, temporal lobe structures have received little
attention in bipolar disorder. Only two studies have compared more than four patients
with bipolar disorder to controls (Damadzic et al. 2001;2002), both by the same group,
and only glial fibrillary acidic protein (GFAP) positive astrocytes were considered in the
earlier of the two. No differences were found between the groups.
2.2.5 Subcortical structures
In parallel to structural imaging findings in schizophrenic subjects,
neuropathological studies have also found macroscopic decreases in thalamic size
(Pakkenberg 1990;1993a;Danos et al. 2002;2003) and increases in basal ganglia
(Heckers et al. 1991b). The same studies also found cytoarchitectural evidence for
decreased numbers of neurones in the dorsomedial nucleus and anteroventral nuclei,
both of which project primarily to the prefrontal cortex. The evidence for other
subcortical structures in bipolar disorder is too weak to make any conclusions (Vawter et
al. 2000;Harrison 2002) but there is limited evidence that hypothalamic neurones may be
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increased in number and raphe neurones may be reduced in mixed bi and unipolar
samples (Zhou et al. 2001;Purba et al. 1996;Baumann and Bogerts 2001).
2.3 Pneumoencephalography
The technique of pneumoencephalography was introduced by Dandy in 1919 and
its main use became the investigation and diagnosis of possible hydrocephalus.
Pneumoencephalography was also used to detect cerebral atrophy and ventricular
enlargement in other neurodegenerative conditions and was employed fruitfully as a
research tool in schizophrenia for this reason.
2.3.1 Methodological considerations
Pneumoencephalography involved the introduction of air into the subarachnoid
space by lumber puncture, and allowing it to ascend to outline the ventricular system and
basal cisterns of the brain where it could be imaged using a plain x-ray of the skull
(Lishman 1998). The technique was painful, was associated with a significant mortality
and could cause tentorial herniation in the presence of space occupying lesions. Even
cerebral atrophy itself could be worsened, at least temporarily, by this technique. The
spatial resolution of pneumoencephalography is poor compared to MRI and modem CT
and the technique does not allow the direct visualisation of brain substance or allow
images to be acquired in several different planes. Because of safety concerns the
American Rotengen Ray Association stated that the use of pneumoencephalography on
healthy controls was unethical in 1929 which led in part to the demise of the technique
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and of neuroimaging in psychiatry until more advanced in vivo techniques became
available with the advent of CT (Johnstone et al. 1976).
2.3.2 Findings in affected patients
The first pneumoencephalography study in psychiatry was published by Jacobi
and Winkler (1927) and showed 'unmistakable hydrocephalus' in the brains of people
with chronic schizophrenia. The findings were replicated by other groups with very few
negative or equivocal results.
Table 2.3.2: Pneumoencephalography studies in the functional psychoses
Study Summary of findings
(Jacobi and Winkler
1927)
Internal hydrocephalus in 18 out of 19 schizophrenic subjects
(Moore et al. 1933) Increased ventricular and cisternae in 21 of 60 schizophrenics
(Lemke 1935) Ventricular dilatation found in 50% of schizophrenics and
12% of controls
(Borenstein et al. 1957) 118 of 134 schizophrenic cases described as abnormal
(Huber 1957) 135 of 195 schizophrenics had dilated ventricles. Dilated
ventricles were more common in those with defect state
(Haug 1962) Ventricular enlargement greater in schizophrenics than
controls and associated with poor outcome
(Nagy 1963) 260 cases (mixed schizophrenia and manic-depressive
illness). 58% of schizophrenics and 28% manic-depressives
showed cerebral 'atrophy'.
(Storey 1966) No differences found between schizophrenics and controls.
Scans were performed as investigations for suspected
neurological disease.
(Asano 1967) Lateral and 3 rd ventricular enlargement found in
schizophrenic subjects. Greatest in 'nuclear' group of
schizophrenics.
(Hunter et al. 1968) Lateral ventricular enlargement in 15 of 27 cases with a
tendency to L>R
(Young and Crampton In schizophrenics referred for investigation of suspected
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1974) neurological disease, 'atrophy' found in 24 of 36 patients.
(Haug 1982) Qualitative ventricular abnormalities found in 58 of 101
chronic schizophrenics reported previously by Haug (1962)
Ventricular enlargement was repeatedly found in schizophrenics without
suspected neurological disease. In a single study (Nagy 1963) comparing schizophrenic
subjects with manic-depressive subjects, cerebral atrophy was reported in a substantial
proportion of patients with affective illness.
Pneumoencephalography increased interest in the neuropathology of
schizophrenia and led to further studies with more advanced techniques. It had little
effect on the study of bipolar disorder. This is to some extent surprising since many
studies included people who were simply 'psychotic' or used outdated criteria which
were not operationally based. Therefore, many groups of individuals described either as
'psychotic' or schizophrenic' would have been likely to include people with bipolar
disorder as it is now defined.
2.4 Computed tomography
2.4.1 Methodological considerations
Computed Tomography (CT) uses a thin x-ray beam which rotates 360 degrees
around a patient in order to obtain an axial image of the underlying structures. The
absorption of x-rays is detected at each point on the trajectory of the beam and the
resultant structure reconstructed by back projection. Whereas conventional x-rays are
unable to visualise white/grey matter contrast, this is improved in CT by allowing the
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range of x-ray absorption to be widened to a stage where it can be appreciated by the
human eye.
CT scans are subject to a number of important artefacts which limit their
application to psychiatric research. If the x-ray beam paths do not intersect as they trace
a 360 degree path around the patient then different intensity values may wrongly be
assigned to the same voxel causing streaking. Probably the most common cause of this
artefact is patient motion although similar problems can be caused by equipment
misalignment. Artefacts are also created by objects such as bone or fillings which have
high x-ray absorption. These structures tend to absorb low energy x-ray photons from
the source and lead to the average energy of the transmitted signal increasing. This
phenomenon is known as beam hardening and can also lead to 'streaking' in the
resulting images. A final and important source of artefact on a CT image is the effect of
'partial voluming'. Each 3-dimensional volume of tissue in a patient's brain is converted
to a two dimensional pixel on a photographic plate or computer screen. Where image
pixels lie at the boundary of two tissue types then the resulting signal from that pixel
will tend to represent weighted mean attenuation value from each tissue. This leads to
poorer spatial resolution and contrast and is greatest at the periphery of the patient where
the x-ray beam is at its widest.
Technical problems in terms of the measurement techniques used have also been
a limitation to the use of CT. Although more recent studies have used semi-automated
methods to trace regions using the original CT data, earlier studies involved tracing over
the structures on photographic film, and were prone to lower reliability. However, both
techniques were relatively subjective compared to modem methods. The ventricle to
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brain ratio was commonly used as a measure of ventricular size/area, often traced on a
single section of brain. This assumed that there was a linear relationship between brain
and ventricle size, and that schizophrenic patients had similar head sizes to that of
healthy controls. There is evidence that neither assumption was correct (See Lewis 1990
for a review of this area).
In addition to the technical limitations of this technique, each CT scan is
associated with a significant exposure to ionising radiation. The health consequences of
these exposures (e.g. foetal teratogenesis, neoplasm, genetic damage to germ cells) has
generally limited the use of CT in children, adolescents, women of childbearing age and
also in repeated measurements of adult subjects of both sexes.
2.4.2 Findings in affected patients
The first controlled study of psychiatric patients using CT was carried out at a
time when psychosocial theories of schizophrenia were very fashionable (Johnstone et
al. 1976). In her study of 17 chronic schizophrenics and 8 normal controls, lateral
ventricles were significantly larger in affected patients. Between 1976 and 1990 there
had been a further 30 CT studies, although most have also concentrated on the
measurement of cortical atrophy, ventricular size, and their clinical associations. Two
studies specifically addressed cerebral asymmetry and both reported a greater frequency
of fronto-occipital asymmetry in schizophrenics than in normal controls (Naeser et al.
1981;Luchins et al. 1982). Ventricular enlargement was shown to be associated with
neuropsychological impairment (Donnelly et al. 1980;Johnstone et al. 1978), negative
symptoms (Andreasen et al. 1982;Takahashi et al. 1981), poor premorbid adjustment
83
(Pearlson et al. 1985) and extrapyramidal syndromes (Owens et al. 1985). Physical
treatment including medication was shown not to be a confounder for the relatively
consistent findings of these studies (Owens et al. 1985).
CT has also been applied to the study of unipolar and bipolar affective disorders
(Beyer and Krishnan 2002). At least nine studies have specifically addressed ventricular
enlargement and cerebral atrophy in bipolar disorder, although many more studies have
compared individuals with unselected affective disorders to both healthy controls
(Targum et al. 1983;Shima et al. 1984) and schizophrenics (Weinberger et al.
1982;Schlegel and Kretzschmar 1987a;1987b). Results in bipolar subjects are less
consistent than in schizophrenia although the majority also find ventricular enlargement
compared to controls (see table 2.4.2).
Table 2.4.2: CT studies in bipolar disorder and manic-depressive illness
Study Sample Summary
Pearlson and Veroff (1981) 16MDP
22 SCZ
35 CTRL







Enlarged VBR in SCZ and BPD
compared to CTRL
Tanaka et al (1982) 9 BPD
31 MDD
40 CTRL
BPD showed cortical 'atrophy' in
temporal and occipital cortices at
an earlier age than CTRL
Rieder et al (1983) 19 BPD
15 SCZAff
28 SCZ
No significant differences between
groups. Each group showed
qualitative cortical atrophy and
ventricular enlargement
Pearlson (1985) 19 SCZ
27 BPD
27 CTRL
BPD had larger ventricles than
controls. Increased VBR associated
with greater hospitalisation and
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unemployment
Dewen et al (1988) 26 BPD
22 CTRL
Enlarged 3r ventricle, increased •
white matter density and increased
signal from caudate and thalamus
in BPD
Andreasen (1990) 24 BPD
27 MDD
75 CTRL
BPD had larger ventricles than
controls (males only)
Young et al (1999) 30 BPD
18 CTRL
Greater cerebral 'atrophy' in BPD
compared to controls but no
difference in ventricular size.
^defined by the presence of a manic episode, BPD - bipolar disorder, MDP - manic-
depressive psychosis, MDD- major depressive disorder, CTRL - controls
2.5 Structural magnetic resonance imaging
The brain images created by MRI arise because of the properties of the
component tissues, and in particular, the magnetic properties of protons (hydrogen
nuclei).
When a tissue is placed in a magnetic field (Bo), a proportion of the hydrogen
nuclei will align with the magnetic field and precess around it, at a frequency known as
the Lamor frequency, at an angle to the direction of the magnetic field. The hydrogen
nuclei will not be in phase with one another (i.e. at the same frequencies, as if 'marching
in step with one another', Suckling and Bullmore 2000) and the tissue itself will generate
no coherent signal under these conditions. When a radiofrequency pulse is applied to the
tissue, the spinning nuclei tip further from the direction of the field and spin briefly in
phase with one another. Over time the spins of the respective nuclei to return to their
original state both by returning to their original angle of spin before the field was applied
and also by de-phasing with one another. The tendency for nuclei to return from their
'tipped state' to their original angles occurs exponentially and can be summarised using
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a rate constant called Tl. The tendency for nuclei to de-phase from one another again
also occurs exponentially at a rate which can be expressed using a constant called T2.
Figure 2.5a: Shows the increase in displacement of hydrogen nuclei
following the application of a radiofrequency pulse.
Figure 2.5b: The phasing of hydrogen nuclei after the application of a brief
radiofrequency pulse. The tendency for protons to return (decay) to their
original (out of phase) state is summarised using the T2
constant
Before RF pulse After RF pulse
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T1 is sometimes known as the spin-lattice rate constant while T2 is sometimes
known as the spin-spin constant. Measuring the decay constants T1 and T2, as well as
the overall proton density (PD) has many clinical applications as the values reflect the
underlying anatomy and also physiology of the brain. Tl, T2 and PD signals at each unit
of brain volume (voxel) can be presented as a grey-scale image with the highest signals
represented as white voxels and low signals as black. However, a single radiofrequency
pulse as described above would produce signals from brain tissue decaying as a function
of Tl, T2 and proton density (PD) and also from brain tissue on many different slices.
For this reason, sequences have been devised which generate signals that are highly
dependent upon either the Tl or T2 decay constants or on PD and which are slice
selective, acquiring image data from one slice of brain tissue at a time. The most
common sequences used are the spin-echo sequence and gradient echo. Many other
sequences exist (e.g. diffusion weighted, T2* etc).
2.5.1 Spin-echo sequence
Spin-echo sequences involve the application of a radiofrequency pulse at time 0
and, after a time TE/2 later, an inversion pulse of 180° to displace those protons that
have decayed most from their "excited' state. Images can be acquired during the period
between the first two pulses, or after the 180° pulse and the beginning of the next
sequence. By varying the timing of the image acquisition, the echo time (TE) and the
repeat times, PD, Tl or T2 weighted images can be acquired from the same imaging
sequence.
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Figure 2.5.1: Typical spin echo scanning sequence. RF refers to radiofrequency
pulse, S to signal and TR and TE refer to repeat and echo times respectively
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Magnetic field gradients are also applied during the scan in three (x, y, z) dimensions.
2.5.2 Gradient-echo
A typical gradient echo sequence is shown below. The first event in the
sequence is the application of a radioffequency pulse at time 0. This pulse can flip the
protons by an angle, usually between 5 and 90 degrees, known as the 'flip angle'. At a
given time (TE) after the radiofrequency pulse the image signal is acquired. After a
further interval, the radioffequency pulse is reapplied and the sequence is repeated. The
time between cycles is called the repetition time (TR).
The flip angle, TR and TE together determine the scan time, image resolution
and T1 or T2 weighting. Smaller flip angles phase spinning protons but do not displace
them very far from their original axes. The images acquired from these sequences tend
therefore to be T2 weighted. Conversely, larger flip angles tend to produce T1 weighted
images. The gradient echo sequence can also be modified by the application of a 180°
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pulse before the subsequent cycles. This 'pre' pulse allows the faster acquisition of T1
weighted images using low flip angles. These sequences are sometimes called
magnetisation prepared gradient echo sequences (MPRAGE).
Figure 2.5.2: A gradient echo scanning sequence. RF refers to
radiofrequency pulse, S to signal and TR and TE refer to repeat and echo
times respectively
Magnetic field gradients are also applied during the scan in three (x, y, z) dimensions.
2.5.3 Measurement of tissue signal
The image itself is created from the measurement of energy 'released' from
tissue by several radiofrequency detectors located in a coil placed around the head of the
subject. Images are created using Fourier analysis of this information to make a 'back
projection' of the properties of the tissue which gave rise to the signal in the first place.
2.5.4 Image acquisition
The first MRI study of schizophrenia was conducted by Smith et al (1984) with
only 9 schizophrenic subjects and 5 controls using a single unreliably positioned slice.
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No significant differences in cortical areas were found between the groups. The methods
of MRI studies have greatly advanced over the last 20 years in parallel with advances in
the technology of image acquisition and analysis.
Parameters influencing MRI image quality
• Magnet strength
• Field inhomogeneity
• Time to echo, repeat time, flip angle etc
• Slice thickness
• Contiguous vs. interleaved vs. spaced slices
• Plane of acquisition
The main factors influencing image quality are shown in the box above (Beck et
al. 2002;Davidson and Heinrichs 2003). Greater magnetic strength has the effect of
increasing signal to noise ratio and provides greater tissue contrast. However, magnetic
field strength is usually maximal at the centre or core of the magnet and decays slightly
at distances further away from the centre. This 'field inhomogeneity' can lead to
differences in tissue contrast and quality which increases noise and may lead to
unreliable results. Conventionally, field inhomogeneity is controlled for by scanning an
object of homogeneous density and correcting the images for any inhomogeneity
observed in the object. The object used is typically a fluid phantom which bears little
resemblance to a complex structure like the brain. Slice thickness is an important
consideration in MRI studies of the brain because thinner slices give rise to greater
resolution and brain tissue present at one anatomical level is separated from that at
another level more effectively. A signal in one plane of brain tissue from two adjacent
regions is sometimes called a 'partial volume'. Early sMRI studies often acquired
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images from several slices of the brain but left interslice gaps of the brain from which no
data was acquired. This meant planar or volumetric data on a brain region was often
incomplete and potentially inaccurate. Generally brain 'slicing' is now contiguous.
Finally, volumes or areas are commonly acquired as T1 weighted coronal images and,
for most purposes, this is probably adequate. However, some regions (e.g. the
hippocampus) are better visualised in an oblique or transverse plane, parallel to the long
axis of the structure.
2.5.5 Image Analysis
Methods of image analysis





o Statistical parametric mapping (SPM)
o Other methods (e.g. those based on fuzzy logic)
The results from structural magnetic imaging studies are influenced by the
method of image analysis as well as the method of image acquisition. Until the last five
years studies have mainly used semi-automated methods which extract the brain from
the surrounding tissues. A researcher then manually traces around regions of interest
with a cursor with the aid of a tissue contrast facility. Tracings are usually made with the
aid of an anatomical atlas and using previously established methods for delineating brain
structures with operationalised criteria. Volumes are then calculated by multiplying each
regional area by the slice thickness, summing all slice volumes over the brain region in
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question. This technique involves a certain amount of subjectivity and it is essential to
first establish adequate inter-rater and intra-rater reliability. Large structures (e.g. whole
brain, temporal and frontal lobes) have high measurement reliability whereas smaller
structures (e.g. hippocampus, amygdala, caudate) are generally subject to greater
measurement error. In an attempt to measure smaller volumes more reliably parcellation
techniques have been developed. These generally involve tracing in three dimensions
simultaneously although this technique is very time consuming and subjective
judgements continue to be necessary (Caviness et al. 2000).
An alternative approach to image analysis has been developed called voxel based
morphometry (VBM). VBM involves the transformation of each brain into a common
three dimensional space and segmentation into grey and white matter and cerebro-spinal
fluid (CSF). Differences in e.g. grey matter density are then computed by comparing
these 'normalised' brains from each group on a voxel by voxel basis (see chapter 6 for
details of this and other automated techniques). VBM avoids subjective judgements
about where a region of interest begins and ends, although the results obtained reflect
differences in tissue density rather than volume and cannot be interpreted with the same
ease as a mean difference in volume. However, the results obtained from samples using
both region of interest analysis and VBM suggest that the results are generally similar
(Wright et al. 1999;Lawrie et al. 2001 ;Job et al. 2002 and in press). VBM has the
additional advantage in that very small structures can be investigated.
2.5.6 Patient and control selection
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In sMRI studies of patients of schizophrenia, the usual study design is to
compare a sample of cases with unaffected controls, healthy relatives or patients with
another psychiatric disorder. The primary interest of such a study is to examine whether
the volume of a brain region differs between groups. Where a significant difference is
shown, the difference is usually attributed to the diagnosis. However, the many
differences between controls and established patients with schizophrenia mean that
anatomical differences may be attributable to treatment, the effects of an ongoing
disease process or the effect of a risk factor. A more rigorous design is to follow
unaffected patients prospectively before and as they become unwell. This is rarely
feasible (see later), and for these and other practical reasons the predominant design, as
in the rest of medicine, has been the case-control study.
Case-control studies are however susceptible to several sources of bias. Firstly,
patients and controls may be dissimilar in many ways, in addition to their diagnostic
status. Patients recruited from hospitals are often those with the most severe illnesses,
greatest social adversities and complicating factors e.g. substance misuse. The
recruitment of socially comparable well controls is not easy. Non-schizophrenic
psychiatric or neurological controls can be used as an alternative control group, being
more similar than groups of well volunteers in terms of potential confounders of brain
volume such as social class and educational level for example. Healthy controls are
however almost always required. It is sometimes possible to recruit healthy controls
from the non-genetic relatives and social networks of the patients themselves, thereby
establishing both a more generally comparable control group and one which may be
more committed to the research in question (having first hand knowledge of the effects
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of psychosis). However, studies using this design run the potential problem that the
controls are themselves atypical of unaffected people from the general population. Many
studies attempt to match schizophrenic patients to one or more controls for known
influences on brain volume (e.g. age, sex, IQ). Matched designs have great value when
the potentially confounding variables are well understood and can be measured
accurately, but this may well not be the case for schizophrenia. IQ for instance has been
shown to be both a risk factor and a state indicator (Cosway et al. 2000) such that
matching patients with controls of equal current IQ might effectively select intellectually
inferior controls and vice-versa for premorbid IQ matching. There is also the danger of
over-matching patients and controls on variables which are important in the
pathogenesis of schizophrenia itself (i.e. are on the causal pathway).
An ideal approach might be to randomly select affected subjects and healthy
controls from a population. This is however easier said than done and still has hazards.
Population sampling (e.g. from the electoral register) may select subjects who are
relatively affluent and patients who are atypical of patients in general. Ethics committees
might be reluctant to agree to the unsolicited approach of potential study participants and
some participants will inevitably refuse to be scanned, but the design has obvious
theoretical advantages over the aforementioned. I am unaware of any studies using this
approach in sMRI studies of functional psychiatric illness.
In practice, the influence of methodological and descriptive variables on the
results obtained from case control studies has been examined by very few studies. One
study that has assessed the influence of methodological confounds on observed effect
sizes is a study by Davidson and Heinrichs (2003) using meta-analytic methods. This
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study found that sample size was negatively correlated with effect size overall,
suggesting that publication bias may be an important source of bias in imaging studies of
schizophrenia (but see Lawrie and Abukmeil 1998;Wright et al. 2000). In addition, the
proportion of right handed males were also significant confounds (but see Nelson et al.
1998). Slice thickness and time to echo were also related to observed effect sizes,
although magnetic strength was not. This study suggests that methodological issues are
important sources of potential bias in sMRI research. Nonetheless, their effects are not
as large as those of the illness.
2.6 Structural MRI findings in affected patients
Early sMRI studies were generally small in size and used area measures such as
the ventricle to brain ratio (VBR). sMRI methodology has greatly improved and, in
particular, thin contiguous slicing through the brain has facilitated accurately measuring
regional brain volumes. Studies consistently show differences between controls and
people with schizophrenia and two meta-analytic reviews of more than 50 individual
studies have summarised our knowledge of the location and extent of these regional
differences (Lawrie and Abukmeil 1998;Wright et al. 2000).
2.6.1 Whole brain
Whole brain volume in schizophrenia has been examined in multiple studies and
reviewed in several systematic reviews and meta-analyses. Although whole brain
volume is reduced compared to controls when studies are combined (Lawrie and
Abukmeil 1998;Wright et al. 2000), most individual studies fail to find a significant
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difference between schizophrenics and controls (Shenton et al. 2001). The effect size
appears to be around -0.31 for grey and -0.19 for white matter. This corresponds to an
average volume reduction of 4% in grey matter (95%CI 1-6%) and 2% in white matter
(95%CI 0-5%) (Wright et al. 2000). Whole brain volume reductions appear to be more
equivocal in first episode studies, with the majority of studies failing to find any
differences (Bilder et al. 1994;Velakoulis et al. 1999;Lawrie et al. 1999) with only an
occasional exception (e.g. in adolescents, James et al. 1999).
Several reviews of bipolar disorder consider the evidence for whole brain volume
reductions compared to controls (Jeste et al. 1988;Elkis et al. 1995g;Videbech
1997;Bearden et al. 2001) . In view of the fact that they include substantially the same
primary studies it is surprising that they come to differing conclusions. Elkis (1995f) in a
quantitative review of the literature found that sulcal prominence was greater in bipolar
subjects compared to controls (effect size d=0.42). However, it is far from clear which
measures of sulcal prominence were used. Other reviews in this area are more cautious
in their interpretation of the literature (Bearden et al. 2001) but point out that almost all
primary studies have had negative results. The only systematic review and quantitative
meta-analysis in this area which sets clear inclusion and exclusion criteria found that
there were no significant differences in brain volume between bipolar subjects and
controls (7 studies, 160 bipolars, 215 controls, d=0.04, 95%CI -0.17 to 0.25 Hoge et al.
1999).
Since the numbers of studies to examine whole brain volume in subjects with
schizophrenia or bipolar disorder are relatively few, it is not surprising that the evidence
comparing schizophrenia to bipolar disorder is weak. A single meta-analysis has
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compared schizophrenic and affective disordered subjects from studies involving direct
comparisons. (Elkis et al. 1995e). The review concludes that there is a statistically
significant difference between schizophrenics and controls, with schizophrenics having a
larger degree of sulcal prominence. It is however unclear which measure of sulcal
prominence they use and many of the included studies also recruited unipolar patients. It
is also possible that sulcal prominence does not reflect an underlying reduction in whole
brain volume. From an indirect comparison of two reviews by the same group, (Ward et
al. 1996;Hoge et al. 1999) the authors conclude that whilst schizophrenic subjects have
significantly smaller whole brain volumes than controls, that no such difference is found
in bipolar subjects. They present a graph of the two meta-analyses demonstrating that
the confidence intervals for each effect size barely overlap further suggesting that whole
brain volume is significantly different in schizophrenia and bipolar disorder.
There appears to be some doubt as to whether bipolar disordered subjects have
whole brain volume reductions compared to controls. However, if present, it is likely to
be somewhat less than found in schizophrenia. Since the publication of the only
quantitative review to directly compare bipolars and schizophrenics, new studies have
emerged which use higher magnetic field strengths, producing better images which have
then been analysed using reliable semi-automated methods. Some of these studies have
found whole brain reductions in bipolar subjects (Lim et al. 1999) and necessitate a
further quantitative review of this area (see below).
2.6.2 Ventricles and CSF
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An increased ventricle to brain ratio (VBR) was one of the first standardised
measures to be used in psychiatric neuroimaging (Johnstone et al. 1976) and the results
of studies using this measure showed increases in VBR (DeQuardo et al. 1996).
However, the measure conflated whole brain width with ventricular width and provided
results which had low reliability (Arndt et al. 1991). Most MRI studies measure
ventricular size separately for all ventricles and occasionally divide the lateral ventricles
into their inferior hom, anterior hom, and body.
In schizophrenia, the lateral and third ventricles appear to be larger than in
controls (Lawrie and Abukmeil 1998;Wright et al. 2000;Shenton et al. 2001). Wright et
al (2000) demonstrated that the bodies of the left and right ventricles contributed the
largest amount to this effect being increased in volume by about 48% compared to
control subjects and the frontal homs contributed the least. The fourth ventricle showed
a non-significant increase of 7% in schizophrenic compared to control subjects. Studies
of first episode patients and healthy relatives tend to confirm that differences in lateral
and third ventricular volumes are present at first presentation (Barr et al. 1997;DeLisi et
al. 1991; 1998) and are related to genetic liability being present in unaffected close
relatives (Seidman et al. 1997;Lawrie et al. 2001;McDonald et al. 2002).
Table 2.6.2: Increases in ventricular size in schizophrenic subjects
compared to controls. Data from Wright et al (2000)
Ventricular Effect size % Increase compared to controls
Region (Cohen's d) mean 95%CI
Lateral ventricle (L) 0.51 130 120-141
Lateral ventricle (R) 0.39 120 113-128
Third ventricle 0.59 126 119-134
Forth ventricle 0.21 107 96-119
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In bipolar disorder some early studies found that lateral ventricular size was also
increased compared to healthy controls (Swayze et al. 1990a;Fiegiel et al. 1991). Not all
studies were positive however (Johnstone et al. 1989), and some studies found that
ventricular enlargement was greater in male patients or those with psychotic symptoms
or poor early outcomes (see Bearden et al. 2001 for a review). However, overall, it
appears likely that lateral ventricular volume is increased in bipolar disorder compared
to controls (Elkis et al. 1995d). Third ventricular enlargement is also found in some
studies compared to healthy controls (Strakowski et al. 1993b;Kato et al. 1994), but not
all studies are positive (Botteron et al. 1995;Lim et al. 1999). However, the 'negative'
studies tend to be small (< 25 patients).
Direct comparisons of schizophrenia and bipolar disorder are even fewer in
number. Lateral ventricular enlargement appears to be greater in schizophrenic subjects
compared to samples with mixed uni and bi-polar mood disorders (Elkis et al. 1995c).
Studies comparing only bipolar subjects with schizophrenics either find no difference
(Zipursky et al. 1997;Johnstone et al. 1989;Friedman et al. 1999) or find greater lateral
ventricular volumes in schizophrenic subjects (Lim et al. 1999). Only two studies (Lim
et al. 1999;McIntosh et al. 2001) to my knowledge have directly compared
schizophrenic and bipolar patients in terms of third ventricular volume, and both were
'negative'. Both studies were small and only Lim (1999) was specifically designed to
address the hypothesis but included only 9 bipolar and 9 schizophrenic patients.
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2.6.3 Frontal lobes
Most studies of prefrontal cortex volume in schizophrenia have found lower
volumes in schizophrenic patients compared to controls in their own right (Shenton et al.
2001), regardless of whether chronic (Andreasen et al. 1994b;Harvey et al. 1993) or
first episode patients (Bilder et al. 1994;Gur et al. 2000) were examined (see Shenton et
al. 2001 for a review). Overall, the volume reductions appear to be of the order of 2-8%
(Wright et al. 2000). However, since prefrontal cortex accounts for approximately 30%
of total cerebral volume and has diverse regional specialisation, the finding of reduced
volume is not in itself very revealing. Frontal volume reductions have been further
characterised using parcellation or voxel-based morphometry (VBM). Reductions in
anterior cingulate, orbitofrontal, dorsolateral and ventromedial cortices have been found
using parcellation (Crespo-Facorro et al. 1999;Goldstein et al. 1999;Gur et al. 2000),
VBM (Wright et al. 1999;Chua et al. 1997) or a related technique call deformation based
morphometry (DBM, Gaser et al. 1999). However, the studies tend to be small and each
individual finding, with the exception of the anterior cingulate, has not been broadly
replicated.
Early studies comparing bipolar disorder with healthy controls found mostly
negative results (Zipursky et al. 1997;Strakowski et al. 1993a; 1999) with only a few
exceptions (Sax et al. 1999). However, positive findings from neuropathology and
functional imaging have motivated a re-examination of this region using automated
techniques and parcellation. Drevets (1997) examined blood flow in bipolar depressed
subjects (n=6) and healthy controls (n=24) using low resolution PET. Finding reductions
in blood flow in the subgenual region of the prefrontal cortex, grey matter volume was
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then examined in a group of medicated depressed unipolar (n=17) and bipolar (n=21)
subjects and compared to that of healthy controls (n=21). Reductions were found in left
subgenual prefrontal cortex in mood disordered subjects compared to controls. Post-hoc
tests found that his difference was also significant for the bipolar-control contrast, but
that the difference was greater in patients with unipolar as opposed to bipolar mood
disorders (48 vs. 39% reduction). However, in a larger and better reported study of
unipolar (n=18) and bipolar (n=27) patients compared to controls (n=38), Brambilla et al
(2002) failed to replicate the subgenual prefrontal cortex reductions found by Drevets et
al. Instead, subgenual volumes were slightly, and non-significantly, increased in both
familial and non-familial bipolar patients compared to healthy controls.
A further study (Sharma et al. 2003) has reported subgenual prefrontal cortex
reductions, but on the opposite side to that of Drevets et al. However, their chosen
hypothesis test was negative and the significant difference was only found on post-hoc
testing. In another study of the frontal cortex in bipolar disorder, Lopez-Larson (2002)
found reductions in left middle and superior grey matter and also in right inferior and
middle grey matter using ROI in 17 bipolar and 12 matched healthy volunteers. In the
only VBM study of bipolar patients, Kubicki et al (2002a) compared fist episode
schizophrenic (n=16), first-episode affective psychosis (n=14 bipolar plus 2 unipolar)
and healthy controls (n=18) and found no differences between bipolar patients and
healthy controls in the prefrontal cortex or insula but found that hippocampal and
superior temporal gyral density reductions were greater in the schizophrenic sample.
2.6.4 Temporal cortex
101
Abnormalities of temporal cortex are well described in schizophrenic patients. Of
51 MRI studies of whole temporal lobe volume in schizophrenia, 61% were positive and
showed reductions in schizophrenic patients compared to healthy controls (Shenton et al.
2001). Medial temporal lobe volume (typically hippocampus and amygdala combined)
were significantly reduced in schizophrenic patients compared to controls in 74% of the
49 studies identified. Wright et al (2000) pooled the results from 25 studies comparing
schizophrenic patients with controls and found a reduction of between 2 and 4% in
affected patients. In first-episode studies however, temporal lobe reductions are less
consistently found than for chronic patients, but medial temporal lobe volumes remain
consistently smaller compared to controls (Lieberman et al. 1993;Lawrie et al. 1999).
The reason for this is unclear, but there is some evidence that temporal lobe differences
may progress over time (DeLisi et al. 1998;Jacobsen et al. 1998). Alternatively, the
tendency for first-episode studies to be smaller may have led to insufficient statistical
power.
Superior temporal gyrus (STG) volume in schizophrenia has also been the
subject of several studies. The attention this region receives in perhaps because of its
close association with language and because of functional imaging studies which have
shown changes in perfusion in schizophrenic subjects with clinical associations.
Superior temporal gyrus volume appears to be reduced in schizophrenic subjects
compared to controls, with a relatively greater effect size for the left anterior superior
and posterior superior segments (Cohen's d~ 0.4) (Wright et al. 2000). Studies focussing
on hallucinations or delusions have shown a tendency to implicate the temporal lobes,
particularly on the left (Shapleske et al. 2002;Levitan et al. 1999;Barta et al. 1990) and
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there is some evidence that these reductions are greatest in the left anterior superior
temporal gyrus (Levitan et al. 1999;Rajarethinam et al. 2001). Reductions in left
posterior superior temporal gyrus grey matter have also been repeatedly found in
association with thought disorder (Shenton et al. 1992;Menon et al. 1995;Rajarethinam
et al. 2000).
Unfortunately, no quantitative review of temporal lobe volume has been
performed in bipolar subjects. There are several studies examining differences between
bipolar subjects and healthy controls, but their results find decreases (Altshuler et al.
1991;Hauser et al. 1989a;Schlaepfer et al. 1994), no difference (Johnstone et al.
1989;Altshuler et al. 2000) and increases (Pearlson 1997;Harvey et al. 1994) in bipolar
subjects compared to controls. Overall it is difficult to make any firm conclusions about
the probable direction and size of effect without a quantitative review. Differences
between bipolar and schizophrenic subjects appear a little clearer. Bipolar subjects have
been found to have larger whole temporal lobe and STG volumes than schizophrenic
subjects (Harvey et al. 1994;Pearlson et al. 1997) with no studies reporting significant
changes in the opposite direction so far as 1 am aware.
The fusiform gyrus, has also been found to be abnormal in schizophrenic patients
compared to controls (Paillere-Martinot et al. 2001;Onitsuka et al. 2003) using both ROI
and VBM. Evidence from a single study suggests that fusiform gyrus volume reductions
in schizophrenic patients, especially on the left, are specific to schizophrenia; whereas
those on the right are found in both affective psychosis and schizophrenia (Lee et al.
2002). Visual inspection of the data suggests that there is considerable overlap between
patients and controls and suggests further replication is required.
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2.6.5 Amygdala
Of the 44 regions considered by Wright et al (2000) in their meta-analysis of
regional volumes in schizophrenia the left and right amygdala had two of the largest
volume reductions of all, in comparison to healthy controls (Cohen's d=-0.72 and -0.69,
for left and right respectively) being reduced by around 10% in schizophrenic subjects.
Wright et al (2000) considered ROI studies where regions were defined using
established and operationalised criteria. Further evidence of grey matter loss has come
from VBM studies which have shown reduced amygdala grey matter density in several
studies (Wright et al. 1999;Job et al. 2002) and evidence of abnormal shape (Shenton et
al. 2002) although there are some contradictory studies (Levitt et al. 2001) and some
important methodological difficulties associated with its measurement (David et al.
2002).
Interestingly, there is some evidence in bipolar disorder that amygdala volumes
are greater than those of controls (Altshuler et al. 1998;2000;Strakowski et al.
1999;Brambilla et al. 2003) with only a few contradictory results (Swayze et al. 1992)
which can potentially be explained by sampling error. Since amygdala volumes may be
decreased in schizophrenia and increased in bipolar disorder, the amygdala might
provide the first structural measure by which schizophrenia and bipolar disorder can be
discriminated from one another. Direct comparisons of schizophrenic and bipolar
patients appear supportive (Pearlson et al. 1997;Altshuler et al. 1998;2000).
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2.6.6 Hippocampus and parahippocampus
Early studies of the hippocampus in schizophrenia tended to incompletely image
the structure using only a few interleaved slices which did not fully measure the
structure, sometimes dramatically underestimating its true volume. The tendency for
slices to be contiguous has greatly improved the accuracy of hippocampal measurement
and there are now more than 30 well conducted studies which show a reduction of
around 6% in both left and right hippocampi compared to healthy controls (Wright et al.
2000). The changes appear also to be present at first presentation (e.g. Whitworth et al.
1998;Velakoulis et al. 1999) although there is some doubt as to whether changes may be
acquired as patients become unwell (Lawrie et al. 2001;2002b) and whether they
progress once psychotic symptoms have become established (Gur et al. 1998a;Jacobsen
et al. 1998). The pattern for left and right parahippocampus is also similar (8 studies,
>350 subjects, Cohen's d~-0.4 to -0.7) being smaller in schizophrenic subjects than in
controls although there is evidence that studies vary by more than one would expect by
chance alone, suggesting some unexplained clinical or methodological heterogeneity.
In contrast, few studies have measured hippocampal volume in bipolar disorder,
and of those that have, most find no differences compared to healthy controls (Hauser et
al. 2000;Altshuler et al. 2000;Brambilla et al. 2003). There is some evidence from one
study that hippocampal volumes are smaller in schizophrenic than in bipolar subjects
(Altshuler et al. 2000) although there is also at least one negative study (Brambilla et al.




Abnormalities in several psychophysiological measures (e.g. ERPs, gating and
habituation of startle) could be attributed to a defective filtering of information from the
sensory organs (Braff and Geyer 1990). It has been suggested that the role of the
thalamus in modulating ascending sensory information makes it a likely candidate as a
filter (Tennigkeit et al. 1998). Evidence suggesting a reduced volume of the thalamus in
schizophrenia has come relatively recently in schizophrenia research (Andreasen et al.
1994a;Flaum et al. 1995), and has been replicated by some (Staal et al. 1998;Gur et al.
1998b;Gilbert et al. 2001), although not all (Deicken et al. 2002;Hazlett et al. 1999)
subsequent studies. The thalamus is however a collection of several nuclei and the
inability to clearly visualise each individual nucleus with MRI probably contributes to
greater 'noise' and leads to some inconsistency. Voxel based morphometry is less reliant
on the ability of operators to separate the thalamus into its constituent nuclei but has not
confirmed the results of ROI analyses so far (Kubicki et al. 2002a;Job et al. 2002). There
is also some evidence that antipsychotic medication may increase thalamic size, further
confounding any association with diagnosis (Gur et al. 1998b).
Thalamic size in bipolar disorder has been assessed in a fewer number of studies,
and although the rationale for the thalamus being involved in mood regulation is also a
strong one, the available evidence form sMRI has not so far been supportive (Caetano et
al. 2001;Strakowski et al. 1993a). The question of whether thalamic volumes
differentiate schizophrenia and bipolar disorder is one which awaits appropriately
designed studies.
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2.6.8 Basal ganglia and nucleus accumbens
In contrast to other nuclei, there is good evidence that patients with
schizophrenia have a larger left and right globus pallidus than healthy subjects of the
same age. Several studies (Kelsoe, Jr. et al. 1988;Jernigan et al. 1991;Elkashef et al.
1994) have shown increases of around 18% (L) and 21% (R) overall (Wright et al.
2000) including some data from first episode studies. However, some studies measure
lentiform nucleus rather than globus pallidus and putamen separately and the evidence
for an increased volume of the putamen in chronic patients is somewhat weaker with
both positive (Elkashef et al. 1994;Hokama et al. 1995) and 'negative' studies. First-
episode studies do not generally find increases in putamen compared to healthy controls,
although putamen and globus pallidus volumes are significantly smaller in first-episode
compared to chronic patients (Gunduz et al. 2002;Lang et al. 2001). The possibility that
such changes are an effect of antipsychotic treatment has been substantiated by several
studies which correlate basal ganglia volumes with antipsychotic exposure (Chakos et al.
1994;Keshavan et al. 1994). However, both studies found associations between
antipsychotic exposure and caudate volumes, and not globus pallidus or putamen
volumes as expected. This finding is difficult to explain in the broader context of the
MRI literature which does not consistently find increases in caudate volume compared
to controls (e.g. Wright et al. 2000 10 studies, 565 patients). However, there is some
evidence that caudate volume is decreased in first-episode patients (Keshavan et al.
1998) which might suggest that antipsychotic exposure minimises these reductions
which predate treatment. No convincing evidence that the nucleus accumbens differs in
size between schizophrenia and controls has yet been shown (Gunduz et al. 2002).
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In bipolar disorder six studies have addressed basal ganglia volumes compared to
controls and have had negative results (Swayze et al. 1992;Strakowski et al.
1993a;Harvey et al. 1994;Dupont et al. 1995;Sax et al. 1999;Brambilla et al. 2001a).
Only two studies have so far been positive. Aylward (1994) examined 30 bipolar
patients and 30 normal controls and found patients had significantly larger caudate
nuclei than controls, but showed no differences in terms of putamen and globus pallidus
volumes. Getz (2002) studied 12 bipolar patients, 12 controls and 12 patients with
schizoaffective disorder. Bipolar patients had a larger globus pallidus, caudate and
putamen than healthy controls and had a larger striatum (caudate and putamen
combined) than patients with schizoaffective disorder. Harvey (1994) is the only other
study to compare bipolar patients with schizophrenia and related psychoses, but
produced no useable data in terms of individual basal ganglia volumes, combining
several volumes together in one measure.
2.6.9 Insula
The insula is a region of cerebral cortex not usually included within the
previously mentioned structures. It lies buried within the depths of the lateral sulcus,
concealed by the frontal, temporal and parietal lobes and is situated overlying the site at
which the telencephalon and diencephalons fused during embryological development
(Nolte 1988). There is some evidence from both ROI (Kim et al. 2003) and VBM
(Sigmundsson et al. 2001;Kubicki et al. 2002a;Shapleske et al. 2002) that there may be
grey matter reductions in the insula in schizophrenic patients compared to controls. So
far no evidence exists for volumetric reductions in bipolar patients.
108
2.7 Structural MRI findings in relatives
2.7.1 Monozygotic twin studies
Studies of monozygotic twins discordant for schizophrenia have the potential to
distinguish environmental from genetic effects. In the context of these studies, greater
neuroanatomical similarity would be presumed to reflect common genetic effects and
greater difference to reflect environmental or disease contingent effects. Studies of
discordant monozygotic twins are however limited by the unusual circumstances of twin
birth and differences between twins may be a reflection of different gene expression or
gene-environment interaction. Notwithstanding these potential limitations, studies of
discordant MZ twins have enhanced our understanding of genetic and environmental
influences in schizophrenia.
CT and MRI studies have generally been consistent. Unaffected relatives of
schizophrenic patients have a degree of quantitative brain anomaly which is intermediate
between that of their affected relatives and healthy controls. Such findings suggest that a
degree of brain anomaly is inherited at least by a proportion of those who never develop
schizophrenia. Studies of discordant monozygotic (MZ) twins have the added ability to
quantify the effect of environmental factors on subsequent illness. In a study of 15 pairs
of MZ twins discordant for schizophrenia (Suddath et al. 1990), it was the affected twin
which had larger ventricles, reduced temporal lobe grey matter and reduced
hippocampal volumes. These findings are difficult to explain without the effect of
environmental factors or gene-environment interactions. However, no differences were
found in either frontal lobe volume or white matter. Since frontal lobe volume has been
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shown to be consistently reduced in schizophrenia (Lawrie and Abukmeil 1998;Wright
et al. 2000) compared to non-related healthy controls, it is possible that a reduced frontal
lobe volume may predispose to psychosis while a reduction in temporal lobe grey matter
and hippocampal volumes might be associated more closely with the onset of illness
itself.
A further study of monozygotic twin pairs discordant for schizophrenia used 15
pairs of discordant monozygotic twins, 14 pairs of discordant dizygotic twins and 29
healthy twin pairs matched on a number of important confounders (Baare et al. 2001).
Frontal brain volumes were smaller in affected versus unaffected monozygotic twins but
not for the same sib-wise comparison within the discordant dizygotic twin group.
Irrespective of zygosity however, affected twins had smaller whole brain, hippocampal
and parahippocampal volumes than their healthy co-twin. Unaffected co-twins had
smaller whole brain volumes than twins from unaffected sibships. These findings
suggest that frontal brain volumes are associated with the development of illness itself
and that small whole brain, hippocampal and parahippocampal volumes may also be
associated with the development of illness. The relationship of these brain regions to
genetic vulnerability could however not be excluded due to the relatively small sample
sizes. Whole brain volume however, appeared to be both a marker both of illness and
genetic vulnerability. A further study specifically examining differences in thalamic and
caudate volumes in discordant MZ twins (Bridle et al. 2001) found larger caudate nuclei
in affected twins but found no differences in thalamic volumes between twin pairs.
In an attempt to further characterise the significance and extent of grey matter
deficits in affected and unaffected co-twins, Cannon (2002) conducted an MRI study of
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discordant MZ and DZ twins along with a sample of demographically matched control
twins. The study used a relatively novel technique of constructing three dimensional
probabilistic maps of the cortex. Cortical maps were used to compute 3D vector
deformation fields which allowed researchers to compute a measure to reflect grey
matter density at each cortical point. Differences between well twins and their
schizophrenic co-twin were found in the region of the dorsolateral prefrontal cortex,
superior temporal gyrus and superior parietal lobule and were associated with measures
of disease severity and cognitive function. No relationship was found with duration of
illness or antipsychotic dmg treatment. A cortical map of grey matter density associated
with genetic proximity to affected patients found deficits in the polar and dorsolateral
prefrontal cortex. These findings suggest that different cortical areas may be associated
with genetic and disease specific influences. Medial prefrontal and medial temporal lobe
structures could not be assessed in this approach as they could not be extracted using the
surface extraction method employed in the study.
The functional significance of structural abnormalities in twins discordant for
schizophrenia has been investigated in few studies, probably because of the practical
limitations of this kind of research. Berman (1992) measured cortical blood flow in
monozygotic twins discordant and concordant for schizophrenia and a group of health
co-twins. Three conditions were studied: a resting task, the Wisconsin Card Sorting Test
and a number matching task designed to act as a non-specific active control task.
Affected subjects showed hypofrontality compared to their well sibling. However, well
siblings of schizophrenic MZ twins showed no differences compared to healthy twins
from unaffected pairs suggesting that hypofrontality is related to non-genetic factors.
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Hypofrontality in the schizophrenic co-twins was also associated with a higher life time
exposure to antipsychotic medication. A further publication by the same group
(Weinberger et al. 1992) examined the relationship between functional deficits and
regional brain volumes measured by MRI in both healthy MZ and twins discordant for
schizophrenia. Differences between discordant MZ twin pairs in prefrontal dysfunction
measured during the Wisconsin Card Sort Test were found to be related to differences in
left hippocampal volume. Within the affected twin group alone, prefrontal activation
was strongly related to both right and left hippocampal volumes. A third publication
(Goldberg et al. 1994) from the group examined intra-pair differences in anatomic
structures, prefrontal rCBF and cognitive function. The study found left hippocampal
volume to be related to a parameter of verbal memory and prefrontal rCBF to be related
to psychotic symptom scores and preservation on the Wisconsin Card Sort Test. These
findings suggest that prefrontal and medial temporal lobe regions are important in the
aetiology of psychotic symptoms and cognitive dysfunction.
MRI findings in twins discordant for bipolar study have only been published in
two independent studies study (Noga et al. 2001;Kieseppa et al. 2002;2003). Noga et al
(2001) studied 6 monozygotic twin pairs discordant for bipolar disorder and 11 healthy
concordant MZ twin pairs. Affected MZ twins had smaller right hippocampi than their
normal co-twins whereas caudate volumes were increased in both the healthy and ill co-
twins compared to members of concordant MZ pairs. Kiesappa (2002;2003) studied 24
twins with bipolar 1 disorder, 15 healthy co-twins and 27 twins with no history of
psychiatric disorder. Patients and co-twins showed reductions in left hemispheric white
matter volume compared to control twins. No grey matter differences were found.
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2.7.2 Findings in the extended family
The underlying rationale of examining the first degree relatives of patients with
schizophrenia is that they share approximately 50% of their genome and that common
differences versus controls probably reflect genetic factors, while differences between
unaffected and affected relatives presumably represent disease specific effects. A similar
degree of abnormality in relatives and patients implies that the volume alterations are not
related to the disease itself but are probably related to genetic factors. In some cases
however, studies may be small and of low statistical power rendering a conclusion of no-
difference between two groups insecure. It is clear that these studies cannot distinguish
genetic and environmental causation, but as schizophrenia is usually found to reflect
mainly genetic factors, with a relatively small unique environmental effect, and almost
no familial environment involvement (McGuffin et al. 1994), the commonalities
between patients and their relatives are probably genetic in origin.
Most of these relatives' studies have examined the volumes of the lateral
ventricles (LVs) and/or the AHCs. Only one study has reported significantly enlarged
LVs in relatives as compared to controls (Sharma et al. 1998), although most of the
studies in siblings (Cannon et al. 1998;Seidman et al. 1999;Staal et al. 2000b) or
offspring (Keshavan et al. 1997;Schreiber et al. 1999;2002;Lawrie et al. 2001) give
results in that direction. The few comparisons of patients and sibs are on the other hand
universally significant (Cannon et al. 1998;Sharma et al. 1998;Staal et al.
2000b;McDonald et al. 2002) , as are the twin studies, suggesting stronger
environmental and phenotypic effects. Indeed, in older 'obligate gene carriers' lateral
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ventriculomegaly (Sharma et al. 1998;McDonald et al. 2002) has yet to be externally
replicated (Steel et al. 2002). An increased VBR in relatives may therefore primarily
reflect a reduction in brain volume, although the results on sMRI are equivocal. While
some studies find the brain is smaller in relatives than controls (Cannon et al.
1998;Keshavan et al. 1997;2002) with no patient-relative differences (Cannon et al.
1998;McDonald et al. 2002;Seidman et al. 1999) many studies comparing relatives or
obligates with controls find no differences (Seidman et al. 1999;Sharma et al.
1998;McDonald et al. 2002).
The evidence from relatives' studies is similarly inconclusive for most other
brain regions, in some cases because of insufficient studies and in others due to low
power. There are for example isolated reports of abnormal cerebral torque (Sharma et
al. 1999), but the most consistent abnormalities in patients have not been found in
relatives (Bartley et al. 1993;Frangou et al. 1997); and findings of abnormal sylvian
fissure (Honer et al. 1995) and AHC asymmetry (Schreiber et al. 1999) have yet to be
replicated (Bartley et al. 1993). There is however a degree of agreement with the twin
and automated studies reviewed above for ffonto-temporal differences with the changes
greatest in schizophrenic subjects, intermediate in relatives and smallest in controls. The
main support for this from ROI studies in relatives is as trends from a large study using
sophisticated segmentation algorithms (Cannon et al. 1998), and studies contrasting
patients with their unaffected relatives (Staal et al. 2000b;McDonald et al. 2002;Steel et
al. 2002). Preliminary voxel based morphometry (VBM) analyses of the latter study
suggest both frontal and temporal reductions, with common genetic and disease effects.
Small (Keshavan et al. 1997;2002;Schreiber et al. 1999) and large studies (Lawrie et al.
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2001) of high risk offspring have not found such differences, and neither have medium
sized studies which do not control for family membership (Sharma et al. 1998). It
appears that the relatively small effects require automated approaches and should control
for within family clustering.
The importance of statistical power is again illustrated in studies of the third
ventricle (3V) and the thalamus (the increase in the former probably reflecting
reductions in the latter and other surrounding structures). The only negative studies of
the third ventricle in relatives (n=15, Schreiber et al, 1999) and the thalamus (n=ll,
Keshavan et al, 1997) are the two smallest offspring studies and Keshavan et al (2002)
found thalamus reductions when they increased the sample size to 19 (although
differences have been found with samples as small as six). While most of the available
literature suggests 3V increases and or thalamus reductions in relatives more than
controls, the only significant patient-relative difference reported is for the thalamus
(Staal et al. 1998). Thalamus reductions, which were related to genetic liability but not
psychotic symptoms in the Edinburgh High Risk Study (Lawrie et al, 2001 and see
below), may therefore be genetically mediated risk markers not related to the disease
itself. Ventricular enlargement may be related to disease specific or other environmental
effects rather than genetic liability.
Relatives' studies are relatively clear that amygdala-hippocampal complex
(AHC) reductions are both genetic and disease related. Relatives have smaller AHCs
than controls (Keshavan et al. 1997;Schreiber et al. 1999;Seidman et al. 1999;Lawrie et
al. 2001;2002), and schizophrenics have smaller AHCs than relatives (O'Driscoll et al.
2001;Lawrie et al. 2001;Steel et al. 2002), although there are some negative studies
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(Staal et al. 2000b). There are suggestions that the reductions may be more marked
anteriorly (Keshavan et al. 2002;0'Driscoll et al. 2001), and on the left side (Lawrie et
al. 2001;Keshavan et al. 2002). There is however good evidence for hippocampal
differences as well (Waldo et al. 1994;Harris et al. 2002;Seidman et al. 2002a;van Erp et
al. 2002).
Functional studies of unaffected family members and their close relatives have
been conducted and are also relevant to the understanding of structural findings. A
SPECT study of 19 schizophrenic patients, 36 first degree relatives and 34 unrelated
healthy controls found decreased left inferior prefrontal cortex and anterior cingulate
perfusion in both relatives and schizophrenic patients compared to controls (Blackwood
et al. 1999). Increases in perfusion were also found in schizophrenics and relatives
compared to controls in the periventricular white matter, occipital-frontal fasciculus and
internal capsule. A further study by O'Driscoll et al (1999) used positron emission
tomography (PET). The first degree relatives of schizophrenic patients with eye tracking
dysfunction (ETD) showed decreased perfusion in the frontal eye fields compared to
those without ETD and healthy controls. The authors suggest that hypoperfusion of the
frontal eye fields may be caused by genes which predispose to schizophrenia.
In bipolar disorder only one study could be found that examined MRI findings in
the extended family (Ahearn et al. 1998). Twenty-one members of a single family with a
strong family history of bipolar disorder were examined using MRI. Four of nine family
members with bipolar disorder had deep white matter changes and eight had lesions of
subcortical grey matter nuclei. Six of ten unaffected family members also had lesions of
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subcortical grey matter nuclei, although only one had evidence of subcortical white
matter changes.
2.7.3 Studies of obligate carriers
Studies of the healthy relatives of schizophrenic subjects have provided a useful
design in which to study the effects of genes which raise the liability to schizophrenia.
Such studies are generally unconfounded by the effects of medication and are not
associated with the expression of the illness itself. However, the proportion of genes
shared with the affected relative may be much less than 50% and the relative importance
of shared genetic factors is likely to be less the more distant the relationship. A
potentially stronger design is to consider the unaffected relatives of schizophrenic
probands who have both a parent and a child with schizophrenia. Unaffected 'obligate
carriers' can therefore be assumed to have transmitted the genotype from one generation
to the next without succumbing to the illness themselves. They also share approximately
50% of their genes with both relatives, and since both are affected, the shared genes are
more likely to contain alleles which increase the genetic liability to schizophrenia.
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Figure 2.7.3: Family tree indicating affected patient, obligate carrier and
non-affected non-carrier
Sharma et al (1998; 1999) were one of the first to use the 'obligate carrier'
approach to studying the effects of genes for schizophrenia. Thirty one people with
schizophrenia were compared to 39 unrelated controls and 57 relatives, of whom 11
were presumed 'obligate carriers'. Obligate carriers had larger left and right lateral
ventricles volumes than any other group. A subsequent study by Steel et al (2002)
compared 6 affected sibships of three individuals in which one sibling was an affected
subject with schizophrenia, one was a presumed obligate carrier with a child with
schizophrenia and one sibling had no children with schizophrenia ('non-obligate'). In
terms of cortical structures (WB, FL, TL), obligates resembled their non-obligate
unaffected siblings, both having significantly larger volumes than their affected siblings.
However, the amygdala-hippocampal complex was significantly smaller in
schizophrenic siblings and their obligate siblings than it was in the non-affected non-
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obligate sibling. Premorbid IQ, measured by the NART, was also unexpectedly higher in
the sample of obligate carriers.
Positron emission tomography (PET) has been used to compare obligate carriers
with stable schizophrenic patients and healthy controls in one study which used H2150 to
examine the functional correlates of verbal fluency (Spence et al. 2000). The 'normal'
functional response is said to be characterised by left dorsolateral prefrontal cortex
(DLPFC) activation and deactivation of the left superior temporal gyrus (STG) and was
found in both normal controls, obligate carriers and affected patients. The same research
group found similar results in asymptomatic patients with schizophrenia in an earlier
study (Dye et al. 1999) who showed similar responses to both normal controls and a
further group of six patients with schizophrenia. Previously replicated findings of
reduced fronto-temporal connectivity (Frith et al. 1995;Fletcher et al. 1999;Lawrie et al.
2002a) in schizophrenia were not replicated in either study suggesting that at least some
patterns of dysconnectivity may be related to psychotic symptoms rather than be
markers of genetic liability.
2.7.4 Studies of familial and sporadic psychosis
Studies of the ventricle to brain ratio (VBR) in 'sporadic versus familial'
schizophrenia provide less consensus, as one of the originators of the distinction noted in
a review of the early studies (Lewis 1990). Patients without a family history of
schizophrenia may have repeatedly been shown to have a higher VBR and more marked
ventriculomegaly than family history positive patients (Vita et al. 1994;DeQuardo et al.
1996), and some notable large studies (n>100) may have failed to find an association
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between family history and the VBR (Johnstone et al. 1989;Jones et al. 1994c); but
several studies do report such an association (Owens et al. 1985), including those which
go some way to supporting the distinction (Vita et al. 1994;Silverman et al. 1998). It
may be that schizophrenics without an obvious genetic loading are more likely to have
had environmental triggers which may increase the VBR, but determining sporadic
status is not easy when many healthy relatives are likely to be carrying the gene(s) and,
especially in families where there is a poor knowledge of family psychiatric history an
affected subject may be misclassified as 'sporadic' (Johnstone et al. 1995). The limited
resolution of CT studies increases measurement error and the use of VBR may have
further compounded these difficulties. Indeed, the few sMRI studies to have adopted
similar approaches have all reported similar or greater abnormalities in familial cases
(Schwarzkopf et al. 1991;Roy and Crowe 1994;Falkai et al. 2002;Harris et al. 2002),
with the exception of McDonald et al (2002), and some suggest specific genetic effects
in frontal and temporal lobes, the ventricles and the basal ganglia.
Studies of familial and sporadic bipolar disorder are less frequent and have
generally concerned a finding of reduced volume or density in the region of the
subgenual prefrontal cortex (SGPFC). In the first study to report this finding, a reduced
volume and blood flow in familial and non-familial bipolar disorder was shown by
Drevets et al (Drevets et al. 1997). Unfortunately, this result was not replicated by
Brambilla et al (2002) in a similar study which failed to find SGPFC volume reductions
in either familial or non-familial bipolar disorder compared to controls.
2.7.5 High risk studies
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Contemporary "high risk" studies follow a cohort of unaffected individuals at
increased risk of schizophrenia prospectively through the period of high risk (circa 23 in
males, 27 in women, see Hafner et al. 1989) in the knowledge that some subjects will
become affected. This design overcomes several of the difficulties of case-control
studies. Subjects can be scanned and interviewed repeatedly over the period of risk
allowing any effects to be unaffected by medication or positive symptoms. Imaging
findings may be associated to symptoms or neuropsychological performance and
subjects who develop schizophrenia may be scanned before medication has been
prescribed. In addition, because the matter of who will develop schizophrenia is not
known, investigators are less liable to observer bias.
In spite of the considerable advantages of 'high risk' studies, they have many
practical limitations. Patient attrition, cost and the tendency for both staff and
technology to change over time has meant that few centres have undertaken this study
design. The first high risk imaging study to be completed was the Copenhagen high risk
project (CHRP), although the scans (CT) were not repeated over time (Cannon 1993).
Two further studies are ongoing, both using sMRI, the Edinburgh high risk study
(EHRS) and the Australian high risk study (AHRS).
The Copenhagen High Risk Study (Mednick 1966) concerned the children of
mothers with schizophrenia Subjects received a CT scan of the brain and
neuropsychological assessments. High risk subjects were compared to healthy controls
with no family history of mental illness that were matched to high risk subjects on age,
sex social class and IQ. CT scans were not repeated over time and the main results
compare the scans from high risk subjects with healthy controls. Their results suggest
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that widened fissures and sulci are positively associated to genetic risk but that only
schizophrenic subjects have enlarged ventricles (Cannon et al. 1989). A subsequent
study of 16 twin pairs discordant for schizophrenia (Zorrilla et al. 1997) found that the
sulci to brain ratio and VBR differed between the twin pairs suggesting an
environmental effect or gene-environment interaction.
Researchers in Melbourne have adopted a different but complementary approach.
They have examined groups of people at 'ultra high risk' (UHR) of psychosis, those
with first episode psychosis (FEP, including about 50% with schizophrenia or
schizophreniform psychosis) and a large group of healthy controls. The UHR group
consisted of referrals to a clinic in Melbourne, of people aged 14-30 with: 'attentuated'
partial (positive) psychotic symptoms several times a week for one week to 5 years,
transient symptoms of less than one weeks duration in the past year, and/or both trait and
state risk factors for psychosis (a family history and a worsening in mental state or
general functioning in the past year). Preliminary ROI results suggested non-significant
hippocampal reductions in the UHR group and the sub-group of them that developed
psychosis (Copolov et al, 2000). An early VBM study of nine who developed psychosis
and twelve who remained well did however identify volume reductions in the
hippocampus, entorhinal cortex, inferior frontal and fusiform gyri during the transition
to psychosis (Pantelis et al. 2003).
Phillips et al (2002) recently reported on their traced whole brain and
hippocampal volumes as possible predictors of psychosis. 75% of eligible referrals were
scanned between 1995-8 and 5% of scans were lost due to movement artefact, leaving
60 scans. Twenty (33%) of those with usable scans developed an acute psychosis
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(defined as an increase of one or more points on the BPRS or CASH, several times a
week, for more than one week) within a year. A SCID interview identified diagnoses of
schizophrenia spectrum disorder in 11, affective psychosis (3), bipolar disorder (3) and
others (3). The UHR groups who did not develop psychosis included four patients with
depression, and 11 with an anxiety state.
The scans were conducted at two sites and there was a weak tendency for the
scanners to deliver different whole brain volumes and for more of those who developed
psychosis (and of one sex) to be scanned at one site (Phillips et al, 2002). Nonetheless,
controlling for a slightly smaller whole brain, the 60 UHRs has significantly smaller
hippocampi (by about 11%, effect size- 0.9) than the controls but did not differ from the
FEPs. However, the UHRs were on average 10 years younger and 11 points lower in
premorbid IQ than the normals. The 20 who became psychotic were much more closely
similar in demographics to the 40 who remained non-psychotic but, rather counter-
intuitively, the (left) hippocampus was larger in those who went on to develop a
psychosis. These confusing results may be attributable to scanner effects, selection bias
and/or confounding by e.g. other diagnoses or gender.
Pantelis et al (2003) have recently reported on their VBM findings in a slightly
extended sample. In 75 people with prodromal symptoms, defined as above, 23 (31%
developed a psychotic disorder (roughly equal numbers of schizophrenia and affective
psychoses). Compared to those who did not develop a psychosis, they had less grey
matter in right medial temporal, lateral temporal and inferior frontal cortex, and in
bilateral cingulate cortex. Twenty-one subjects had repeated scans at 1-2 year intervals
- 10 of whom had become psychotic (five with schizophrenia). They showed reductions
123
over time in left parahippocampal, fusiform, orbitofrontal and cerebellar grey matter,
while those who did not remain psychotic only exhibited cerebellar reductions. These
are intriguing results that suggest grey matter reductions in the run up to psychosis and
immediately after it. There are however some important issues outstanding - in
particular, whether some of those in the UHR group actually had a psychosis before or at
study entry, and why the ROI and VBM studies appear to have such different findings.
The Edinburgh High Risk Study concerns the families of known patients
throughout Scotland whose consultant thought might have a family history of
schizophrenia. Healthy family members were included if they had at least two close
relatives with a confirmed diagnosis of schizophrenia using the OPCRIT computer
program (McGuffin et al. 1991). 162 high risk subjects provided some data and 150 had
at least one sMRI scan in the first phase of the study between 1994 and 1999. Two
control groups were also recruited. The first consisted of healthy non-related controls
matched as closely as possible for age and sex. The second consisted of patients with
first schizophrenic episodes but without a known family history of psychosis. High risk
subjects were further classified at each of up to 3 interviews, according to the Present
State Examination, into those with schizophrenia, those with one or more psychotic
symptoms and those without psychotic symptoms.
High risk subjects and controls were reassessed every eighteen months.
Assessments performed included neuropsychological testing and clinical examinations
and an MRI scan of the brain. Obstetric complications were also assessed from maternal
recall and health service records (Mcintosh et al. 2002) and the mothers of subjects and
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controls were interviewed with a view to obtaining information about childhood
behaviour (Miller et al. 2002).
Numerous differences in neuropsychological measures were shown (Byrne et al.
2003). In general controls performed best followed by high risk subjects followed by
first episode patients. After controlling for IQ high risk subjects performed worse on the
Hayling sentence completion test and the Rivermead Behavioural memory Test (RBMT)
of delayed memory. Both measures were negatively correlated with both measures of
genetic liability used in the study.
Early region of interest analysis of the first 100 MRI scans found the amygdala-
hippocampal complex to be approximately 4% smaller than controls and about 4%
larger than subjects with schizophrenia (Lawrie et al. 1999). Thalamic size was also
smaller in high risks compared to controls. An increase in third ventricular volume was
found in high risk subjects compared to controls, although this was not significant after
the correlation in volumes between subjects from the same family had been taken into
account (Lawrie et al. 1999). Voxel based morphometry confirms these early results and
also shows medial prefrontal and temporal lobe reductions in grey matter density with a
gradient which is greatest in first episodes, intermediate in high risks and lowest in
controls (Job et al. 2002). Within high risk subjects, higher genetic liability was
associated with smaller left and right prefrontal lobes and smaller left and right thalami
(Lawrie et al. 2001).
Changes in brain size were also measured using repeat scans in the 66 high risk
subjects and 20 healthy controls (Lawrie et al. 2002b). Changes within the high risk
group were also compared for subgroups according to whether or not they had fully
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rated psychotic symptoms in the first phase of the study. No differences were found
between controls and high risk subjects. When high risks with symptoms were compared
to those without symptoms however, several other differences emerged. Those with
psychotic symptoms showed a greater reduction in right temporal lobe volume compared
to those without symptoms and similar, though non-significant differences were also
reported in respect of the left temporal lobe and the prefrontal cortex bilaterally. Over
the same time period, neuropsychological measures also continued to favour controls
over high risk subjects and those with psychotic symptoms performed less well than
those without particularly in the area of memory (Cosway et al. 2002). Decline in
memory performance also appeared greatest in those with symptoms though the change
was not statistically significant
2.8 The molecular genetics of schizophrenia and bipolar disorder
2.8.1 Evidence for single gene loci
The increased risk to schizophrenia or bipolar disorder conferred by an affected
relative has been established by many twin, family and adoption studies (Gottesman and
Shields 1976;Kessler 1980;Tsuang et al. 1991;Mitchell et al. 1993). However, the
genetic linkage and association studies which have sought to identify the genes
responsible have so far failed to account for the majority of genetic liability to either
disorder although several positive findings have been replicated in both disorders
(Berrettini 2002;Levinson 2003). The failure to widely replicate most positive findings
may be because gene effects are specific to a given population, because the effect is
small and detectable only in large samples or because there is a tendency for small
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positive studies to show a positive finding but for small negative ones to remain
unpublished. The consistency of findings from one population to another, and the
possibility of publication bias have been addressed in several reviews of this area.
In schizophrenia, a review of 20 genome wide linkage studies found evidence
form linkage at several loci including 5q, 3p, llq, 6p, lq, 22q, 8p, 20q and 14p and
further loci emerged as the threshold for statistical significance was lowered (Lewis et
al. 2003). However, the study did not identify specific genes and neither publication bias
nor heterogeneity was addressed. Linkage, but not association, has been found for the
Catechol O-Methyltransferase Val allele and schizophrenia, although the linkage studies
were generally smaller in number and in sample size (Glatt et al. 2003a). Other reviews
have substantiated associations between the dopamine receptors D2 (Glatt et al. 2003b),
D3 (Jonsson et al. 2003a;Shaikh et al. 1996) and D4 (Jonsson et al. 2003b). Recent
evidence has also emerged regarding Neuroregulin, D-Amino Acid Oxidase and
Dysbindin, although only Neurotrophin A3 has been subject to a confirmatory meta-
analytic review (Jonsson et al. 1997a).
Linkage and association studies in bipolar disorder have not yet been subject to a
systematic review and meta-analysis, although several narrative reviews exist. This is
surprising since heritability estimates for bipolar disorder are generally greater than for
schizophrenia and gene effects might be easier to detect under these circumstances,
particularly if one or two genes of major effect exist. Linkage has been found, and
subsequently replicated, to 18pl 1.2, 21q22, 22ql 1-13, 18q22, 12q24 and 4pl5
(Berrettini 2002). Using both linkage and association techniques, polymorphisms have
been found in the monoamine oxidase-A (MAO-A) gene which increase the risk of
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bipolar disorder (odds ratio=1.49, Berrettini 1997;Furlong et al. 1999), although there
are also several published negative studies (e.g. Norton et al. 2002). The negative studies
tend to be underpowered however, and their presence is probably consistent with a
modest effect size. Positive and negative findings have also been found for COMT
(Kirov et al. 1998;Geller and Cook, Jr. 2000;Rotondo et al. 2002) and the serotonin
transporter gene (5HTT, Collier et al. 1996;Oruc et al. 1997;Saleem et al. 2000) but it
will be difficult to quantify their true effect without further large studies.
Linkage for 18p 11, 13q32, 10pl4 and 22qll has been established in both
schizophrenia and bipolar disorder and the COMT Val allele also appears to raise the
probability to both disorders (Egan et al. 2001;Rotondo et al. 2002). However, most loci
are not shared by both disorders and the majority of locus-dependent risk appears to be
disease-specific (Bramon and Sham 2001). This is consistent with the twin, family and
case-control studies referred to in the previous chapter which suggest that having a
relative with schizophrenia increases the probability that an unaffected subject will
develop bipolar disorder in the future, and vice versa. However, the apparent specificity
of loci to either schizophrenia or bipolar disorder might be explained by a failure to
systematically investigate disease specificity in the primary studies, the presence of
small underpowered studies or the selective publication of small positive studies.
There are now several chromosomal and gene loci which appear to raise the risk
for either schizophrenia, bipolar disorder or both. However, methodological problems
have limited our confidence in these findings and the matter of which alleles raise the
probability of either disorder in the general population has yet to be resolved. For each
locus, the effect size is generally small (typically OR<2) which suggests that the
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proportion of cases accounted for by 'known' mutations is very small. Given that the
heritability of both schizophrenia and bipolar disorder is substantial and that genetic
models examining their mode of inheritance tend to suggest several genes of minor
effect, it seems likely that several genes of quantitative effect are responsible for the
increased genetic liability. Certainly, classical Mendelian inheritance is an unlikely
prospect given the nature of the data available.
2.8.2 Imaging gene effects in psychosis
The discovery of an allele associated with an increased liability to schizophrenia
or bipolar disorder is not in itself very informative, unless it is related to the biology of
the disorder. For example, the discovery of the gene for Huntingdon's disease
'Huntingtin' has not yet led to the discovery of a mechanism, although some theories
have been suggested. Individual gene effects might best be quantified by relating their
presence or expression to clinical features and/or regional brain volumes in both affected
subjects and their well relatives. To date, however, very few studies have attempted to
use this method. Difficulties with this approach are almost certainly contingent on the
fact that few specific gene effects have been consistently replicated in schizophrenia.
Kunugi et al (1999) looked at the relationship between the neurotrophin-3 A3 allele and
regional brain volumes in schizophrenia and bipolar disorder. The results showed A3
allelic status to be associated with reduced volumes in schizophrenic but not bipolar
subjects. This unconfirmed finding suggests that bipolar subjects may be subject to
genetic or environmental factors which ameliorate the effects of this gene. Without
further information about the clinical associations of A3 allelic status it is difficult to
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draw any firm conclusions from this study. ApoE status has also been related to
hippocampal volume in schizophrenia (Fernandez et al. 1999;Hata et al. 2002), although
the results are inconsistent.
The catechol-O-methyl transferase (COMT) is a potential candidate gene for
schizophrenia, having a role in dopamine metabolism and also a relationship between its
expression and prefrontally medicated cognition. A study of 175 patients with
schizophrenia, 219 unaffected siblings and 55 controls (Egan et al. 2001) demonstrated a
dose like effect of COMT genotype expression and performance on the Wisconsin Cart
Sorting Test. COMT allelic expression was further related to brain physiology during a
working memory task in three subgroups (n=l 1-16) of the original sample. Met allele
load predicted a stronger prefrontal response and in a subsequent analysis of 104 trios it
was shown that the Val allele was preferentially transmitted to schizophrenic offspring.
These findings suggest that the COMT Val allele may raise the liability to schizophrenia
possibly by an impairment of dopamine function and consequent impairment of
executive function. At the time of going to press, there had been no independent
replication of this finding.
Studies attempting to image the effects of specific loci in bipolar disorder are
much less common. A gene (NOTCH3) implicated in 'Cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy' (CADASIL) has been
investigated in a large family multiply affected family with bipolar disorder. Twenty-one
family members were scanned using sMRI and, although subcortical white matter
hyperintensities were common in both affected and unaffected family members, linkage
was not shown to NOTCEB (Ahearn et al. 2002). A further study examined the 5178
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mitochondrial DNA polymorphism in 145 patients with bipolar disorder and 184
controls (Kato et al. 2000). The rate of the 5178C polymorphism was significantly
higher in affected patients than in controls and was associated with higher brain pH
(measured using 3IP-MRS). No differences were found in subcortical hyperintensities
between the bipolars with and without the polymorphism.
2.9 Conclusions
Early pneumoencephalography studies have clearly demonstrated that there are
macroscopic anatomical differences between schizophrenic subjects and controls. CT
has succeeded in this regard for bipolar disorder where pneumoencephalography
evidence has been lacking. However, advances in image acquisition, particularly MRI
and in image analysis, have greatly increased our understanding of these disorders.
There is good evidence that schizophrenic subjects have reductions in several cortical
and subcortical regions and increases in ventricular CSF volume.
Many of the same regions are implicated in both bipolar disorder and
schizophrenia. However, a few regions show some promise as discriminators between
the disorders. In particular, the amygdala and thalamus may be larger in bipolar disorder
than in schizophrenia. Furthermore, the amygdala may be larger in bipolar subjects than
in healthy controls, suggesting that the degree of overlap with schizophrenic subjects
may be much less than for other regions.
Neuropsychological abnormalities appear to be present in both schizophrenia and
bipolar disorder. Verbal memory appears to be disrupted in both, but for virtually all
other domains of neuropsychological function there is some doubt as to whether it
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discriminates between the disorders. In particular, IQ appears to possibly separate the
phenotypes although the effect of symptoms and possibly medication may also confound
these findings.
Strong evidence of neuropsychological impairments in relatives of people with
psychosis exists for schizophrenia only. The failure to demonstrate such deficits in
relatives of patients with bipolar disorder may largely be because such studies have yet
to be conducted.
2.10 Hypotheses and aims
This study seeks to clarify the neuropsychological and neuroanatomical
differences between schizophrenia, bipolar disorder and their affected relatives. The
neuropsychological domains of intelligence, executive function, psychomotor
performance and memory will be measured in a sample of patients with schizophrenia,
bipolar disorder and well relatives from both groups. Bipolar patients and their relatives
will be of two types a) those with a family history of bipolar disorder only and b) those
with a family history of both bipolar disorder and schizophrenia. In this way we hope to
clarify which deficits are related to phenotype and which are related to family history.
The patient and relative groups will be compared to a group of healthy controls with no
personal or family history of either bipolar disorder or schizophrenia.
The same sample will also undergo an MRI scan of the brain to clarify similar
issues with regard to brain anatomy. Amygdala volumes are hypothesised to
discriminate between schizophrenic and bipolar patients. Thalamic volumes, having
found to be reduced in both schizophrenia and their close relatives, are hypothesised to
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be reduced in all patient groups reflecting a common underlying mechanism by which a
liability to psychosis may be expressed.
The specific hypotheses are:
1. That reduced IQ will be associated with a genetic liability to schizophrenia, but
not bipolar disorder
2. The executive function will be impaired to a greater extent in schizophrenia and
relatives of patients with schizophrenia than in bipolar subjects of their relatives
3. That thalamic reduction will be found in schizophrenic subjects, but not in
bipolar subjects or their close relatives.
4. That amygdala and hippocampal reductions will be found in schizophrenia and
the relatives of schizophrenic subjects, but not in bipolar subjects, or their close
relatives.
The general hypothesis is that the genes which are associated with an increased
liability to schizophrenia or bipolar disorder act on regional brain systems. When certain
brain systems are affected (e.g. the thalamus, cortical-thalamo-striatal loops) then the
clinical picture is one of affective psychosis. Genes affecting prefrontal grey matter are
additionally necessary for the development of schizophrenia and for the cognitive and
other abnormalities shown by sufferers.
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2.11 Power calculation
The number of people required to detect a standardised effect size of 1.0 with 80%
power and at a significance level of p=0.05 in 2-groups is 38 in each group (STATA
Software). Therefore, in comparison with controls, there should be about 76 subjects or
more in the comparison.
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The question 'is the brain structure of people with bipolar disorder different from
that of either healthy controls or people with schizophrenia?' is of some importance.
Firstly, characterisation of differences between bipolars and controls may give clues to
the biology of this illness, ranked by the WHO in the top thirty leading worldwide
causes of disability (Murray and Lopez 1997). Such information could be combined in
future studies, particularly ones which relate genetic liability to any volumetric
differences found. Secondly, if the differences were large enough, and different from
those found in schizophrenia, diagnostic testing, and the quantification of risk in subjects
who have been hitherto unaffected, may be possible. Finally, by characterising the
changes found in bipolar disorder, this might enable us to better understand the biology
of mood.
There have been over 58 structural magnetic resonance imaging studies (sMRI)
of over 1588 patients with schizophrenia compared to controls (Wright et al 2000). That
there are established differences in cerebral, ventricular, amygdala and hippocampal
volume is scarcely beyond doubt. However, attempts to compare patients with bipolar
disorder to unaffected controls are sparser reflecting a general paucity of bipolar
disorder research in general (Clement et al. 2003a). Combining the available studies
might resolve uncertainty about the volumes of certain cerebral structures compared to
both controls and schizophrenics (e.g. the amygdala and hippocampus) and any
associated heterogeneity could also be measured and its potential causes investigated.
Several reviews of sMRI studies in bipolar disorder have been performed (Elkis
et al. 1995b;Soares and Mann 1997b;Norris et al. 1997;Videbech 1997;Baumann and
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Bogerts 1999;Hoge et al. 1999;Stoll et al. 2000;Bearden et al. 2001;Baumann and
Bogerts 2001;Strakowski et al. 2002a;Sheline 2003). In many cases, a systematic search
was either not reported in the text of the article, or was clearly not performed (Norris et
al. 1997;Soares and Mann 1997a;Videbech 1997;Baumann and Bogerts 2001;Sheline
2003). In either case, because no search strategy was reported, the identification of
articles may have been unsystematic and liable to represent the views of the authors
rather than an unbiased estimate of effect size. Other reviews considered samples where
unipolar and bipolar patients were taken together as one sample (Elkis et al. 1995a),
others combined studies using CT or MRI (Hoge et al. 1999). Since it cannot be
assumed that bipolar disorder and unipolar disorders are different expressions of the
same process, it seems unsafe to combine them statistically. Similarly, the combination
of CT and MRI studies in one meta-analysis is not without difficulty and it is perhaps
surprising that the only systematic review to do this found no heterogeneity (Hoge et al.
1999). However, the review considered only whole brain size and does not address the
many other regions of interest implicated in bipolar disorder.
In contrast, the review by Bearden et al (2001) appears systematic,
comprehensive and has clear inclusion and exclusion criteria. However, the authors
made no attempt to combine studies statistically. Given there is no up-to-date,
comprehensive systematic review and meta-analysis of brain structure in bipolar
disorder, this study sought to fill this publication gap in a way which would allow both
direct and indirect comparison of bipolar disorder with schizophrenia.
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3.1.1 Aims
The primary aim of this systematic review was to examine the evidence that the
brains of people with bipolar disorder are different in structure from those of healthy
controls and to describe and quantify any differences found. In addition, studies
comparing patients with bipolar disorder and schizophrenia were also reviewed in order
to assess the diagnostic specificity of any structural MRI findings compared to controls.
In order to address these questions, observational studies meeting pre-specified criteria
were sought and, where appropriate, combined mathematically.
3.2 Methods
3.2.1 Study ascertainment
Primary studies were considered for inclusion if they were published between
1984 and 2003 and compared patients with operationally defined bipolar disorder with a
group of unrelated healthy controls or subjects with schizophrenia. Studies which
included patients with unipolar as well as bipolar affective disorder were only included
if the bipolar patients made up 80% of the sample size or more. Conference abstracts
and letters were included only if there were other publications from the same study that
had been published in full as peer reviewed articles. Studies reporting means and
standard deviations were included in the meta-analysis, but if standard deviations were
missing from the published articles, these were conservatively estimated from the largest
standard deviation from other studies measuring the same structure in the same
volumetric units. In order to facilitate an indirect comparison with the review by Wright
et al (2000), the same brain regions were considered by this review. In addition, the total
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volumes of lateralised brain structures were also considered in addition to their volumes
for each hemisphere separately.
Studies were excluded if they failed to report means for each group, or if they
reported volumes as a proportion of whole brain volume only. Similarly, studies
reporting areas from a single slice only were excluded. Where a single study was
published in several journal articles, the article reporting the largest group size for that
volume of interest was used. Multiple publication of the same sample was suspected
when two or more articles had the same grant numbers, reported the same means and
standard deviations for a single structure and where at least two of the authors were
named on all articles. Multiple publications were also identified when the text of an
article referred to some of the patients or controls having participated in an earlier study
which had already been judged eligible for inclusion. Multiple publications were
identified by three of the authors (AM, SL and JC) and disagreements were resolved by
discussion.
Studies were also excluded when there was a co-morbid diagnosis of learning
disability, chromosomal or genetic disorder. Studies were included irrespective of slice
thickness or inter-slice gap, though these factors were recorded as potential sources of
heterogeneity. Studies were not included when control subjects were genetically related
to affected probands.
3.2.2 Search strategy
The databases Medline, Embase and PsychlNFO were searched using the search
terms 'Bipolar Disorder' and 'MRI' and related terms both as free text and expanded
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subject headings. Details of specific search strategies are given in tabular form below.
Schizophrenia was also included as a subject heading in order to identify studies whose
primary objective was to describe brain volumes in patients with schizophrenia, but
which also included a bipolar group to examine diagnostic specificity.
Figure 3.2.2: Search strategy for location of articles
Medline (Ovid interface at http://gateway.ovid.com)
1. Explode Magnetic Resonance Imaging/ all subheadings
2. "MRI".ti,ab
3. Explode Bipolar Disorder/
4. Explode Mania/
5. Explode Mood Disorders/
6. Explode Schizophrenia/
7. 1 OR 2
8. 3 OR 4 OR 5 OR 6
9. 7 AND 8
Embase (Ovid interface at http://gateway.ovid.com)
1. Explode Magnetic Resonance Imaging/
2. "MRI".ti,ab
3. Explode Bipolar Disorder/
4. Explode Mania/
5. Explode Mood Disorders/
6. Explode Schizophrenia/
7. 1 OR 2
8. 3 OR 4 OR 5 OR 6
9. 7 AND 8
PsychlNFO (WinSPiRs interface at http://www.bids.ac.uk/)




5. Nuclear Magnetic Resonance/
6. 1 OR 2 OR 3
7. 4 OR 5
8. 6 AND 7
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In addition, an online search of the journals Bipolar Disorders, Schizophrenia
Research, Psychiatry Research: Neuroimaging, Psychological Medicine, British Journal
of Psychiatry, American Journal of Psychiatry, Archives of General Psychiatry and the
Journal of Neurology, Neurosurgery and Psychiatry. Most searches were completed
through the web portals of the journals themselves or through the electronic resources of
Elsevier (Science Direct, www.sciencedirect.com) or Blackwell Publishing (SwetsWise,
www.swetswise.com). The initial search took place in November 2002 but was updated
on the 21st November 2003 and 13th January 2004.
3.2.3 Study quality assessment
Abstracts were assessed for possible relevance by one reviewer (AM) and full
text articles were obtained where appropriate. The threshold at which an article was
retrieved in full text for further inspection was set very low. Full text articles were then
reviewed by 3 reviewers (AM, GD, UK: AM read all full-text articles, GD and UK
reviewed 50% each). Studies were included if they met the inclusion criteria above. An
agreed pro-forma was used by all reviewers to extract the necessary information from all
studies.
3.2.4 Data extraction and analysis
Data was extracted by a single reviewer (AM) and checked by a second (SL)
who checked the spreadsheets containing the numbers, means and standard deviation
from each group against the data given in the original articles . Extracted data (numbers,
means, standard deviations and selected covariates) were then entered into STATA SE
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version 8 for windows and stored in a flat text file. Where standard deviations were not
available for a study, these were estimated conservatively from the largest standard
deviation of all other studies included in that comparison.
Statistical analysis was conducted using STATA SE using the 'metan' computer
program written by Michael Braidburn (Centre for Statistics in Medicine, Oxford, UK,
Personal communication). Standardised mean differences were calculated using Cohen's
d statistic:
Where Xj and X2 are the mean volumes from the first and second groups respectively
and Sp is the pooled standard deviation estimated from both groups:
Where n; and SDj are the mean and standard deviation of the ith group. Standardised
effect sizes were then combined using the inverse variance method. The variance of
Cohen's d is estimated as:
Where N is the total sample size for the study, d is Cohen's d and ni and n2 are as
defined above. Random effects analyses (DerSimonian and Laird 1986) were used
throughout to weight each study taking into account the between study heterogeneity Q:




Where w, is the standard deviation of Cohen's d (given above), 0j is the effect size
(Cohen's d) from the ith study and Op/ is the fixed effects estimate of overall effect
calculated using the following formula.
0rv —= Z
2>,
The overall effect size for the comparison was then calculated using the following
formula:
y wo
a — L—t ' 1Wdl ^——
Lw,
Where 0dl is the pooled effect size, w' refers to the amended weight applied to the ith















and can be interpreted as the proportion of variation in effect size due to heterogeneity.
Confidence intervals for the overall effect size 0Dl were calculated from its standard
error:
Where statistically significant heterogeneity was found and accounted for 50% or more
of the variation in standardised effect size, Galbraith plots of the standardised normal
deviate (z) were made against study precision. The Galbraith or Radial Plot was first
described by Galbraith (1988) in the context of clinical trials. The numerical outcome
from each study is divided by its standard error to give a deviation in standard normal
deviation units (i.e. deviation in terms of a normal distribution with mean 0 and standard
deviation 1, often referred to as z). The statistic z is then plotted on the y-axis or ordinate
against study precision (1/standard error) on the x-axis or abscissa. The degree to which
a study lies to the right of the graph is a measure of its weight in the meta-analysis. The
gradient of the line from the origin to a particular study represents its effect size. The
gradient of an unweighted regression line through all of the points represents the fixed-
effects analysis of all studies combined. Studies which form a homogeneous group will
scatter with constant variance along the regression line, with unit standard deviation.
Points far away from the regression line indicate outlying studies which contribute
greatly to the between study heterogeneity. The identification of such trials may be
assisted by the addition of two lines indication the upper and lower 95% confidence
intervals for the regression line. Studies identified as outliers were inspected for critical
methodological differences from other trials and removed from the analysis where
1
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appropriate. The estimates of effect size and heterogeneity were then re-calculated. In
order to re-calculate I2 with the heterogeneous studies removed, Galbraith plots were
only conducted when there were 3 or more studies comparing a specific region of
interest between 2 groups.
For comparisons where the Galbraith plot could not identify an obvious cause for
heterogeneity, a meta-regression analysis was conducted. Meta-regression examines the
relationship between summary effect size and methodological and clinical variables at a
summary level. Effect size is effectively plotted against the characteristic of interest and
the linear equation summarising their relationship is calculated using the restricted
maximum likelihood technique (REML). However, unlike conventional regression
analysis where each data point is given equal weight, meta-regression takes into account
the individual study precision by weighting it by the inverse of its standard error
squared.
A priori meta-regression analyses were conducted for the mean age of bipolar
subjects and the proportion of males in each sample. The rationale for these analyses
was to examine whether any differences exist between males and females, and also to
examine whether any differences between subjects and controls are could be
progressive. We considered using the years of elapsed illness as a more accurate
measure of disease duration. However, in an earlier narrative review of this area it was




The search strategy (last updated 13 January 2004) identified 1746 unique
articles of which 256 appeared were retrieved in full-text. Twenty-nine studies published
in 41 separate articles met the pre-stated inclusion criteria and were tabulated (see table
3.3.1) and entered into STATA for further analysis.
3.3.1 Included studies
Twenty-seven studies compared patients with bipolar disorder with healthy,
unrelated controls. Although one study (Noga et ah, 2001) used a twin design, the
control twins were unrelated to the concordant twins with bipolar disorder used in the
analysis. Included studies are presented in table 3.3.1.1 by main publication and again in
table 3.3.1.2 and 3.3.1.3 by region of interest. Table 3.3.1.2 considers studies comparing
bipolar disorder with healthy controls whilst table 3.3.1.3 considers only those studies
comparing bipolar with schizophrenic patients. Studies finding a larger volume in
bipolar disorder are marked with a + sign and those finding a smaller volume in bipolar
disorder are marked with a - sign. Studies finding an equal volume in bipolar subjects
and controls are marked with a (NC). For most brain regions, measured in at least 3
studies, there is evidence of both increases and reductions in bipolar disorder compared
to controls. However, no studies were identified finding an increased volume of the total
prefrontal cortex in bipolars compared to controls, although differences were found in
both directions when each side was considered separately. The left amygdala-
hippocampal complex was smaller in bipolar patients compared to controls in all studies
measuring this volume, although the differences were less one-sided when the amygdala




































































































































































































































































































Table 3.3.2.2: Volumes in bipolar disorder compared to healthy non-related
controls.
Studies showing larger volumes in bipolars are marked with a (+) sign, differences in the
opposite direction are given a (-) sign and (NC) is used the direction of overall effect is
unclear.
Brain volume Studies
Intracranial volume (ICV) (-) (Harvey et al. 1994)
(Kasai et al. 2003c)
(Getz et al. 2002)
(+) (Lim et al. 1999)
(Sassi et al. 2001)
Whole brain volume (-) (Harvey et al. 1994)
(Strakowski et al. 1993a)
(Strakowski et al. 2002b)
(Schlaepfer et al. 1994)
(Dasari et al. 1999)
(Mcintosh et al. 2001)
(Getz et al. 2002)
(Brambilla et al. 2001a)
(+) (Roy et al. 1998)
(Aylward et al. 1994)
(Dupont et al. 1995)
(Sax et al. 1999)
(Strakowski et al. 1999)
(DelBello et al. 1999)
(Sharma et al. 2003)
Whole brain (grey matter (+) (Strakowski et al. 1993a)
only) (Sassi et al. 2002)
(Sharma et al. 2003)
(-) (Lim et al. 1999)
(Lopez-Larson et al. 2002)
(Schlaepfer et al. 1994)
(Zipursky et al. 1997)
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Brain volume Studies
Whole brain (white matter
only)
(-) (Strakowski et al. 1993a)
(Lopez-Larson et al. 2002)
(Pearlson et al. 1997)
(+) (Zipursky et al. 1997)
(Lim et al. 1999)
(Sassi et al. 2002)
(Sharma et al. 2003)
Total left cerebellum (+) (Brambilla et al. 2001b)
(DelBello et al. 1999)
Total right cerebellum (-) (Brambilla et al. 2001b)
(DelBello et al. 1999)
Cortical limbic structures
Left hemisphere (-) (Noga et al. 2001)
(Botteron et al. 1995)
Right hemisphere (-) (Noga etal. 2001)
(Botteron et al. 1995)
Prefrontal cortex (-) (Sax etal. 1999)
(Strakowski et al. 1999)
(Getz et al. 2002)
(Strakowski et al. 1993a)
Left prefrontal cortex (-) (Strakowski et al. 1999)
(Mcintosh et al. 2001)
Right prefrontal cortex (-) (Strakowski et al. 1999)
(Mcintosh et al. 2001)
Left Subgenual prefrontal
cortex
(-) (Hirayasu et al. 1999)
(Sharma et al. 2003)
(+) (Brambilla et al. 2002)
Right Subgenual prefrontal
cortex
(-) (Hirayasu et al. 1999)
(Sharma et al. 2003)
(+) (Brambilla et al. 2002)
Temporal lobes (-) (Roy etal. 1998)
(+) (Altshuler et al. 2000)
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Brain volume Studies
Left temporal lobe (+)
(-)
(Harvey et al. 1994)
(Swayze et al. 1992)
(Hauser et al. 2000)
(Brambilla et al. 2003)
(Altshuler et al. 1998)
(Mcintosh et al. 2001)
(Pearlson et al. 1997)
Right temporal lobe (+) (Harvey et al. 1994)
(Pearlson et al. 1997)
(Swayze et al. 1992)
(Altshuler et al. 1998)
(-) (Hauser et al. 2000)
(Mcintosh et al. 2001)
(Brambilla et al. 2003)
Amygdala (-) (Blumberg et al. 2003)
(Getz et al. 2002)
(+) (Strakowski et al. 1999)
(Altshuler et al. 2000)
Left amygdala (+) (Swayze et al. 1992)
(Altshuler et al. 1998)
(Strakowski et al. 1999)
(Brambilla et al. 2003)
(-) (Pearlson et al. 1997)
Right amygdala (+) (Altshuler et al. 1998)
(Strakowski et al. 1999)
(Swayze et al. 1992)
(Brambilla et al. 2003)




Left AHC (-) (Noga et al. 2001)
(Mcintosh et al. 2001)
(Kasai et al. 2003a)
(Swayze et al. 1992)
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Brain volume Studies
Right AHC (-) (Noga et al. 2001)
(Mcintosh et al. 2001)
(Kasai et al. 2003a)
(+) (Swayze et al. 1992)
Hippocampus (+) (Altshuler et al. 2000)
(Strakowski et al. 2002b)
(NC) (Sax et al. 1999)
(-) (Strakowski et al. 1999)
(Getz et al. 2002)
(Blumberg et al. 2003)
Left hippocampus (+) (Strakowski et al. 1999)
(Pearlson et al. 1997)
(Hauser et al. 2000)
(Noga et al. 2001)
(Altshuler et al. 1998)
(-) (Swayze et al. 1992)
(Brambilla et al. 2003)
Right hippocampus (+) (Strakowski et al. 1999)
(Brambilla et al. 2003)
(Altshuler et al. 1998)
(-) (Swayze et al. 1992)
(Hauser et al. 2000)
(Pearlson et al. 1997)
(Noga et al. 2001)
Parahippocampus (-) (Altshuler et al. 2000)
Left parahippocampus (+) (Pearlson et al. 1997)
Right parahippocampus (-) (Pearlson et al. 1997)
Left entorhinal cortex (+) (Pearlson et al. 1997)
Right entorhinal cortex (+) (Pearlson et al. 1997)
Left STG (+) (Brambilla et al. 2003)
(Kasai et al. 2003a)
Right STG (-) (Brambilla et al. 2003)
(Kasai et al. 2003a)
Left anterior STG (-) (Pearlson et al. 1997)
(Hirayasu et al. 1998)
Right anterior STG (+)
(-)
(Pearlson et al. 1997)
(Hirayasu et al. 1998)
153
Brain volume Studies
Left posterior STG (-) (Pearlson et al. 1997)
(Hirayasu et al. 1998)
Right posterior STG (+) (Pearlson et al. 1997)




(+) (Getz et al. 2002)
(Aylward et al. 1994)
(Strakowski et al. 2002b)
(Dupont et al. 1995)
(-) (Sax et al. 1999)
Left caudate (+) (Noga et al. 2001)
(Mcintosh et al. 2001)
(-) (Brambilla et al. 2001c)
(Swayze et al. 1992)
Right caudate (+) (Noga et al. 2001)
(Mcintosh et al. 2001)
(-) (Brambilla et al. 2001c)
(Swayze et al. 1992)
Putamen (+) (Getz et al. 2002)
(Strakowski et al. 2002b)
(Aylward et al. 1994)
Left putamen (-) (Brambilla et al. 2001c)
(+) (Swayze et al. 1992)
Right putamen (-) (Brambilla et al. 2001c)
(+) (Swayze et al. 1992)
Globus pallidus (+) (Getz et al. 2002)
(Strakowski et al. 1999)
(Aylward et al. 1994)
Left globus pallidus (+) (Strakowski et al. 1999)
(NC) (Brambilla et al. 2001c)
Right globus pallidus (+) (Strakowski et al. 1999)
(-) (Brambilla et al. 2001c)
Striatum (+) (Getz et al. 2002)
(Strakowski et al. 1999)
Left striatum (+) (Strakowski et al. 1999)
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Brain volume Studies
Right striatum (+) (Strakowski et al. 1999)
Lenticular nucleus (LN) (+) (Dupont et al. 1995)
Left LN (-) (Noga et al. 2001)
(+) (Mcintosh et al. 2001)
Right LN (-) (Noga et al. 2001)
(+) (Mcintosh et al. 2001)
Thalamus (-) (Sax et al. 1999)
(Strakowski et al. 2002b)
(Getz et al. 2002)
(+) (Strakowski et al. 1999)
(Caetano et al. 2001)
Left thalamus (+) (Strakowski et al. 1999)
(Mcintosh et al. 2001)
(Caetano et al. 2001)
Right thalamus (-) (Strakowski et al. 1999)
(Mcintosh et al. 2001)
(Caetano et al. 2001)
Ventricles
Left and right lateral
ventricle
(+) (Swayze et al. 1990a)
(Roy et al. 1998)
(Getz et al. 2002)
(Lim et al. 1999)
Left lateral ventricle (-) (Brambilla et al. 2001b)
(+) (Harvey et al. 1994)
(Swayze et al. 1990a)
(Strakowski et al. 2002b)
(Botteron et al. 1995)
(Strakowski et al. 1999)
(Mcintosh et al. 2001)
(Hauser et al. 2000)
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Brain volume Studies
Right lateral ventricle (-) (Harvey et al. 1994)
(Brambilla et al. 2001b)
(Hauser et al. 2000)
(+) (Swayze et al. 1990a)
(Strakowski et al. 2002b)
(Botteron et al. 1995)
(Strakowski et al. 1999)
(Mcintosh et al. 2001)
Third ventricle (+) (Roy et al. 1998)
(Pearlson et al. 1997)
(Botteron et al. 1995)
(Strakowski et al. 1999)
(Lim et al. 1999)
(Strakowski et al. 2002b)
(-) (Mcintosh et al. 2001)
(Brambilla et al. 2001b)
Fourth ventricle (-) (Mcintosh et al. 2001)
In total 11 studies, that met inclusion criteria, compared bipolar patients with
patients with schizophrenia. The volumes of several brain regions were not measured in
any of the identified studies (e.g. total prefrontal cortex, subgenual prefrontal cortex
(SGPFC)). Most studies reporting left or right temporal lobe volumes found reductions
in bipolar compared to schizophrenic patients. In terms of direction of overall effect, the
results for other brain regions were more discordant.
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Table 3.3.2.3: Volumes in bipolar disorder compared to patients with
schizophrenia.
Studies showing larger volumes in bipolar patients are marked with a (+) sign,
differences in the opposite direction are given a (-) sign and (NC) is used the direction of
overall effect is unclear.
Brain volume Studies
Intracranial volume (ICV) (-) (Harvey et al. 1994)
(+) (Kasai et al. 2003c)
(Lim et al. 1999)
Whole brain volume (+) (Harvey et al. 1994)
(Roy et al. 1998)
(Schlaepfer et al. 1994)
(-) (Dasari et al. 1999)
(Mcintosh et al. 2001)
Whole brain (grey matter (+) (Lim etal. 1999)
only) (Schlaepfer et al. 1994)
(Zipursky et al. 1997)
Whole brain (white matter (-) (Zipursky et al. 1997)
only)
(+) (Pearlson et al. 1997)
(Lim et al. 1999)
Total left cerebellum No studies
Total right cerebellum No studies
Cortical limbic structures
Left hemisphere No studies
Right hemisphere No studies
Prefrontal cortex No studies
Left prefrontal cortex (-) (Mcintosh et al. 2001)
Right prefrontal cortex (-) (Mcintosh etal. 2001)
Left Subgenual prefrontal No studies
cortex
Right Subgenual prefrontal No studies
cortex
Temporal lobes (+) (Altshuler et al. 2000)
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Brain volume Studies
Left temporal lobe (+) (Harvey et al. 1994)
(Rossi et al. 1991)
(Swayze et al. 1992)
(Pearlson et al. 1997)
(Altshuler et al. 1998)
(-) (Mcintosh et al. 2001)
Right temporal lobe (+) (Harvey et al. 1994)
(Rossi et al. 1991)
(Swayze et al. 1992)
(Pearlson et al. 1997)
(Altshuler et al. 1998)
(-) (Mcintosh et al. 2001)
Amygdala (+) (Altshuler et al. 2000)
Left amygdala (+) (Altshuler et al. 1998)
(-) (Pearlson et al. 1997)
Right amygdala (+) (Altshuler et al. 1998)




Left AHC (-) (Mcintosh et al. 2001)
(Kasai et al. 2003a)
(+) (Swayze et al. 1992)
Right AHC (-) (Mcintosh et al. 2001)
(Kasai et al. 2003a)
(Swayze et al. 1992)
Hippocampus (+) (Altshuler et al. 2000)
Left hippocampus (+) (Pearlson et al. 1997)
(Altshuler et al. 1998)
(-) (Swayze et al. 1992)
Right hippocampus (+) (Pearlson et al. 1997)
(Altshuler et al. 1998)
(-) (Swayze et al. 1992)
Parahippocampus (+) (Altshuler et al. 2000)
Left parahippocampus (+) (Pearlson et al. 1997)
Right parahippocampus (+) (Pearlson et al. 1997)
Left entorhinal cortex (+) (Pearlson et al. 1997)
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Brain volume Studies
Right entorhinal cortex (+) (Pearlson et al. 1997)
Left STG (+) (Kasai et al. 2003a)
Right STG (-) (Kasai et al. 2003a)
Left anterior STG (+) (Pearlson et al. 1997)
(Hirayasu et al. 1998)
Right anterior STG (+) (Pearlson et al. 1997)
(Hirayasu et al. 1998)
Left posterior STG (+) (Pearlson et al. 1997)
(Hirayasu et al. 1998)
Right posterior STG (-) (Pearlson et al. 1997)
(+) (Hirayasu et al. 1998)
Subcortical structures
Caudate No studies
Left caudate (+) (Mcintosh et al. 2001)
(-) (Swayze et al. 1992)
Right caudate (+) (Mcintosh et al. 2001)
(-) (Swayze et al. 1992)
Putamen No studies
Left putamen (-) (Swayze et al. 1992)
Right putamen (-) (Swayze et al. 1992)
Globus pallidus No studies
Left globus pallidus No studies
Right globus pallidus No studies
Striatum No studies
Left striatum No studies
Right striatum No studies
Lenticular nucleus (LN) No studies
Left LN (-) (Mcintosh et al. 2001)
Right LN (-) (Mcintosh et al. 2001)
Thalamus No studies
Left thalamus (+) (Mcintosh et al. 2001)
Right thalamus (+) (Mc Intosh et al. 2001)
Ventricles
Left and right lateral
ventricle
(+) (Roy et al. 1998)
(-) (Lim et al. 1999)
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Brain volume Studies
Left lateral ventricle (-) (Harvey et al. 1994)
(Swayze et al. 1990a)
(+) (Mcintosh et al. 2001)
Right lateral ventricle (-) (Harvey et al. 1994)
(Swayze et al. 1990a)
(+) (Mcintosh et al. 2001)
Third ventricle (-) (Roy et al. 1998)
(Lim et al. 1999)
(Mcintosh et al. 2001)
(+) (Pearlson et al. 1997)
Fourth ventricle (-) (Mcintosh et al. 2001)
3.3.2 Excluded Studies
Thirty articles were retrieved which compared patients with bipolar affective
disorder with either controls or patients with schizophrenia, but which either a) failed to
present mean volumes for each group separately, b) expressed volumes as a proportion
of whole brain only, or c) reported a summary measure conflating two volumes (e.g.
ventricle to brain ratio, VBR). Seven studies provided useable data for patients with
affective disorder compared to either controls or patients wit schizophrenia. However,
these studies could not be included because patients with bipolar disorder comprised less
than 80% of the affective disordered sample. The studies excluded are listed in table
3.3.2.1.
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Table 3.3.2.1: Studies excluded from the review
Study Reason for exclusion
Besson (1987), Hauser (1989b), Johnstone (1989),
Swayze (1990b), Olson (1990), Altshuler (1991),
Risch (1992), Juijus (1993a;1993b), Strakowski
(1993b), Bullmore (1994), Kato (1994), Altshuler
(1995), Lewine (1995), Shiori (1996), Hirayasu
(1998), Loeber (1999), Friedman (1999), Bilder
(1999), McDonald (1999), Krabbendam (2000),
Deicken (2001), Moore (2001a), Moore (2001b),
Pillai (2002), Cecil (2002), Loeber (2002),
McCarley (2002), Kieseppa (2003), Sassi (2003)
No useable data reported.
Variety of reasons (no volumes,
VBR only, volumes expressed as
proportion of whole brain
volume)
O'Brien (1996a), O'Brien (1996b), O'Brien (1997),
Velakoulis (1999), Wood (2001), Kegeles (2003),
Keshevan (2003)
Affective disordered group
contained <80% bipolar patients
3.3.3 Meta-analysis of region of interest studies
Random effects analyses were conducted for 60 separate regions of interest for
the bipolar versus control comparison. However, many of these regions have not been
compared between patients with bipolar disorder and schizophrenia, which limited the
number of analyses that could be performed.
Statistically significant evidence of an increase in volume in bipolar compared to
controls was found for the following structures: right amygdala (5 studies, 318 subjects),
total globus pallidus (3 studies, 130 subjects), left (1 study, 44 subjects), right (1 study,
44 subjects) and total striatum (2 studies, 70 subjects), left thalamus (3 studies, 153
subjects), left (8 studies, 434 subjects) and total lateral ventricles (3 studies, 78 subjects).
Left anterior STG (2 studies, 121 subjects) volume was reduced in bipolar patients
compared to controls. Evidence was also found for larger total temporal lobe (1 study,
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44 subjects), total hippocampus (1 study, 44 subjects), left (1 study, 73 subjects) and
right (1 study, 73 subjects) entorhinal cortex, total (1 study, 34 subjects) and right (2
studies, 99 subjects) amygdala, left total STG (1 study, 28 subjects), and left posterior
STG (2 studies, 106 subjects) in bipolar disordered patients compared to those with
schizophrenia. Bipolar patients showed significant reductions in right prefrontal cortex
(1 study, 30 subjects) compared to patients with schizophrenia, and left lateral ventricle
volume showed a non-significant trend in this direction.
There was evidence of considerable heterogeneity, both in terms of magnitude
and statistical significance. The variation in effect size due to statistical heterogeneity
was in most cases greater than 40%, and in some cases (e.g. total and left amygdala
volume for bipolar-control, and left and right hippocampus for bipolar-schizophrenia)
greater than 80%. However, in comparisons using fewer than 3 studies, the magnitude of
heterogeneity could not be quantified using I2 although statistical significance can be
calculated with a few as two studies. Statistical heterogeneity was present in all cases
where I2 was greater than 70% and also in some comparisons where there were only two
studies (e.g. right globus pallidus for bipolar-control comparison). The results of the
meta-analysis are shown in the following 2 tables.
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Sensitivity analyses were conducted for those brain regions where the proportion
of variation in effect size attributable to heterogeneity (I2) exceeded 50% and the number
of included studies for that region was greater or equal to 3. Standardised effect size was
plotted against study precision in order to identify those studies contributing most to
heterogeneity. The summary effect size was then re-calculated excluding those studies
whose contribution to overall heterogeneity was the greatest. Possible methodological
reasons for the observed heterogeneity were identified by inspecting the methods
sections of the excluded articles.
For the bipolar versus control comparison, four brain regions merited further
consideration using the planned sensitivity analysis described above (whole brain grey
matter, total amygdala, left amygdala and total globus pallidus). Similarly, in bipolar
patients compared to patients with schizophrenia, four regions merited further
consideration using sensitivity analysis (intracranial volume, whole brain white matter,
left hippocampus and right hippocampus). The results of the sensitivity analyses are
given in the following Galbraith plots along with explanatory text.
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The only study to lie outside the 95% confidence intervals was the study by
Lopez-Larson et al (2002). However, the exclusion of this study made little difference to
the effect size (-0.05, 95%CI -0.48 to 0.37) or heterogeneity which remained high and
statistically significant (I2=0.61, p=0.03). Since there seemed to be no obvious
methodological reason to exclude this study in the final analysis, it was retained for the
next stage of meta-regression.
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Three studies lay outside the 95% confidence intervals (Strakowski et al.
1999;Altshuler et al. 2000;Blumberg et al. 2003). Exclusion of these studies left a single
study (Getz et al. 2002) from which heterogeneity could not be calculated. There seemed
to be no methodological reason to exclude the three studies contributing most to overall
heterogeneity. However, a visual inspection of the Galbraith Plot revealed a possible
relationship between year of publication and effect size, with more recent studies
tending to find reductions in bipolar subjects compared to controls. All studies were
therefore retained for meta-regression analysis.
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Figure 3.3.4.3: Galbraith plot of standardised effect size for left amygdalain bipolar patients versus controls
b/se(b) Fitted values
1997H I ! 1 [~0
4.86761
1/se(b)
Two studies lay clearly outside the 95% confidence intervals (Pearlson et al
1997; Altshuler 1998) but in opposite directions. Exclusion of these studies changed the
results such that there was an effect size of 0.47 (95%CI 0.06 to 0.88) and no statistically
significant heterogeneity (I2=0.50, p=0.14). This result excluding these two studies
suggests that left amygdala volumes are increased in bipolar patients compared to
controls. However, since there appeared to be no sound methodological basis on which
to exclude these studies, they were retained and analysed further by meta-regression.
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One study lay outside the 95% confidence intervals for standardised effect size
(Getz et al., 2002). After removal of this study, the effect size became marginally non¬
significant (test for overall effect z=l .95, p=0.051) showing a trend to larger total globus
pallidus volumes in bipolar patients compared to healthy controls (effect size=0.46,
95%CI 0.00 to 0.93) with no statistically significant heterogeneity (x2=1.42, p=0.23).
Unfortunately, since only two studies were then included in this compassion, the
magnitude of any associated heterogeneity could not be quantified. Methodological
differences between two of the studies were slight (Strakowski et al 199;Getz et al 2002)
although the third study used interleaved rather than contiguous slicing to image the
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whole brain (Aylward et al, 1994). Consequently, a obvious cause for the relatively
extreme effect size found in Getz et al (2002) could not be identified.
The Galbraith plots presented in the following pages concern bipolar disorder versus
schizophrenia comparisons.
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Figure 3.3.4.4: Galbraith Plot of intracranial volume in bipolar patients











The study by Lim et al (1999) lay clearly outside the 95% confidence intervals.
Because this study used an automated instead of conventional region of interest analysis
(ROI), we decided to remove it from the analysis. Once removed, the effect size was
estimated as -0.13 (95%CI -0.46 to 0.20) with no statistically significant heterogeneity
(I =0.12, p=0.32). This result suggests that, after excluding the study using automated
instead of ROI, no statistically significant differences between bipolar and schizophrenic
patients were found.
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The study using an automated rather than a conventional ROI approach was the
only study to lie clearly outside the 95% confidence limits. Removing this single study
lead to an observed effect size of 0.07 (95%CI -0.46 to 0.60) with no statistically
significant heterogeneity (p=0.19). However, since the exclusion of Lim et al (1999) left
only two remaining studies, I2 could not be quantified.
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The plot shows that the study by Altshuler et al (1998) is the only one to lie
outside the 95% confidence limits. Exclusion of this single study resulted in an effect
size of 0.08 (95%CI -0.63 to 0.78). However, heterogeneity remained statistically
significant (p=0.02), although I2 could not be calculated with only 2 remaining studies.
However, since there was no obvious methodological reason to exclude this study, it was
retained for further analysis.
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The Galbraith Plot shown above demonstrates that Altshuler (1998) is an extreme
observation and lies outside the 95%CI for standardised effect size. Excluding this study
results in a standardised effect size of -0.003 (95%CI -0.49 to 0.48) with no statistically
significant heterogeneity (p=0.12). However, since only two studies were included, I2
could not be calculated and since there appeared to be no strong methodological reason
to exclude this study, it was retained for further analysis.
3.3.5 Meta-regression
Since some of the heterogeneity was reduced and explained by the inclusion of a
study using automated rather that semi-automatic analysis, meta-regression was used
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only for the comparisons where this methodological difference between studies did not
apply, and where there were three or more studies. Therefore, meta-regression analyses
were performed for intracranial, total grey matter, left and right amygdala and total
globus pallidus volumes for the bipolar-control comparison, and also for left and right
hippocampal volumes for the bipolar-schizophrenia comparison.














WB (Grey) -0.01 0.78 -1.06 0.35 0.02 0.81
(-0.2, 0.09) (3.25, 1.14) (-0.12,0.15)
Total amygdala 0.04 0.55 0.02 0.26 -0.53 <0.001
(-0.09, 0.16) (-0.01, 0.05) (-0.70, -0.35)
Left amygdala 0.03 (-0.07, 0.54 10.4 0.15 0.07 0.51
0.13) (-3.7, 24.47) (-0.14, 0.28)
Total GP -0.08 0.46 0.02 0.013 0.18 0.03
(-0.28, 0.23) (0.00, 0.04) (0.02, 0.35)
BPD vs. SCZ
Left hippocampus 0.06 0.14 IC IC 0.17 0.002
(-0.02,0.15) (0.06, 0.28)
Right 0.08 0.012 IC IC 0.19 0.12
hippocampus (0.02,0.15) (-0.05, 0.42)
*Proportion of bipolar group who are male, GP: Globus Pallidus, IC: Incalculable because proportion of
male subjects not reported in >2 studies
Meta-regression analyses found that higher proportions of male patients tended
to find larger effect sizes for total globus pallidus volume compared to controls,
suggesting that the enlargement found in bipolar patients may be greater in males than in
females.
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Larger right hippocampi in bipolar subjects compared to schizophrenic subjects
were also positively associated with advancing years compared to schizophrenic
patients.
Year of study publication was associated with smaller amygdala sizes in bipolar subjects
compared to controls, larger globus pallidus volumes in bipolars compared to controls
and larger hippocampi in bipolars compared to patients with schizophrenia.
3.4 Discussion
3.4.1 Main Findings
This review found that compared to controls there is good evidence that patients
with bipolar disorder have a smaller total frontal lobe volume (4 studies) and left
anterior superior temporal gyrus (2 studies). Bipolar subjects also appear to have a larger
right amygdala (5 studies), left thalamus (5 studies), total globus pallidus (3 studies),
total striatum (2 studies) and total lateral ventricles (3 studies).
Limited evidence was also found for a larger right thalamus and larger left and
right lateral ventricles, although these findings were not statistically significant at a p-
value of less than 0.05. Large standardised effect sizes (d> 0.6) were found for total
striatum and for left and right ventricle combined, without significant heterogenity. This
meta-analysis did not find a decrease in subgenual prefrontal cortex volume based on
three studies of 129 subjects. This direction of effect size suggests a possible reduction
but there are insufficient studies to investigate potential sources of heterogeneity or
publication bias.
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The number of studies comparing bipolar and schizophrenic patients was much
less. Right amygdala volume was increased in bipolar subjects with a greater effect size
than that seen for the bipolar-control comparison. This suggests that amygdala volumes
are decreased in schizophrenia but increased in bipolar disorder. This finding has
further support from a systematic review and meta-analysis of schizophrenic subjects
which showed reductions in patients compared to controls (Wright et al. 2000). Left
posterior STG was also significantly larger in bipolar subjects compared to those with
schizophrenia. Limited evidence was found for larger temporal lobe and left lateral
ventricle volumes in bipolar subjects, although these findings did not reach statistical
significance. The largest effect size was for right amygdala enlargement in bipolar
disorder, although this was based on only two studies with a total of 99 subjects and
although there was no statistical significant heterogeneity, the number of studies was
inadequate to investigate this rigorously.
Heterogeneity was found for many bipolar-control and bipolar-schizophrenia
comparisons. Some of this heterogeneity was explained by the presence of a single study
which used an apparently automated technique (Lee et al, 2002) which appeared to find
a systematically different result from the other studies. This does not necessary imply
that the remaining studies provide a more accurate or true estimate; it is possible that the
reverse is the case. However, the fact that the heterogeneity was largely accounted for
by this methodological difference justified the re-calculation of summary effect size with
it excluded from the analysis.
Heterogeneity was also partially explained by age, proportion of male subjects or
year of publication. The greater volume of the right hippocampus found in bipolar
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subjects compared to schizophrenic patients appears to increase in magnitude with
increasing age. This may be due to a tendency for the hippocampus to diminish in size in
schizophrenia as successive years of illness pass by in affected patients (Jacobsen et al.
1998). The proportion of male subjects in each study was also associated with larger
total globus pallidus volume in patients compared to controls. This finding suggests that
males have a greater degree of striatal enlargement than females and this may be
associated with antipsychotic medication exposure. It is unfortunate that this could not
be investigated directly in this study, although it may provide a basis for future analyses.
Finally, the degree to which amygdala, globus pallidus and whole brain volumes
differed between controls and schizophrenic patients differed according to the year of
publication. We suggest that these differences may be due to advances in image
acquisition and analysis that have occurred over time, but may also reflect a tendency for
studies to vary in their inclusion and exclusion criteria over time.
The relationship of brain structure to the development of bipolar disorder has
been hampered by the lack of appropriately designed and sufficiently powered studies.
The case-control studies identified by this review are generally small and are unable to
address whether brain differences arose prior to illness or are as a consequence of the
disease process or its treatment. The added difficulty of multiple publication from one
centre (particularly Kasai, Hirayasu, Lee and others) is likely to afford that study more
weight in the literature than if it had been published only once.
There is however, some evidence from this review that bipolars may differ from
controls in terms of prefrontal cortex, amygdala, anterior STG, striatum and thalamus.
There is also some (lesser) evidence that bipolars differ from schizophrenic patients in
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prefrontal cortex, amygdala, temporal lobe, entorhinal cortex and left STG. Many of the
regions implicated in this review have been associated with abnormalities in emotional
processing (Phillips et al. 2003). In depressed and manic states, abnormal activity in the
dorsal prefrontal cortex has been found in several studies (O'Connell et al. 1995;Ketter
et al. 2001), although the direction of difference compared to controls is not always the
same. Amygdala and thalamic perfusion may increase in depressed bipolar patients
compared to controls during the performance of executive tasks (Ketter et al. 2001)
although the results for manic patients are more conflicting (O'Connell et al.
1995;Gyulai et al. 1997) but also suggest a possible decrease in striatal activity during
these tasks (Blumberg et al. 2000). The findings in euthymic patients have not been
investigated to the same degree but generally suggest an lower degree of abnormality
compared to depressed or manic subjects (Phillips et al. 2003). However, a study
examining cerebral perfusion during facial expressions of fear found reduced prefrontal
and increased amygdala perfusion in bipolar subjects (Yurgelun-Todd et al. 2000).
It is not easy to suggest a single common mechanism for the structural and
functional imaging findings found in bipolar disorder. There is no doubt that connections
exist between temporal lobe, prefrontal cortex and amygdala, that many of these
connections involve the thalamus (Nolte 1988) and that researchers have proposed
several sub-cortical loops each sub-serving a specific function (Papez 1937;Alexander et
al. 1990). Dysfunction in any one of these structures might give rise to problems in
emotional sensitivity or regulation in itself. Since abnormalities are found in several of
these structures in bipolar patients, it is possible that these circuits may require several
'hits' before symptoms of bipolar disorder emerge.
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3.4.2 Strengths and Limitations
3.4.2.1 Publication bias
Statistically significant evidence of publication bias was evident for two
structures. Total amygdala volume in bipolar subjects compared to controls, and left
amygdala-hippocampal complex for the bipolar-schizophrenia comparison (see
following funnel plots). Total amygdala volume in bipolar disorder shows a significant
tendency for smaller studies to find a larger volume in healthy controls. This may have
been because a finding in this direction was initially viewed as more plausible and small
studies finding a similar effect, but in the opposite direction, have been difficult to
publish. Studies measuring amygdala-hippocampal complex volumes in bipolar disorder
show a tendency for smaller studies to find greater reductions in schizophrenic subjects.
The largest study finds no significant difference between bipolar and schizophrenic
subjects in either direction. This finding may reflect a perception amongst researchers
that amygdala-hippocampal volumes were specific to schizophrenia and a tendency for
small studies finding no difference to be less interesting and therefore less likely to be
published.
The explanation of publication bias using the funnel plot is however somewhat
speculative. Funnel plot asymmetry may reflect a bias in the location, identification as
well as the publication of articles. Therefore the observed funnel plot asymmetry may
reflect the fact that other evidence is available in non-indexed journals, foreign
languages, and conference proceedings. Alternatively, small studies showing results in
the opposite direction may not have been identified by the search strategy.
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Figure 3.4.2.1: Funnel plot of standardised mean difference against
standard error for total amygdala volume in bipolar subjects versus
controls.
Begg's funnel plot with pseudo 95% confidence limits
Figure 3.4.2.2: Funnel plot of standardised mean difference against
standard error for left amygdala-hippocampal volume in bipolar subjects
versus schizophrenics.
Begg's funnel plot with pseudo 95% confidence limits
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3.4.3 Future studies
The differences between healthy controls and patients with bipolar disorder are
in general more modest than those found in schizophrenia and many show considerable
heterogeneity. However, the average sample size is small and most studies are
underpowered to detect the magnitude of effect sizes quoted in table 3.3.3. When bipolar
subjects are compared to subjects with schizophrenia, the problem is compounded
further by a lack of any publications for several regions of interest.
The comparison of bipolar and schizophrenic patients has much to tell us about
the biology of both disorders and their component symptoms. Unfortunately, until
studies with at least modest sample sizes of more than fifty are conducted, it is likely
that sMRI research in bipolar disorder will trail that of schizophrenia by several years.
Studies should not consider the distinction between Bipolar I and Bipolar II disorders
prematurely since several issues for bipolar disorder as a whole continue to require
clarification. The emphasis on sub or endophenotypes of bipolar disorder is likely to
pose practical problems for researchers that will limit sample sizes.
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Chapter 4: Clinical, Neuropsychological and Imaging
Methods
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4.1 Patient identification and recruitment
At the beginning of 2001 a study protocol was sent to all consultant psychiatrists in
Lothian informing them of the proposed study. A letter enclosed with the protocol
invited them to refer patients aged 18-65 who belonged to one of the following groups.
• Patients with a diagnosis of schizophrenia who had one or more close relatives
with either bipolar disorder or schizophrenia.
• Patients with a diagnosis ofbipolar disorder who had one or more relatives with
either bipolar disorder or schizophrenia.
Consultants were asked not to refer patients with a history of neurological illness,
learning disability or those with a diagnosis of alcohol dependence syndrome. Patients
were also identified through informal contacts with Specialist Registrars in Psychiatry,
General Practitioners and also from families already known to the Department of
Psychiatry. Permission from the patient's responsible consultant was sought in all cases.
Once a potentially suitable patient had been identified, they were then approached in
writing with a view to obtaining their informed consent. Those patients who gave their
consent were then invited to attend the Division of Psychiatry at the Kennedy Tower,
Royal Edinburgh Hospital with a view to their involvement in the current study.
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4.2 Recruitment of well relatives
Well relatives were identified from the families of affected patients by referring
to psychiatric records and from family history data given by the subjects themselves.
The permission of the affected subject was also sought before unaffected relatives were
approached and there was always some discussion about what historical material may or
may not be revealed to their well relative. In most cases the affected subject themselves
would then approach their well relative with the department's contact details, although
on some occasions patients asked if we would approach their relatives directly, either in
writing or by telephone. Relatives giving informed consent were then invited to the
Division of Psychiatry with a view to their involvement. All relatives were then screened
with the schedule for affective disorders and schizophrenia to ensure a lifetime absence
of schizophrenia, bipolar disorder or major depression.
4.3 The Present State Examination (PSE)
All patients and healthy relatives were interviewed using the Present State
Examination version 9 (Wing et al. 1974) with a view to categorising their current
symptoms according to one of the following groups:
1. No symptoms
2. Unspecified symptoms from the PSE not rated in items 2 or 4 (below)
3. Anypartially rated psychotic symptoms from sections 55-92 or 49-54
4. Anyfully rated psychotic symptoms from sections 55-92 or 49-54
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Patient relatives who met CATEGO criteria for affective disorder or schizophrenia
were excluded from the study. Information obtained from the PSE was also used to
supplement information obtained from psychiatric records.
4.4 Case note assessment
The psychiatric records of index patients were obtained in all cases. In addition
the psychiatric records of other affected family members were also sought.
4.4.1 The OPCCI
Using the psychiatric records and information obtained from the PSE the lifetime
ever occurrence of 90 signs, symptoms and other variables was recorded using the
Operational Criteria Checklist (McGuffin et al. 1991). Additional information was
obtained on age of onset, the relationship between affective and psychotic symptoms and
several other clinical and demographic variables.
4.4.2 The OPCRIT computer program
The data obtained from psychiatric records and the PSE using the OPCCI was
entered into the OPCRIT computer program. The OPCRIT computer program runs in a
Microsoft DOS operating environment and generates operational diagnoses according to
several international classifications. The clinical diagnoses of patients referred with
Bipolar Disorder or Schizophrenia were confirmed according to the Diagnostic and
Statistical Manual of the American Psychiatric Association (volume 4) using this
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instrument. Subjects who failed to meet diagnostic criteria for either bipolar disorder or
schizophrenia were excluded from the study
4.5 Recruitment of healthy controls
4.5.1 Method of identification
Healthy controls aged 18-65 were identified first from the social networks and
non-genetic family members of the patients themselves. Additional healthy controls
were also recruited using a number of other methods including:
• Advertising through two local village newsletters
• Advertising through the notice board of a local leisure centre
• By asking controls who had completed all assessments to identify other potential
control subjects
Controls giving written informed consent were then invited to attend the Division of
Psychiatry with a view to their involvement in the current study.
4.5.2 Control screening procedure
Controls without a known personal or family history of affective disorder or
schizophrenia were then interviewed by the principle researcher (AM) with the Schedule
for Affective Disorders and Schizophrenia (Endicott and Spitzer 1978). Those meeting
criteria for major depressive disorder, bipolar disorder or schizophrenia were excluded
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from further consideration. Relatives of affected probands were also screened using this
instrument to ensure that they too had no lifetime history of affective disorder or
schizophrenia.
4.6 Demographic data set collected on all subjects and controls
4.6.1 Personal and paternal socio-economic status
The occupation of all subjects and controls was recorded at the time of
participation in the study. These occupations were then classified according to the
Register Generals Occupational Classification into the following mutually exclusive
ordinal categories.








Socioeconomic status is a potential covariate in neuropsychological and
neuroimaging studies. However, its role may be partly explained by other factors such as
IQ. Furthermore, socioeconomic status may decline at the time of illness and be a poor
measure of the original socio-economic group to which patients would have originally
belonged. Therefore, no attempt was made to match groups on social class since this
might have the effect of selecting controls that were from relatively disadvantaged
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backgrounds compared to the affected patients. Since individual levels of social class are
ordinal and unlikely to be linearly related to any neuropsychological or brain measures,
socio-economic status was tabulated as manual (IIIb to V) or non-manual (I To Ilia).
This also had the additional effect of collapsing tables which had expected cell counts of
less than 5, and enabled socioeconomic status to be entered, where necessary, as a single
2-level dummy variable, rather than as 6 2-level dummy variables with the consequent
reduction in degrees of freedom and added complexity that would have entailed.
4.6.2 Alcohol, substance and cigarette History
All participants were asked about their weekly alcohol consumption in the weeks
leading up to the study. In particular participants were asked on average how many days
a week they drank and on each occasion how much they drank. By multiplying these
figures together we obtained an approximate weekly consumption of alcohol in standard
8g units of ethanol. Information was also collected on alcohol consumption on the day
preceding neuropsychological testing. Patients were also asked how many cigarettes
they smoked on an average day.
Information regarding illicit drug misuse was also recorded at face-to-face
interview. Participants were asked in particular whether they had ever used cannabis,
cocaine, heroin, LSD, barbiturates, benzodiazepines or ecstasy. Current use was also
recorded, but if participants were clearly dependent on illicit substances they were
excluded from further consideration.
4.6.3 Height, weight and handedness
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The height of each participant was recorded at interview in centimetres. Later,
when patients attended for an MRI scan of the brain, they were routinely weighed and
each weight was recorded in kilograms. Handedness was recorded by asking which hand
people used for writing. Where patients were able to use both hands equally well,
handedness was recorded as ambidextrous.
4.6.4 Educational history
The educational history of each participant was recorded by asking the age at
which they left full time education. In those subjects who left education at 16 or under,
their educational attendance was recorded as 'compulsory only'. Where participants left
school after the age of 16, or immediately went onto further or higher education, the
educational history was recorded as 'more than compulsory'.
4.6.5 Marital status
Marital status was recorded as married, when subjects were currently married,
single when they had never been married and divorced when they had previously been
divorced from a spouse but had not remarried.
4.6.6 Current medication
Current medication was recorded at face-to-face interview. When participants
could not remember the drugs or doses being prescribed, this information was sought
from psychiatric records. The prescription of conventional and 'atypical' antipsychotics,
benzodiazepines, lithium and antidepressants were recorded as 'yes' or 'no'.
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Additionally, conventional antipsychotic doses were converted into chlorpromazine
equivalents and all lithium prescriptions were converted to bioequivalent doses of
lithium carbonate.
4.7 Measurement of genetic loading for psychosis
Most common psychiatric conditions, including schizophrenia do not show a
Mendelian pattern of inheritance. However, those who are affected can be graded along
a continuum of severity and even those who are unaffected, but closely related to one or
more schizophrenic relatives may show partial signs of the disorder. It is possible to fit a
genetic model to this data which assumes an underlying liability to the disorder which is
continuously distributed in thee general population (Pearson and Lee 1901). Individuals
who pass a threshold on genetic liability would therefore be expected to manifest the
condition. If the underlying liability is mediated by many genes, then it can be assumed
that genetic liability to schizophrenia is approximately normally distributed.
Furthermore, the relatives of affected probands would also be expected to have an
approximately normally distributed genetic liability whose modal value would be shifted
to the right compared to the general population. Since higher numbers of people would
be expected to cross the threshold of genetic liability, more relatives would be predicted
to develop symptoms than unselected members of the general population.
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Figure 4.7.1: Genetic liability-threshold model of disease
F hreshold
Population mean \) population affected
Proportion of
Liability
4.7.1 Method of calculation
Assuming that genetic liability (z) has normal distribution and that at a given
threshold (z=t) people with liabilities greater than t develop schizophrenia; a
mathematical model can be fitted. The area under the normal curve to the right of a
given threshold represents the probability of being affected and, taking the example of
schizophrenia, the area bounded by the curve, infinity and the threshold liability (z=t)
will equal the prevalence of the disorder (p). In order to fit the model, we first assume
that the genetic liability of an individual selected at random for a population is zero. The




Where O"1 is the inverse standard cumulative normal distribution function. For
schizophrenia, p can be assumed to take the value 0.005 (Jablensky 1997), from which
t=2.58 (®_1(0.995)) can be calculated. The mean liability of those affected and
unaffected can then be calculated as follows:
The general formula for the mean of a continuous variable:
[ z.f(z) dz
allz
where f(z) is the probability density function. The denominator of this function
disappears because the sum of all probabilities for a continuous probability density












For schizophrenia (prevalence=0.005) and bipolar I disorder (prevalence^.008)
(Judd and Akiskal 2003), the equations can be solved to give the following result:
Table 4.7.1: Expected liabilities in schizophrenia and bipolar disorder







However, the above expected liabilities do not take in account sample
information about the affected or unaffected status of family members. In order to take
this information into account, the relatedness of family members to each other and the
genetic contribution to the disorder needs to be expressed. Relatedness of family
members to one another is usually expressed as (0.5)n. For example, a given person
shares 100% of his genetic liability with himself, so his relatedness is 1 or 0.5°. The
same individual shares only 50% of his genetic material with his parents, siblings and
children and only 25% with his grandparents, grandchildren, nieces, nephews, aunts and
uncles. The relatedness is therefore expressed as 0.5 (0.5!) and 0.25 (0.52) respectively.
The matrix of relatedness for a given family can be expressed as a square matrix.












Where the rows and columns of the matrix represent the members of the family
numbered in figure X.
If a disorder was not genetic however, the degree of relatedness would not need
to be taken into account, since an affected relative would not be a risk factor for the
disorder in other healthy probands. If however, the genetic contribution to a disorder is
expressed as h2, then the liability posed by an additional relative would be h2 x
relatedness. Therefore, in order to reflect this fact, the off diagonals of the matrix of
relatedness are multiplied by h2. Taking h2 to be 0.7 for schizophrenia, then the matrix
becomes:
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f 1 0 0.5x0.7^
0 1 0.5x0.7
0.5x0.7 0.5x0.7 1
f 1 0 0.35a
0 1 0.35
v 0.35 0.35 1 /





In order to calculate the actual genetic liabilities for each family member, the
product RV_1X is calculated to give another 3 cell column vector:
(RV ')X



















Therefore the liability for the affected father, unaffected mother and unaffected
son are 2.85, -0.19 and 0.81 respectively. This method was used to calculate the genetic
liability of all individuals in the current study from their family's pedigree. Pedigrees
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were constructed from information obtained from the subjects themselves, their well
relatives and from psychiatric case notes. For families in whom some individuals were
affected with bipolar disorder and others schizophrenia, the genetic liability for both
disorders was calculated separately. Affected relatives with bipolar disorder were
assumed to be unaffected when calculating the genetic liability for schizophrenia and
vice versa. This method was chosen partly for the sake of simplicity and partly because
the degree to which a family history of schizophrenia predisposes to affective disorder
had not been adequately quantified at the time of the experiment.
4.8 Baseline clinical data set collected on all subjects and controls
In addition to the demographic and historical information collected on all
participants, a core dataset of current manic, depressive and positive psychotic
symptoms was also collected. Symptoms were assessed using established rating scales
administered to all subjects no more than 24 hours from the time of their
neuropsychological assessments. The details of each assessment are given in the
following sections.
4.8.1 The Positive and Negative Symptom Scale
The positive and negative symptom scale (PANSS, Kay et al. 1987) is a 30 item
scale derived partly from the Brief Psychiatric Rating Scale (BPRS, Overall and Gorham
1962). The scale is subdivided into three subscales: positive, negative and general
psychopathology. The individual items of each scale are shown in the table below. Each
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item is rated according to a glossary definition. All assessments using the PANSS were
completed by the same researcher (AM) after a period of training.
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Difficulty in abstract thinking



















Rating of individual items from the Positive and Negative Symptoms Scale
1 = Absent
2 = Minimal 5 = Moderately severe
3 = Mild 6= Severe
4 = Moderate 7= Extreme
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4.8.2 The Young Mania Rating Scale
Table 4.8.2: The Young Mania Rating Scale
Elevated Mood
0. Absent
1. Mildly or possibly increased on questioning
2. Definite subjective elevation; optimistic, self-
confident; cheerful; appropriate to content
3. Elevated, inappropriate to content; humorous
4. Euphoric, inappropriate laughter
Language-Thought Disorder
0. Absent
1. Circumstantial; mild distractibility; quick
thoughts
2. Distractible; looses goal of thought; changes
topic frequently; racing thoughts
3. Flight of ideas; tangentiality; difficult to follow;
rhyming, echolalia




2. Animated; gestures increased
3. Excessive energy; hyperactive at times; restless
(can be calmed)




2. questionable plans, new interests
4. Special project(s), hyperreligious
6. Grandiose or paranoid ideas; ideas of reference
8. Delusions or hallucinations
Sexual Interest
0. Normal; not increased
1. Mildly or possibly increased
2. Definite subjective increase on questioning
3. Spontaneous sexual content; elaborates on sexual
matters




2. Sarcastic; loud at times, guarded
4. Demanding, threats on ward
6. Threatens interviewer, shouting; interview
difficult
8. Assaultive, destructive; interview impossible
Sleep
0. Reports no decrease in sleep
1. Sleeping less than normal amount by up to one
hour
2. Sleeping less than normal amount by more than
one hour
3. Reports decreased need for sleep
4. Denies need for sleep
Appearance
0. Appropriate dress and grooming
1. Minimally unkempt
2. Poorly groomed; moderately dishevelled;
overdressed
3. Dishevelled; partly clothed; garish make-up




4. Irritable at times during interview; recent
episodes of anger or annoyance on ward
6. Frequently irritable during interview; short, curt
throughout




2. Admits behaviour change but denies illness
3. Admits possible behaviour change, but denies
illness
4. Denies any behaviour change
Speech (rate and amount)
0. No increase
2. Feels talkative
4. Increased rate or amount at times; verbose at
times
6. Push; consistently increased rate and amount;
difficult to interrupt
8. Pressured; uninterruptible, continuous speech
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The Young Mania Rating Scale (Y-MRS) (Young et al. 1978) is an eleven item
rating scale conducted at face-to-face interview. All participants were rated using this
instrument (AM).
4.8.3 The Hamilton Depression Rating Scale
The Hamilton Rating Scale for Depression (HRSD) (Hamilton 1960) is a 21 item
rating scale completed at face-to-face interview with subjects. Each item consists of a
symptom or sign which is rated according to an ordinal scale. By adding the score from
each item a total score is generated which is thought to reflect the severity of depressive
symptoms. All participants in the study were rated using the HRSD by single researcher
(AM).
Table 4.8.3: Items of the Hamilton Depression Rating Scale
Item Description
1 Depressed mood










12 Somatic symptoms (gastrointestinal)




16 Loss of weight
17 Insight
18 Diurnal variation
19 Depersonalisation and derealisation
20 Paranoid symptoms
21 Obsessional and compulsive symptoms
4.9 Neuropsychological battery
The test battery chosen was designed to include tests which had previously been
shown to distinguish individuals with schizophrenia or bipolar disorder from controls.
The battery was organised according to domain of neuropsychological function in
accordance with standard practice.
Table 4.9: Neuropsychological test battery
Neuropsychological function Tests
Current intellectual function
Wechsler Abbreviated Scale of
Intelligence (WASI)
Premorbid intellectual function National Adult Reading Test
Memory
Rivermead Extended Behavioural Memory
Test (version A)
Executive function
Hayling Sentence Completion Test
(Response inhibition)
Verbal Fluency (FAS) and semantic
category (Animals)
(Spontaneous production)




Digit Symbol Substitution Test
CANTAB Simple and Choice Reaction
Time
Handedness Hand preference for writing
4.10 Current and premorbid functioning
4.10.1 The Wechsler Abbreviated Scale of Intelligence
Current intellectual functioning was measured using the Wechsler Abbreviated
Scale of Intelligence (WASI). The WASI consists of 4 subscales: vocabulary, block
design, similarities and matrix reasoning that were selected to provide accurate and
reliable measures of verbal, performance and full scale IQ. The test itself has been
subject to numerous pilot, scoring and quality control studies and has been shown to be
valid and reliable for the age range 6 to 89 years.
All subtests are completed at face-to-face interview with a subject. Directions for
the administration and scoring of each subtest are provided in an accompanying text.
The first (vocabulary) subtest requires subjects to define a word presented to them
verbally. For example, the examiner would say 'tell me what DANCE means'. The
second task (block design) requires the examinee to arrange a series of 4 or 9 coloured
blocks to fit a template pattern within a pre-specified period of time.
Figure 4.10.1: A pre-specified pattern from the block design subtest
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The third (similarities) requires subjects to define a rule which explains why two
items are similar. For example, the examiner would ask 'In what way are a PEN and a
PENCIL alike' to which the subject would be expected to respond along the lines of
'they are both for writing'. The forth and final subtest (matrix reasoning) requires the
examinee to look at a matrix of items from which a single item is missing. The examinee
then selects an item from a list which completes the pattern.
4.10.2 The National Adult Reading Test
The National Adult Reading Test (NART, Nelson 1982) was used to estimate the
subject's premorbid full-scale IQ (NART FSIQ). The test consists of 50 short words,
which the subject is required to read aloud. Each word is selected because of its atypical
grapheme-phoneme conversions (e.g. gauche, leviathan) and each word is presented in
order of increasing difficulty. Therefore subjects must have prior knowledge of how the
word is pronounced in order to read it accurately. The number of pronunciation errors
made is used to estimate premorbid intelligence. The test was originally developed in
order to measure the premorbid IQ of individuals in whom intellectual decline was
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suspected. Reading ability is known to correlate highly with IQ in the general
population. Conclusions can be made about the probable extent of intellectual decline by
subtracting NART full scale IQ from the WASI estimate of full scale IQ. However, a
negative difference could be taken to infer that the subject is currently functioning at a
higher level than in the past.
4.11 Executive functioning
Executive functioning was measured using three tests designed to measure
specific domains: The Stockings of Cambridge Test (planning) from the Cambridge
Neuropsychological Testing Automated Battery (CANTAB, Sahakain and Owen 1992),
The Hayling Sentence Completion Test (HSCT-response inhibition, Burgess and
Shallice 1996) and FAS/Animals (verbal fluency, Benton 1978).
4.11.1 The Stockings of Cambridge Test
The Stockings of Cambridge Test is a spatial planning test based upon the
'Tower of London' test. The subject is shown two displays containing three coloured
balls, presented so they can be perceived as stacks of coloured balls in stockings. In each
trial, the subject must move the balls in the lower display to copy the pattern shown in
the upper. A later motor control task, in which the subject simply copies earlier moves,
allows planning time (versus movement time) to be calculated and taken, relative to the
number of moves required to complete each trial, as a measure of the subject's planning
ability.
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Figure 4.11.1: Atypical screen from the CANTAB stockings of Cambridge
sub test
4.11.2 The Hayling Sentence Completion Test
The Hayling Sentence Completion Test (HSCT) is a timed test of response
suppression and is comprised of two sections. In both sections the subject is presented
verbally with sentences from which the last word is missing and in each case the subject
is asked to provide a one word answer. In the first section (A, response initiation), the
subject is required to provide an answer which sensibly completes the sentence. In the
second section (B, response suppression) the subject is required to give a ridiculous
answer which no sense in the context of the sentence. The errors are scored according to
the degree of sense made by the sentence completion. Category A errors are scored if the
sentences in the incongruous condition are completed correctly. Category B errors are
scored if the sentence completion makes some sense (e.g. 'The whole town came to hear
the Mayor ' answer: 'sing'. Raw scores are then converted to scaled scores.
4.11.3 Verbal fluency
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The test used to measure verbal fluency is known by the names 'FAS',
'FAS/Animals' and also 'The Controlled Oral Word Association Test' (Spreen and
Strauss 1991). The purpose of this test is to provide as many words beginning with a
specific letter, or belonging to a specific category, within a limited amount of time. The
subjects were asked to verbally provide as many words beginning with letters F, A and S
as possible in 1 minute without any repetitions (verbal association fluency). Subjects
were also required to name as many four legged animals as possible in 1 minute, again
without repetition (semantic fluency). An egg timer was used to keep account of time
and one minute was used for each letter and animal category. Inadmissible words were
not positively scored as correct or negatively as incorrect. Preservative answers were
deducted from the overall score. Inter-rater reliability for this test is reported to be near
perfect (Spreen and Strauss 1991) and impairment on this task is also been associated
with frontal lobe impairment in both brain injured subjects (Lishman 1998) and in
functional imaging studies of psychotic patients (Frith et al. 1995).
4.12 Sustained attention
4.12.1 Digit Symbol Substitution Test
The Digit Symbol Substitution Test (DSST) is a subtest of the Wechsler Adult
Intelligence Scale Revised (WAIS-R) and is a test of perceptual motor speed. The test
consists of four rows of 100 blank squares, each paired with a randomly assigned
number from between 1 and 9. Above the test is a key which pairs each number with a
nonsense symbol. The objective of the test is to fill in as many of the 100 consecutive
blank squares in 90 seconds as possible. The test is purported to be a measure of
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psychomotor performance and is relatively unaffected by intelligence, memory or
learning (Erber 1976;Glosser et al. 1977).
4.13 Perceptual and motor speed
4.13.1 The Simple and Choice Reaction Time
The Simple and Choice Reaction Time Test is designed to measure psychomotor
performance. The materials for the task consist of a depressible paddle and a touch
sensitive computer screen which can display a target for the examinee to touch. The
target can be presented within a single area within the computer screen, or presented at
one of five possible areas. There are four conditions:
Condition 1: The subject is asked to depress the paddle and wait for a circular target to
appear on the computer screen within a single location. When the target appears, the
subject is instructed to release the paddle. The task is repeated several times and the time
between target presentation and the release of the paddle is recorded.
Condition 2: The subject is asked to depress the paddle and wait for a circular target to
appear on the computer screen within a single location. When the target appears, the
subject is instructed to release the paddle and then to touch the location on the screen
where the target has just appeared. The task is repeated several times and the time
between target presentation and the screen contact is recorded.
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Condition 3: The subject is asked to depress the paddle and wait for a circular target to
appear on the computer screen within 5 possible locations. When the target appears, the
subject is instructed to release the paddle. The task is repeated several times and the time
between target presentation and paddle release is recorded.
Condition 3: The subject is asked to depress the paddle and wait for a circular target to
appear on the computer screen within 5 possible locations. When the target appears, the
subject is instructed to release the paddle and then to touch the location on the screen
where the target has just appeared. The task is repeated several times and the time
between target presentation and the screen contact is recorded.
The times recorded can be used to construct four parameters: simple reaction
time, choice reaction time and simple movement time and simple reaction time.
Reaction times are assumed to represent processing speed and movement time.
4.14 Learning and memory
4.14.1 The Extended Rivemead Behavioural Memory Test
The original Rivermead Behavioural Memory Test (RBMT) was first devised in
1985 (see Wilson et al. 1989 for a description) and was designed to predict everyday
memory problems in people with acquired, non-progressive brain injury. The RBMT
comprises tasks analogous to situations found in daily living that often appear
troublesome for memory impaired people and population norms exist for people aged 5
to 96 years.
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Using the non-extended version of the test, most non-memory-impaired people
would be at ceiling on the test, and hence the RBMT might not be suitable for picking
up very mild memory impairment. In an attempt to refine the test for use in people with
very mild memory impairments the extended version has been developed (de Wall et al.
1994). In order to make the RBMT-E more sensitive to mild memory impairment than
its predecessor, the amount of material to be remembered has been increased and many
items have been made more complicated.
Studies using the RBMT-E have shown that it is sensitive to age and IQ effects
in non brain injured subjects. The stimuli are presented in standing books so that the
tester is able to read the relevant instructions while at the same time viewing a miniature
representation of each stimulus as it is presented to the subject. The task itself consists of
11 subtests described in table.
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The subject is shown three photographic portraits and
asked to remember the first and second names of all three
people in the photographs. The subject is then asked to
recall the fist and second names later in the test.
3 Belongings
The subject is asked to provide two of their belongings
which are borrowed and secreted (in full view of the
subject) in two hidden locations. The subject is instructed
to ask for their belongings back when the examiner says
'we have now finished the test'.
4 Appointments
An alarm is set for 20 minutes. When the alarm rings the
subject is required to ask two questions 'when do I have to
see you again' and 'when will this session end'. The degree





Twenty line drawings of everyday objects are presented on
a card and the subject is asked to remember as many as
possible in 15 seconds. After 15 seconds has elapsed, the
card is turned over so that the items are no longer visible.
After subtest 6 the subject is then presented with 40
pictures containing the 20 original images. The subtest is
then asked to correctly identify the original images.
6 Story
The subject is instructed to listen to a short passage of
prose and to recall of much of it as possible both





The subject is presented with pictures of 15 faces, one at a
time for a period of 3 seconds each. After the faces have
been presented the subject is later asked to recall the faces




The examiner takes two items (an envelope and a book)
and traces a path around the room comprising 7 sections ;
leaving the two items at two separate locations. The subject
is then asked to retrace the steps of the examiner




The subject is presented with 13 questions regarding their j
orientation in time, place and person. Scores reflect the
accuracy of their answers. !
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Raw scores from the above tests were then converted into profile scores which take
account of the subject's age and current full scale IQ.
4.15 Statistical analysis of neuropsychology data
The following data set was obtained from the neuropsychology test battery:
Table 4.14: Data obtained
Variable Description
Predfsiq Predicted NART full-scale IQ |
Fastot Verbal fluency (total number of words from FAS and animals
Waisdgsy Digit-symbol substitution test, number of correct substitutions
RBMTfnp RBMT, fist names profile score
RBMTsnp RBMT, second names profile score
RBMTaptp RBMT, sum of belongings and appointments profile score j
RBMTprcp RBMT, picture recognition test profile score
RBMTstip RBMT, immediate story recall profile score
RBMTstdp RBMT, delayed story recall profile score
RBMTffcp RBMT, face recognition profile score
RBMTrtip RBMT, route immediate profile score
RBMTrtdp RBMT, route delayed profile score
RBMTmsip RBMT, message immediate profile score
RBMTmsdp RBMT, message delayed profile score
RBMTodtp RBMT, orientation profile score
RBMTtotp RBMT, total profile score
HSCT Hayling sentence completion test,
HSCT Hayling sentence completion test,
WASIvbiq WASI predicted verbal IQ
WASIpriq WASI predicted performance IQ
WASI4iq WASI predicted full-scale IQ
Rtsmt CANTAB simple movement time
Rtsrt CANTAB simple reaction time
Rtcmt CANTAB choice movement time
Rtcrt CANTAB choice reaction time
Socsmntt CANTAB Stockings of Cambridge Test, number of trials in minimum
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number of moves
Emboldened variables represent those used primarily in subsequent analyses
Key to preceding table
NART National Adult Reading Test
RBMT Extended Rivermead Behavioural Memory Test
WASI Wechsler Abbreviated Scale of Intelligence
CANTAB Cambridge Neuropsychological Test Automated Battery
4.15.1 Outlier detection and assessment of normality
The distribution of each neuropsychological variable was examined for
normality. Normality was assessed in two ways: a) by examining a histogram of the
variable for each group individuals and b) by plotting the observed quantile against that
expected under a normal distribution to produce a normal probability plot (Q-Q plot) for
each group. Where the observed and expected quanitiles are equal, the observations will
tend to cluster along the line of equality. Observations situated away from the line,
especially at the extremes, were checked against the written record of the
neuropsychological assessment to ensure they had been transcribed correctly. Where
multivariate tests were used, the assumption of multivariate normality was checked by
examining the Mahalanobis plot of statistical distance squared versus that expected
under the Chi-squared distribution. Standardised residual plots from the many mixed-
effects ANOVAs conducted were also examined for normality.
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Figure 4.15.1: Example of a normally distributed variable
Histogram of a normally distributed
variable (150 observations)
IQ
Q-Q Plot of a normally distributed
variable (150 observations)
Where data were not normally distributed, transformations were applied to
improve the approximation to a normal distribution. Where the Q-Q plot remained
incompatible with an underlying normal distribution, subsequent hypothesis tests were
conducted using non-parametric statistics.
4.15.2 Multivariate analyses
Domains of neuropsychological function (IQ, memory, executive function) were
compared between groups using a mixed model multivariate analyses of variance (mixed
MANCOVA) controlling for WASI full scale IQ (memory and executive function),
psychiatric symptoms (HDRS, PANSS positive and YMRS) and age. A mixed model
MANOVA was used instead of a conventional 'fixed-effects' MANOVA to take
account of the non-independence of observations within families. Family membership
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was modelled as a 'random effect', assumed to represent a sample of possible families
taken from a normal probability distribution. All multivariate analyses were conducted
using the PROC GLM procedure within the statistical package SAS (SAS Institute,
Cary, NC).
A mixed model MANOVA was chosen in order to test the equality of mean
vectors, rather than individual group means, and consequently controls for the
experiment-wise error rate by reducing the number of individual tests required.
4.15.3 Between-group comparisons
Where the mixed model MANOVA showed an overall difference within a
domain of neuropsychological function, further tests were conducted to examine a)
which specific neuropsychological variable means differed between the groups and b)
specific pairwise effect sizes. Both analyses were conducted using a mixed model
ANOVA, with family modelled as a random factor. Where differences were found in the
overall ANOVA, controlling for WASI full scale IQ (for memory and executive
function) and psychiatric symptoms (HDRS, PANSS positive, YMRS) the pairwise
between group differences were estimated from the model. All analyses were conducted
using the PROC MIXED procedure within the statistical package SAS (SAS Institute,
Cary, NC).
The results of the various neuropsychological analyses conducted are given in
chapter 5 of this thesis.
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4.16 Image acquisition
All participants were scanned on a 1.5 Tesla GE MRI scanner. Midline saggital
localisation was followed by two further sequences to image the whole brain. The first
sequence was a transverse spin-echo scan which acquired both T2 and proton density
weighted images of the brain. These images were subsequently reported by a consultant
in neuroradiology. The third and final sequence was a coronal gradient echo sequence
with magnetisation preparation (MPRAGE) and produced 128 coronal high-resolution
T1 weighted images which were used for structural image analysis.














TI=600ms, TE=3.4ms, Flip angle=15°, FOV=22, slice
thickness=1.7mm, matrix=256xl92
All images were acquired in Dicom © format and were then transferred to a
SPARC SUN STATION computer (Sun Microsystems) and backed up onto optical
discs.
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4.17 Voxel based morphometry
Stored images were converted from DICOM to Analyze format using a script
written in the C programming language. Once converted, images were then transferred
to a Dell © computer running Red Hat Linux.
4.17.1 Conversion from Dicom® to Analyze® Format & Origin Setting
Images were initially acquired and stored in Digital Imaging and
Communications in Medicine (DICOM) format. The DICOM format encodes each brain
'slice' as a separate 2 dimensional image file. Since these files could not be processed by
SPM99, they were then converted into ANALYZE 3-dimensional file format for further
processing. Each image was the viewed using SPM99, an automated image analysis
program developed in the Wellcome Department of Imaging Neuroscience (London,
UK) on s SUN SPARC microcomputer (Sun MicroSystems Inc., Mountain View, CA,
USA). Images were inspected for orientation and movement artefact and the origin was
set at the anterior commisure. Images were then transferred to a computer running
SPM99 on MATLAB 6.5 using the Red Hat Linux 8.0 platform.
4.17.2 Template generation
Two optimised T1 study specific templates were made from all 192 T1 MRI
scans, from all subject groups. Images were first re-orientated to neurological
convention and then spatially normalised to the generic MNI 152 T1 template (Montreal
Neurological Institute) provided as part of the SPM99 package using linear affine
normalisation and nearest neighbour interpolation. A grey-matter optimised template
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was made by using the grey matter distribution to normalise the source images to MNI
template. The white-matter optimised template was made by using the white matter
distribution to normalise images. The MATLAB script authored by John Ashburner was
used for the purposes of template generation in both cases (supplied via the SPM
mailbase, www.jiscmail.ac.uk). Extracerebral voxels were removed using the "Xtract
Brain" render function. This function uses the combined grey and white segments and
uses them as a mask to remove extracerebral voxels. This process is accomplished by
multiplying the rendered image by the original grey matter segment. A mean image was
then calculated and smoothed using an 8mm full width at half maximum (FWHM)
Gaussian Kernel. All normalised and segmented images used to construct the template
were subsequently checked to ensure the images had not become corrupted.
4.17.3 Normalisation
All images were spatially normalised to the study-specific T1 template. This
process attempts to register all images in the same 3 dimensional stereotactic space so
that differences in grey matter density can be assumed to relate to the underlying
anatomic space. This was accomplished using a method which attempts to minimize the
sum of squared differences between each image and the T1 template. The twelve point
simple (linear) affine transformation is usually expressed as:
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Where yi, y2 y3 are the transformed coordinates of the original coordinates xi, X2, X3. The
4x4 matrix describes the 12-point transformation applied to the original coordinates in
order to map them to the new coordinates. This matrix actually describes a rigid body
transformation, zoom transformation and shear transformation in one matrix. These
matrices can be calculated separately and multiplied together to give the same solution.
Alternatively, the equation can be given in matrix notation as:
Y = Mx
The transformation M is chosen such that the sum of squared differences




Where x; denotes the reference points in the template image, Mx; represents the points in
the source image (M is the transformation applied) and po is a scaling parameter to
correct for differences in spatial scaling between source and reference images.
Optimal linear normalisation was performed using a Bayesian framework,
whereby the maximum a posteriori estimate of the spatial transformation is made using
prior information about variability in brain size. Linear affine transformations, used for
the construction of a study specific T1 template were also supplemented with non-linear
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basis functions for the normalisation of images to the study specific T1 template. Non¬
linear basis functions consist of discrete cosine transformations (DCT) which produce a
better fit between image and template whilst maximising the smoothness of the
transformations.
The result of transforming the source images to the study-specific template
image is imperfect in the sense that they do not match individual gyri in each source
image with that of the template. Instead, they attempt to correct for overall shape
differences such that differences in grey matter density at each voxel reflect volumetric
and not shape differences between source and template.
4.17.4 Segmentation
Spatially normalised images were then partitioned into grey matter (GM), white
matter (WM) and cerebrospinal fluid (CSF) using an established method (Ashburner and
Friston 2000). This step was accomplished using a maximum likelihood 'mixture model'
clustering algorithm. Each voxel in a normalised image has intensity from 0 to 1 and
these values represent the prior probability that a voxel is GM, WM or CSF. Further
information is also available from MNI (Montreal Neurological Institute) representing
the spatial distribution and variability of GM, WM and CSF clusters from a large
numbers of brains. Using these two sources of information the probability that a voxel of
intensity v belongs to a cluster c can be established using Bayes Theorem.
The segmentation process generates 3 probability maps, for grey, white and CSF.
The solution obtained relies on several assumptions. Firstly, each voxel is assumed to
consist of one several tissue classes (usually grey, white and CSF). Secondly, the
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distribution of voxel intensities for each class has a normal distribution, but with
unknown mean and variance. Thirdly, the distribution of voxel intensities can be
described using the number of voxels within a cluster, the mean intensity and the
variation around that mean. The MNI image represents a prior probability map
representing the prior expectation or probability that a given voxel consists of grey,
white or CSF. This prior information is combined with the sample image data to produce
a posterior probability that each voxel consists of grey white or CSF. Sample image data
is expressed as a likelihood function which is multiplied by the prior probability to give
a posterior probability or likelihood function. The iterative process proceeds in order to
maximise the posterior probability that a given voxel will belong to a particular tissue
class. Nearest neighbour interpolation was used to preserve original tissue values and
grey/white contrast.
4.17.5 Smoothing
Smoothing is a general statistical technique used whenever data contains 'noise'
and an underlying 'signal'. In order to increase the ratio of signal to noise, data at
several time points are averaged to give a mean value which should be less susceptible
to short range fluctuations. The normal curve used to smooth voxel intensities has mean
zero can be described in terms of a single parameter, the 'full width and half maximum"
(FWHM), and is usually set at 12mm for voxel based morphometry. The FWHM kernels
used for VBM represent the usual minimal spatial extent for two clusters to be regarded
as anatomically separate.
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Using a smoothing kernel has two further consequences. Firstly, data which
contains a lot of noise is generally skewed towards high voxel intensity values and is
therefore not normally distributed. This creates difficulties with the subsequent analysis
of such data. However, by taking the weighted average intensity from a given voxel and
the surrounding voxel, averaged data will converge towards a normal distribution more
quickly. A further consequence of smoothing is to reduce the number of independent
observations from an image. In a single image of 128 by 128 voxels there are 16384
observations. When an 8mm smoothing kernel is used, the effective observation size,
termed 'resolution elements' (RJESELS), becomes 8x8mm. Therefore, in an image of
128x128mm smoothed with a 8x8mm smoothing kernel contains 256 RJESELS. By
reducing the number of independent observations within an image, the problem of
multiple hypothesis testing at each individual voxel is minimised somewhat.
A 12mm Gaussian kernel was used to smooth GM, WM and CSF voxel
intensities in the current study.
4.17.6 Statistical analysis
Voxel based morphometry compares the mean voxel intensity for each group and
performs a hypothesis test to see if these values differ between groups. The general
linear model is used to model the voxel intensity (Y, response variable) in terms of one
or more explanatory variables (X) and an error term (s). The relationship between these
variables can be stated in matrix form as:
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Y = Xp + £
where p is a vector of weights which describe the linear relationship between each
explanatory variable and the response (dependent) variable, p is estimated using the
method of least squares such that:
p = (X'X^X'Y
The explanatory variables (X) can be explanatory variables (e.g. patient group)
or covariates (e.g. height, sex etc). The vectors P and s are not known from the data, and
so must first be estimated using the least squares approach. Once these parameters have
been determined, the significance of P can be determined for each explanatory variable
using the matrix of residuals. Where p is significant, then the explanatory variable to
which it corresponds could be said to be significantly associated with GM density at that
voxel. Pairwise between-group comparisons were made using t-contrasts
4.17.7 Gaussian random fields
When an entire brain is imaged, the number of possible statistical tests conducted
means that a proportion of statistical tests could be significant by chance alone. A
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conventional method of correcting for multiple tests is the Bonferroni correction,
whereby the probability of observing at least one significant test given that there is no
overall difference between the groups is calculated. In order to use this correction, each
observation is usually assumed to be independent under the null hypothesis. As regions
of the brain are known to be integrated with one another, this is not a safe assumption.
An alternative approach to the problem uses the principal of Gaussian random fields.
In order to correct for the multiple hypothesis tests conducted by SPM, firstly,
the number of 'resolution elements' (RESELS) within an image is determined.
Secondly, the expected Euler Characteristic (EC) of the image is calculated. For any
statistical parametric map, the image generated can be thought of as the graphical
representation of peaks of difference between one group and another. Each peak is
measured in standard deviation units (Z scores). If an image is 'thresholded' at Z=2.75,
then all peaks of Z=2.75 or less are effectively set to zero. By setting the threshold
higher, we will remove more peaks and the results obtained will be less likely to
represent false positives. An inevitable consequence however, is that significant areas of
difference (true positives) are removed erroneously.
The Euler Characteristic is the expected number of regions of difference in an
image at a given threshold. As the Z score threshold is raised, the expected EC
approaches zero and provides an approximate measure of observing one or more regions
of difference at that threshold. For example, if we set a threshold of Z=x so that the
expected EC is 0.05, then any regions of difference remaining will have a probability of
occurring by chance of p=0.05 or less.
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Regions of significant difference between groups were projected onto a glass
brain. Regions of significant difference were reported if the p-value (corrected, voxel
level) < 0.1 (trend) or <0.05 (significant).
In addition to the voxel-wise analysis of the whole brain, further specific
hypotheses were tested using a small volume correction. A small volume correction
adjusts for the number of false positives expected in an image over a pre-specified
volume of interest. Because the volume of interest is smaller, the correction for multiple
hypotheses is less severe, being based on a smaller number of individual comparisons.
Each region of interest hypothesised to differ was traced onto a single image of the brain
and used as a small volume correction. Brain regions hypothesised to differ between
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schizophrenia and bipolar disorder in terms of grey matter density were contrasted
between groups as before. Throughout all statistical analyses, age sex, handedness and
height were included as covariates (nuisance covariates in the language of SPM).
The actual grey matter SVC image used in the study was constructed from the
averaged scan of all 192 images. The thalamus and both amygdala-hippocampal
complexes were traced on the image and the values of voxels outside this region set to
zero. The image was then smoothed using an 8mm FWHM kernel used in the
subsequent analyses to define a generous region encompassing thalamus and both
amygdala-hippocampal complexes. The SVC image consisted of 12.3 RESSLS in total.
After the grey matter analysis was completed, analysis of white matter density
was conducted using the white-matter optimised study-specific template and a small
volume correction image. Further details of the small volume correction used and the
contrasts performed are given in chapter 6.
4.17.8 Planned image analyses
Six broad groups of voxel based analyses were conducted (see table 4.17.8).
Firstly, each patient group was compared to control subjects in order to examine grey
matter differences contingent upon disease and genetic liability. Secondly, patients were
compared to the appropriate relative group in order to examine differences contingent
upon disease expression only. Thirdly, comparisons were made between patents groups
directly. However, it was anticipated that the variance estimates might be greater for
these comparisons since two diseased groups were being compared with one another. In
conventional statistical analyses, it would be possible to test this possibility by plotting
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residual values in each group, and also by plotting residuals against fitted values. In
cases where the group variances were unequal, it would then be possible to conduct an
analysis using a (Scatterthwaite) correction. To the knowledge of the investigators,
neither solution is a possibility within SPM99. Therefore, a second analysis was
conducted to maximise the precision of between patient comparisons. The control-
patient comparisons were masked using the other control-patient contrasts. Hence
differences between schizophrenic patients and controls not found in bipolar patients
versus controls could be calculated using larger sample sizes and hence greater power
and precision.







All contrasts were 2-sided
Examines differences
contingent upon both disease
and genetic liability
Patients versus patients BPD-SCZ
MIX-SCZ
MIX-BPD














including control group in
each contrast
Patients versus relatives uSCZ-SCZ
uBPD-BPD
MIX-uMIX
All contrasts were 2-sided
Examines differences
contingent on disease between
2 groups both ofwhich are at
increased genetic liability
Relatives versus controls CTR-uSCZ
CTR-uMIX
CTR-uBPD






Patients:SCZ: schizophrenic, BPD: bipolar from bipolar family, MIX: bipolar from mixed
family
Relatives:uSCZ: schizophrenic family, uBPD: bipolar family, uMIX: mixed family
In addition, an analysis of white matter density was also conducted. Any significant
differences in grey matter density were related to white matter density in associated tracts or
subgyral areas. The results of the imaging analyses are given in chapter 6.
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Chapter 5: Clinical & Neuropsychological Results
232
5.1 Introduction
5.2 Flow of patients through the study
Over 300 patients with a clinical diagnosis corresponding to either
schizophrenia or bipolar disorder were identified from the case loads of consultants
across Edinburgh, the Lothians and Fife. All potential subjects were also believed to
have a family history of either schizophrenia or affective disorder. One hundred and
ten subjects were approached of which 102 gave their consent to undergo the Present
State Examination (PSE) and for their case notes to be retrieved. On the basis of
combined information from the PSE and case notes, 80 subjects met study inclusion
criteria and 74 provided complete clinical data and near complete
neuropsychological data. Incomplete neuropsychological data was obtained on three
subjects because of equipment failure in two cases or because subjects had to leave
the testing earlier than expected because of other commitments. Seventy-two patients
also underwent complete MRI scan of the brain, although one patient left the scanner
due to anxiety and one further scan was reported as abnormal (neurodevelopmental
cyst).
A further 160 apparently unaffected close family members were identified
from the families of eligible patients meeting study inclusion criteria. In each case,
the unaffected relative belonged to one of the predefined groups described in the
methods section. Eighty-five relatives gave consent and underwent a semi-structured
interview about previous psychiatric problems using the PSE. This data set was
supplemented with other information about psychiatric treatment obtained from the
subjects themselves. On the basis of this information, 80 subjects met study inclusion
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criteria of which 76 provided complete clinical data and near complete
neuropsychological data and 72 underwent an MRI scan of the brain.
Fifty-four potential control subjects were identified through the social
networks of the patients themselves, through adverts placed on notice boards at local
leisure centres and through the social networks of previously recruited controls. All
54 controls gave consent to be interviewed and all completed a semi-structured
interview using the Schedule for Affective Disorders and Schizophrenia, Lifetime
version (SADS-L, Endicott and Spitzer 1978). Three controls were excluded because
of a history of previous psychiatric disorder (one with anorexia nervosa and two with
a major depressive episode). 50 controls provided near complete neuropsychological
data and all but one control subject underwent a complete MRI scan of the brain. The
one subject who did not provide neuroimaging data could not tolerate the relatively
confined space of the scanner itself. The flow of participants through the study is




5.3 Comparison of data from the Present State Examination
All patients and healthy relatives underwent the PSE version 9 to ensure they met
eligibility criteria and to ascertain their current symptom profile. Complete information
was obtained for all subjects. All patients and relatives were classified according to 4
levels of increasing psychopathology (see previous chapter): a) none, b) one or more
affective or behavioural symptoms, c) one or more partially rated psychotic symptoms
and d) one or more fully rated psychotic symptoms. The results are shown in table 5.3
below.
Table 5.3: Summary of psychopathological status of patients and well
relatives
Psychopathological category
No symptoms 1+ Affective / 1+ Partial psychotic 1+Psychotic
behavioural symptoms symptoms
symptoms
SCZ from SCZ N 0 8 3 16
family % 0% 29.6% 11.1% 59.3%
OK from SCZ N 5 14 6 0
family % 20% 56% 24% 0%
BPD from BPD N 3 12 8 4
family % 11.1% 44.4% 29.6% 14.8%
OK from BPD N 3 13 8 0
family % 12.5% 54.2% 33.3% 0%
BPD from Mixed N 0 7 10 3
family % 0% 35% 50% 15%
OK from Mixed N 7 13 7 0
family % 25.9% 48.1% 25.9% 0%
Although all patients were deemed not to be in need of inpatient care by their
treating clinicians, there were significant levels of psychopathology in all patient groups.
Schizophrenic patients had the highest levels of psychopathology with many (59.3%)
displaying one or more fully rated psychotic symptoms. Subjects with bipolar disorder
from mixed and bipolar families had lower levels of psychopathology than that
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displayed by the subjects with schizophrenia. None of the well relatives displayed any
fully rated psychotic symptoms, although partial symptoms were relatively common
with a rate of around 25%. Partial symptoms elicited consisted mostly of minor
complaints which were not disclosed, except on direct questioning. Most would not be
regarded as clinically significant.
5.4 Description of OPCRIT data
Complete case note data was available for all affected patients in the present
study. This was supplemented with data obtained from structured interview (PSE) and
combined to produce a data set of all recorded symptoms according to the OPCRIT
scheme.
Of primary interest was the frequency with which psychotic symptoms were
experienced by each group. All schizophrenic patients had been deluded in the course of
their illness compared to 24/27 bipolar patients from families affected by bipolar
disorder only and 17/20 bipolar patients from mixed families. No additional subjects
were identified who had hallucinations but not delusions. Duration of illness was
estimated from current age at interview minus the age of first psychiatric contact. This
was similar for schizophrenics (mean=15.8 years, SD=11.4), bipolars from mixed
families (mean=15.7 years, SD=10.5) and bipolars from bipolar families (mean=16.2
years, SD=9.2).
5.5 Comparison of demographic data
5.5.1 Age and gender
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The groups spanned a 7 year interval in terms of mean age, with unaffected
people from bipolar families having the lowest mean age (33.5 years) and bipolar
subjects from mixed families having the greatest (40.5). Unaffected individuals from
bipolar families also had the lowest proportion of males (36%) compared to other
groups. Bipolar subjects from mixed families had the greatest proportion of males at
65%.













11 (44) 14 (56)
BPD from BPD
family
40.3 (11.9) 14(51.9) 13 (48.1)
OK from BPD
family 33.5(12.8)
9 (35.5) 15 (62.5)
BPD from mixed
family




Total 37.0(12.2) 91 (45.5) 109 (54.5) ;
5.5.2 Marital status
Marital status differed widely between groups, with the schizophrenic group
having the greatest proportion of single (81.5%) participants. The other groups were
approximately equal in terms of the ratio of married to single people and the numbers of
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divorced participants were not sufficiently frequent to make meaningful comparisons
between the groups.
Table 5.5.2: Marital status of participants by group
Marital Status
Married Single Divorced Total
Control N 22 23 5 50
% 44.0% 46.0% 10.0% 100.0%
Scz from Scz family N 3 22 2 27
% 11.1% 81.5% 7.4% 100.0%
OK from Scz family N 13 11 1 25
% 52.0% 44.0% 4.0% 100.0%
BPD from BPD family N 11 13 3 27
% 40.7% 48.1% 11.1% 100.0%
OK from BPD family N 10 12 2 24
% 41.7% 50.0% 8.3% 100.0%
BPD from mixed family N 5 11 4 20
% 25.0% 55.0% 20.0% 100.0%
OK from mixed family N 14 13 0 27
% 51.9% 48.1% .0% 100.0%
Total N 78 105 17 200
% 39.0% 52.5% 8.5% 100.0%
5.5.3 Personal and paternal socio-economic atatus
Socio-economic status differed greatly between the groups. The pattern of
impairment was somewhat as expected: schizophrenic patients showed the greatest
socio-economic disadvantage (74.1% unemployed) followed by bipolar patients from
mixed families and bipolar patients from bipolar families in order. Controls were, as
expected, the least socially disadvantaged in terms of the proportions in non-manual
employment, although were similar to the unaffected relatives in terms of the proportion
who were unemployed. With the exception of the healthy relatives from mixed families,
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paternal socio-economic status was more similar between the groups. Unaffected
relatives from mixed families had higher levels of missing data and lower levels of non-
manual employment than all of the other groups.









Scz from Scz family -
OK from Scz family-






Non-manual Manual Unclassified Unemployed Total
Control N 39 7 2 2 50
% 78.0% 14.0% 4.0% 4.0% 100.0%
Scz from Scz family N 2 2 3 20 27
% 7.4% 7.4% 11.1% 74.1% 100.0%
OK from Scz family N 16 6 2 1 25
% 64.0% 24.0% 8.0% 4.0% 100.0%
BPD from BPD family N 15 4 3 5 27
% 55.6% 14.8% 11.1% 18.5% 100.0%
OK from BPD family N 13 2 9 0 24
% 54.2% 8.3% 37.5% .0% 100.0%
BPD from mixed family N 7 0 1 12 20
% 35.0% .0% 5.0% 60.0% 100.0%
OK from mixed family N 18 6 3 0 27
% 66.7% 22.2% 11.1% .0% 100.0%
Total N 110 27 23 40 200
% 55.0% 13.5% 11.5% 20.0% 100.0%
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Figure and table 5.5.3.2: Clustered pie chart and table of paternal socio¬







Scz from Scz fami ly -
OK from Scz family-
BPD from BPD family-
OK from BPD family-
BPD from mixed family-
OK from mixed family -
Pies show counts
Fathers social status
Non-manual Manual Unclassified Missing Total
Control N 32 12 1 5 50
% 64.0% 24.0% 2.0% 10.0% 100.0%
Scz from Scz family N 16 10 1 0 27
% 59.3% 37.0% 3.7% .0% 100.0%
OK from Scz family N 13 9 2 1 25
% 52.0% 36.0% 8.0% 4.0% 100.0%
BPD from BPD family N 15 10 0 2 27
% 55.6% 37.0% .0% 7.4% 100.0%
OK from BPD family N 13 11 0 0 24
% 54.2% 45.8% .0% .0% 100.0%
BPD from mixed family N 10 10 0 0 20
% 50.0% 50.0% .0% .0% 100.0%
OK from mixed family N 9 11 0 7 27
% 33.3% 40.7% .0% 25.9% 100.0%
Total N 108 73 4 15 200
% 54.0% 36.5% 2.0% 7.5% 100.0%
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5.5.4 Alcohol, substance and cigarette history
Within the sample, all groups were similarly balanced in terms of the number of
units of alcohol consumed per week, and also in the number of units consumed in the
24hrs preceding their neuropsychological assessment. There was evidence of greater
weekly alcohol consumption (mean 12.8u) and variability (SD=29.6) of alcohol intake
within bipolar subjects from mixed families. Daily cigarette consumption was higher in
affected patients than in either relatives or controls. Schizophrenic patients smoked the
most and bipolar subjects from mixed and bipolar families smoked smaller quantities of
tobacco which were only slightly greater than control subjects.









Control Mean 1.43 11.53 3.73
SD 2.481 9.226 7.590
Scz from Scz family Mean .65 5.46 19.15
SD 1.917 10.069 17.066
OK from Scz family Mean 2.01 9.08 5.33
SD 4.787 8.861 10.025
BPD from BPD family Mean 1.19 8.15 10.08
SD 2.530 14.201 17.228
OK from BPD family Mean 1.38 10.54 5.13
SD 2.356 8.708 7.303
BPD from mixed family Mean 1.05 12.80 9.20
SD 3.137 29.643 12.493
OK from mixed family Mean 1.28 14.43 2.91
SD 2.300 13.993 5.316
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Just over 50% of the sample reported using cannabis at some point in their lives.
Current use was described in 11.1% of schizophrenic subjects, 18.5% of bipolar subjects
from bipolar families and 10% of bipolar subjects from mixed families. Controls and
relatives smoked less cannabis than patients with the exception of the healthy relatives
of bipolar patients in whom a 20.8% rate of current use was recorded. The proportion
describing past regular cannabis use was more closely matched between the groups
(max=29.6%, min=18%).
Table 5.5.4.2: Cannabis use
Cannabis
Past regular Current
Never used Once or twice use regular use Total
Control N 32 6 9 3 50
% 64.0% 12.0% 18.0% 6.0% 100.0%
Scz from Scz family N 16 0 8 3 27
% 59.3% .0% 29.6% 11.1% 100.0%
OK from Scz family N 20 0 5 0 25
% 80.0% .0% 20.0% .0% 100.0%
BPD from BPD family N 11 5 6 5 27
% 40.7% 18.5% 22.2% 18.5% 100.0%
OK from BPD family N 9 4 6 5 24
% 37.5% 16.7% 25.0% 20.8% 100.0%
BPD from mixed family N 11 3 4 2 20
% 55.0% 15.0% 20.0% 10.0% 100.0%
OK from mixed family N 13 5 6 3 27
% 48.1% 18.5% 22.2% 11.1% 100.0%
Total N 112 23 44 21 200
% 56.0% 11.5% 22.0% 10.5% 100.0%
Occasional use of 'ecstasy', heroin or amphetamine was disclosed by study
participants. However, less than five people reported using these drugs overall and the
numbers are too small to make any reasonable conclusions regarding between group
differences.
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5.5.5 Weight and height measurement
All groups were closely balanced in terms of height, weight and body mass index
(see following table). Bipolar subjects from mixed families had the highest weight and
BMI compared to the other groups.








Control Mean 1.72 72.90 24.31
SD .10 16.16 3.50
Scz from Scz family Mean 1.70 76.93 26.69
SD .08 18.34 5.91
OK from Scz family Mean 1.67 70.39 25.55
SD .07 13.91 5.17
BPD from BPD family Mean 1.69 74.65 25.93
SD .11 17.93 5.61
OK from BPD family Mean 1.70 66.93 23.08
SD .10 13.94 4.80
BPD from mixed family Mean 1.69 80.08 27.83
SD .08 22.64 7.00
OK from mixed family Mean 1.71 73.32 25.03
SD .10 16.81 4.72
Total Mean 1.70 73.36 25.30
SD .10 17.13 5.21
5.5.6 Handedness
Left hand preference for writing was greatest in healthy people from
schizophrenic families (20%). Healthy people from schizophrenic families and bipolars
from bipolar families also had higher levels of left handedness than the other groups,
although no participants in the bipolar group from mixed families who expressed a left
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handed preference for writing (see table 5.5.6). For the sample as a whole, 91.5% of
people stated that they used their right hand exclusively for writing.
Table 5.5.6 Handedness by group
Handedness
R L Total
Control N 47 3 50
% 94.0% 6.0% 100.0%
Scz from Scz family N 24 3 27
% 88.9% 11.1% 100.0%
OK from Scz family N 20 5 25
% 80.0% 20.0% 100.0%
BPD from BPD family N 24 3 27
% 88.9% 11.1% 100.0%
OK from BPD family N 23 1 24
% 95.8% 4.2% 100.0%
BPD from mixed family N 20 0 20
% 100.0% .0% 100.0%
OK from mixed family N 25 2 27
% 92.6% 7.4% 100.0%
Total N 183 17 200
% 91.5% 8.5% 100.0%
5.5.7 Educational history
The educational histories of the study groups differed widely. Patients with
schizophrenia were the least likely to have studied beyond compulsory education,
followed in turn by their well relatives, bipolars from mixed families and healthy
subjects from mixed families. Bipolar patients and their well relatives had similar rates
of continuing past the compulsory leaving age at around 27%. Controls were the most
likely to continue past the compulsory school leaving age.
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Table 5.5.7: Educational history
Years of Full-time Education
More than
Compulsory compulsory Unclear or
or less only missing Total
Control N 8 39 3 50
% 16.0% 78.0% 6.0% 100.0%
Scz from Scz family N 17 10 0 27
% 63.0% 37.0% .0% 100.0%
OK from Scz family N 13 11 1 25
% 52.0% 44.0% 4.0% 100.0%
BPD from BPD family N 7 20 0 27
% 25.9% 74.1% .0% 100.0%
OK from BPD family N 7 17 0 24
% 29.2% 70.8% .0% 100.0%
BPD from mixed family N 8 12 0 20
% 40.0% 60.0% .0% 100.0%
OK from mixed family N 9 13 5 27
% 33.3% 48.1% 18.5% 100.0%
Total N 69 122 9 200
% 34.5% 61.0% 4.5% 100.0%
5.5.8 Current medication
Data was collected on antipsychotics, lithium, antidepressants, anticonvulsants
and antimuscarinic drugs. Controls were receiving no psychotropic medication from any
category. Relatives of affected patients reported antidepressant use, though the rates of
current prescription were low in all unaffected relative groups and were not associated
with a major depressive episode. In most cases the prescription of antidepressants
appeared to be associated with bereavement, isolated insomnia or anxiety. All affected
patient groups reported extensive psychotropic medication use which is described in the
following table. Antipsychotics (conventional and atypical) were most commonly
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prescribed in the schizophrenic group, whereas anticonvulsants and lithium were more
common in the bipolar subjects (table 5.5.8.1).
Table 5.5.8.1: Current medication status
Drug
Group
1 2 3 4 5 6 7
Antidepressant
N (%)
0(0) 5(18.5) 1 (3.6) 10(38.5) 2(8) 7 (33.3) 1 (4.2)
Benzodiazepine
N (%)
0(0) 7 (25.9) 0(0) 3(11.5) 1(4) 2 (9.5) 0(0)
Antipsychotic
N (%)
0(0) 12(44.4) 0(0) 8 (29.6) 0(0) 4(20) 1 (3.7)
Atypical
N (%)
0(0) 13 (48.1) 0(0) 3(11.5) 0(0) 7 (33.3) 0(0)
Lithium
N (%)
0(0) 0(0) 0(0) 12(46.2) 0(0) 7 (33.3) 0(0)
Anticonvulsant
N (%)
0(0) 1 (3.7) 0(0) 9 (34.6) 0(0) 6 (28.6) 0(0)
Antimuscarinic
N (%)
0(0) 5(18.5) 0(0) 1 (3.8) 0(0) 0(0) 0(0)
Key
1 Controls
2 Schizophrenic subjects from schizophrenic families
3 Unaffected from schizophrenic families
4 Bipolar subjects from bipolar families
5 Unaffected from bipolar families
6 Bipolar subjects from mixed families
7 Unaffected from mixed families
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Table 5.5.8.2: Conventional antipsychotic and lithium doses
Medication
Group Dose of lithium Dose of antipsychotic
Scz from Scz family Mean .00 171.538
Median .00 .000
Std. Deviation .00 321.3060
Interquartile Range .00 200.000
BPD from BPD family Mean 433.3333 37.037
Median .0000 .000
Std. Deviation 538.51648 77.9455
Interquartile Range 800.0000 .000
BPD from mixed family Mean 173.6842 21.947
Median .0000 .000
Std. Deviation 339.67649 64.3933
Interquartile Range 100.0000 .000
5.6 Comparison of clinical data collected on all subjects
5.6.1 Clinical rating scales
Complete rating scale data was obtained for all subjects and controls. Positive
symptoms were measured using the PANSS positive subscale, which has a minimum
score of 7 when no positive symptoms are present rising to a possible maximum score of
49. All groups had relatively low positive subscale with higher scores being found in the
patients. Depressive symptoms were measured using the Hamilton Depression Rating
Scale (HDRS) which has a minimum score of 0 and a maximum of 66. Again, all groups
scored closer to the lower end of the scale, although schizophrenics had the highest
scores, followed in turn by bipolars from mixed families and bipolars from bipolar
families. Mania was measured using the Young Mania rating Scale (minimum
possible=0 maximum possible=60) and no group had a median score or greater than 5 or
a mean greater than 6.
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The results of the clinical rating scales are shown in the following table (table
5.6.1), along with the results of the PANSS negative and general psychopathology
subscales. The primary purpose of collecting data on positive symptoms, depression and
mania was to correct for the effect of current symptoms on the results of subsequent
neuropsychological assessments. In order to do this effectively, data were collected on
three relatively uncorrelated dimensions of psychopathology. The results of the general
psychopathology subscale and negative subscales were not used to adjust for symptoms
since they contain items which have counterparts within either the HDRS or YMRS.
251
Table 5.6.1: Rating scale assessments
Statistic
Group PTOTAL NTOTAL GENTOTAL HAMTOT YMRSTOT
Control Mean 7.04 7.04 16.32 .46 .16
Median 7.00 7.00 16.00 .00 .00
SD .198 .198 .768 1.034 .468
IQR .00 .00 .00 .00 .00
Scz from Scz Mean 12.22 12.41 26.70 11.22 5.74
family Median 12.00 11.00 27.00 10.00 3.00
SD 4.458 4.466 7.645 8.959 5.096
IQR 7.00 6.00 10.00 12.00 8.00
OK from Scz Mean 7.16 7.28 17.80 2.64 .40
family Median 7.00 7.00 17.00 1.00 .00
SD .624 .542 2.449 4.122 1.000
IQR .00 .50 3.00 2.50 .00
BPD from Mean 9.56 8.41 22.63 7.33 4.19
BPD family Median 8.00 8.00 21.00 5.00 2.00
SD 2.847 3.104 6.103 7.312 5.485
IQR 5.00 1.00 10.00 9.00 8.00
OK from Mean 7.63 7.63 18.13 2.92 .79
BPD family Median 7.00 8.00 17.00 1.50 .00
SD .970 .576 2.909 3.775 1.503
IQR 1.00 1.00 3.00 3.50 1.00
BPD from Mean 9.95 8.05 22.95 10.30 5.55
mixed family Median 8.00 7.00 22.00 7.00 4.50
SD 3.561 1.572 4.817 8.578 6.236
IQR 5.75 2.50 5.25 14.25 6.50
OK from Mean 7.04 7.15 17.26 2.33 .59
mixed family Median 7.00 7.00 17.00 1.00 .00
SD 1.556 1.680 4.311 3.464 1.394
IQR .00 1.00 3.00 3.00 .00
Key to table
PTOT PANSS positive symptoms total
NTOT PANSS negative symptoms total
GENTOT PANSS general symptoms total
HAMTOT HDRS total score
YMRSTOT YMRS total score
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Figure 5.6.1: Box and whisker plots of rating scale assessments
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5.6.2 Measurement of genetic liability
Genetic liability was calculated for all subjects affected by mental illness, and
their well relatives. Genetic liability was approximately normally distributed in each
group. As expected, patients with schizophrenia had the highest genetic liability for
schizophrenia followed in order by unaffected people from schizophrenic families,
bipolar patients from mixed families and finally unaffected subjects from mixed
families. Genetic liability for bipolar disorder was highest in bipolar subjects from
bipolar families followed in order by bipolar subjects from mixed families, unaffected
subjects from bipolar families and finally unaffected subjects from mixed families.
Table 5.6.2: Genetic liabilities by group
Group Value




OK from SCZ family Mean .46
SD .20
BPD from mixed family Mean .25
SD .19
OK from mixed family Mean .17
SD .13




disorder OK from BPD family Mean .28
SD .14
BPD from mixed family Mean 2.37
SD .18




Figure 5.6.2 showing box and whisker plots of genetic liabilities to
schizophrenia and bipolar disorder
Genetic liability to schizophrenia Genetic liability to bipolar disorder
Scz from Scz family BPD frommi>edfamily





BPD from BPD family
OK from EPD family
BPD from m bed family
OK from mixed family
5.7 Neuropsychological results
More than 90% of the sample provided complete data from all
neuropsychological assessments. The results are given in the following sections,
categorised by domain of neuropsychological function.
5.7.1 Intellectual function
On measures of intellectual function (NART FSIQ, WASI VIQ, PIQ and FSIQ),
there was evidence from mixed model MANCOVA (with HDRS, YMRS and PANSS
positive as covariates) that the groups differed significantly in terms of these measures
(F20,203=2.02, p<0.01). Individual pairwise effects were subsequently estimated using a
multilevel model and 'pedigree' as a random factor. The results of the analyses
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conducted are given in the following pages according to the domain of intellectual
function affected.
Table 5.7.1: Mean intellectual function by group
Group NART FSIQ WASI FSIQ WASI PIQ WASI VBIQ
Control Mean 110.8 114.0 113.5 111.2
SD 8.5 13.3 13.1 12.9
Scz from Scz family Mean 101.3 90.0 87.9 94.0
SD 12.6 14.2 16.2 14.9
OK from Scz family Mean 101.2 99.0 98.7 99.7
SD 9.6 12.1 15.0 11.7
BPD from BPD family Mean 111.5 106.7 102.0 109.9
SD 10.9 13.3 13.6 13.1
OK from BPD family Mean 104.4 105.3 104.1 105.4
SD 11.1 12.1 14.2 12.2
BPD from mixed family Mean 105.9 101.6 99.0 103.4
SD 10.8 16.2 14.9 15.4
OK from mixed family Mean 104.7 104.6 102.8 105.7
SD 10.0 14.4 14.9 14.4
5.7.1.1 NART FSIQ
NART full scale IQ differed significantly between the groups (F6,65=3.12,
p=0.01). Schizophrenic subjects and unaffected subjects from schizophrenic families had
significantly lower NART IQ's compared to healthy controls. Schizophrenic subjects
also had significantly lower IQs compared to bipolar subjects and bipolar subjects had
significantly higher NART IQs than their unaffected relatives. Overall, the results
suggest that NART IQ is impaired in relationship to both the liability, and expression of
schizophrenia. Neither the expression nor liability to bipolar disorder appeared to
convey intellectual disadvantage.
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Figure 5.7.1.1: Means and crude 95% confidence intervals for NART full
scale IQ
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WASI full scale IQ differed significantly between the groups (Fe,64=6.42,
p<0.0001). Schizophrenic subjects, bipolar subjects from mixed families and unaffected
relatives from schizophrenic families had significantly lower WASI FSIQ's than healthy
controls. A trend was also observed which indicated lower WASI FSIQ in the unaffected
subjects from mixed families (p=0.07) compared to controls. Schizophrenic subjects also
had significantly lower IQs than bipolar subjects from either bipolar or mixed families
and indeed from their own healthy relatives.
Overall, the results suggest that WASI FSIQ is impaired in relationship to both
the liability to, and expression of schizophrenia. Neither the expression nor liability to
bipolar disorder appeared to covey an intellectual disadvantage.
Figure 5.7.1.2: Means and crude 95% confidence intervals for WASI full
scale IQ
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5.7.1.3 WASI performance IQ
Performance IQ, as measured by the WASI (WASI PIQ) differed significantly
between the groups (F6,64=5.93, p<0.0001). Schizophrenics, bipolars from bipolar
families and bipolars from mixed families all had significantly lower WASI PIQ's than
controls. The effect size was greatest in schizophrenics, intermediate in bipolars from
mixed families and least in bipolars from bipolar families. Unaffected relatives from
schizophrenic families or mixed families were also significantly more impaired in terms
of the WASIPIQ than healthy subjects. No trend to significance was found for the
unaffected relatives of bipolar families. Schizophrenic subjects were significantly more
impaired than either bipolar group or their own relatives. Bipolar subjects from either
bipolar or mixed families did not differ from their well relatives. Although no significant
differences between the unaffected subject groups were found, impairments were
greatest in the unaffected relatives of schizophrenic subjects, intermediate in the
unaffected relatives from mixed families and the unaffected relatives of bipolar subjects
showed the least impairment.
Overall, the results suggest that WASI PIQ is impaired in relationship to the
expression of psychosis, regardless of diagnosis. However, impairments in unaffected
relatives were found only in healthy relatives where at least one person had
schizophrenia. The genetic liability to bipolar disorder appeared to covey no intellectual
disadvantage in terms of PIQ.
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Figure 5.7.1.3: Mean and crude 95% confidence intervals for WASI
performance IQ
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5.7.1.4 WASI verbal IQ
Verbal IQ, as measured by the WASI (WASI VIQ) differed significantly
between the groups (F6i64=4.04, p=0.002). Schizophrenic patients and their healthy
relatives had significantly lower WASI VIQ than controls. However, both bipolar groups
and their well relatives did not differ significantly from controls. A greater difference
was observed between unaffected relatives from mixed families and controls than
between unaffected relatives from bipolar families and controls. Schizophrenic subjects
also had significantly lower WASI VIQ's than either their own relatives or either group
of bipolar subjects. Bipolar subjects did not differ significantly from their well relatives,
although there was a trend for unaffected relatives from bipolar families to have higher
WASI VIQ's than their ill relatives.
Overall, the results suggest that WASI VIQ is impaired in relationship to both
the liability to, and expression of schizophrenia. Neither the expression nor liability to
bipolar disorder appeared to convey any intellectual disadvantage.
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Figure 5.7.1.4: Means and crude 95% confidence intervals for WASI verbal IQ
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5.7.1.5 Premorbid versus current IQ difference
In studies of people with schizophrenia, a premorbid versus current IQ
discrepancy is often found. This discrepancy is thought to represent a possible
intellectual decline in schizophrenic subjects as they become unwell. The discrepancy
between NART full-scale IQ and WASI full-scale IQ was computed by subtraction and
then compared using a mixed model ANOVA taking the family into account as a
random factor and the PANSS positive, HDRS and TMRS total scores as covariates.
Comparisons were then made between each group and the control group by estimating
the mean difference (NART FSIQ - WASI FSIQ) and its 95% confidence interval.
'NART-WASI IQ discrepancy' (NART FSIQ - WASI FSIQ) differed
significantly amongst the groups (F6>64=4.7, p<0.001). All patients groups differed from
controls, although the difference was greatest for schizophrenic subjects (mean
difference^ 5.6, 95%CI 9.5 to 21.7), whilst bipolars from mixed families (mean
difference=7.8, 95%CI 1.6 to 13.9) and bipolars from bipolar families (mean
difference=8.1, 95%CI 2.5 to 13.6) had similar levels of'decline'. Unaffected relatives
of patients with schizophrenia also showed evidence of a decline in intellectual
functioning of about 5 points compared to controls, although the crude confidence
interval for this IQ difference showns some overlap with the other unaffected relative
groups. The data are represented graphically in figure 5.7.1.5.
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Figure 5.7.1.5: Means and crude 95% confidence intervals for premorbid
current IQ difference
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Memory was compared between groups using the Extended Rivermead
Behavioural Memory Test (E-RBMT). As this was the only index of memory, a
univariate mixed model ANOVA was used to compare mean total E-RBMT profiles
scores between groups.
Table 5.8: E-RBMT total profile scores by group
1 2 3 4 5 6 7
Mean 36.4 26.4 29.0 27.2 32.5 28.1 33.0
SD 4.4 5.3 6.3 6.8 4.9 6.2 4.6
Key
1 Controls
2 Schizophrenic subjects from schizophrenic families
3 Unaffected from schizophrenic families
4 Bipolar subjects from bipolar families
5 Unaffected from bipolar families
6 Bipolar subjects from mixed families
7 Unaffected from mixed families
5.8.1 Extended Rivermead Behavioural Memory Test
Extended Rivermead Behavioural Memory Test (E-RBMT) scores differed
significantly between groups (F6;64=8.8, p<0.0001), regardless of whether WASI FSIQ
was included as a covariate (F6,64=5.9, p<0.0001). Results are presented first without
WASI FSIQ as a covariate, since WASI FSIQ may be related to genetic liability or
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disease expression itself and hence not a true confounder. This is followed by analysis
with WASI FSIQ as a covariate to highlight those differences which may not be
explained simply by a reduction in general intellectual function.
E-RBMT scores were lower in all groups compared to controls. There was no
evidence of disease specificity amongst affected subjects although unaffected subjects
from schizophrenic families were more impaired than unaffected subjects from either
bipolar or mixed families. Once WASI IQ was taken into account, the nature of the
results changed little. Controls performed better than all other groups and, amongst
affected subjects, there was little evidence of disease specificity. Bipolar subjects from
mixed families performed worse than their well relatives (difference=3.8, 95%CI 0.5 to
7.1) and unaffected subjects from schizophrenic families performed worse than
unaffected subjects from mixed families (difference=3.2, 95%CI 0.2 to 6.2). There was
also a trend for unaffected subjects from schizophrenic families to do worse than
unaffected members of bipolar families (difference=2.8, 95%CI -0.4 to 6).
Overall, these differences suggest that memory impairment is impaired in
relationship to both genetic liability and phenotypic expression of psychosis and shows
no evidence of diagnostic specificity. Amongst unaffected relatives, there was a
suggestion than unaffected family members with only schizophrenic relatives may be
relatively more disadvantaged in terms of memory than those with bipolar relatives.
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Figure 5.8.1: Means and crude 95% confidence intervals for E-RBMT total
scores between groups
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5.9 Attention and psychomotor performance
Cognitive and motor (psychomotor) performance was measured using the Digit
Symbol Substitution Test (DSST) from the WAIS and the Simple and Choice Reaction
Time Test from the CANTAB respectively. The combined vector of their means differed
significantly between the groups (Fi5ji66=2.0, p=0.02). Summary statistics for each group
are shown in table 5.9.1.
Table 5.9.1: Mean measures of psychomotor performance by group
Choice RT Simple RT
DSST (msec) (msec)
Control Mean 63.8 323.6 313.8
SD 11.7 35.8 40.3
Scz from Scz family Mean 40.1 411.5 395.7
SD 16.4 91.5 102.5
OK from Scz family Mean 53.8 330.1 332.4
SD 13.3 60.5 57.3
BPD from BPD family Mean 47.2 418.4 379.5
SD 13.5 271.2 110.8
OK from BPD family Mean 58.6 309.0 332.3
SD 9.4 42.5 50.9
BPD from mixed family Mean 46.6 400.4 406.1
SD 11.1 87.9 88.3
OK from mixed family Mean 58.7 341.3 338.2
SD 13.1 77.6 56.3
The number of correct digit symbol substitutions (DSST) differed significantly
between groups (F6,64=, p<0.0001). All patient groups were impaired relative to healthy
controls. Similarly unaffected relatives from all families made fewer correct
substitutions than controls although only unaffected subjects from schizophrenic
families performed significantly worse than controls (difference=6.91, 95%CI 0.94 to
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12.87). Schizophrenic subjects did significantly worse than their close relatives
(difference^ 0.6, 95%CI 3.7 to 17.5) and showed a tendency to do worse than the other
patient groups. There was no evidence of a difference between affected subjects from
mixed or bipolar families and unaffected relatives showed no significant differences
from one another.
Simple reaction time (SRT) also differed significantly between groups. All
patient groups were significantly impaired compared to controls, although no differences
were found between controls and any unaffected relative group. Bipolar subjects from
mixed families did significantly worse than bipolars from bipolar families.
Schizophrenic subjects and bipolar subjects from mixed families did significantly worse
than their well relatives. No difference was found between bipolar subjects and healthy
subjects from bipolar families.
Choice reaction time (CRT) also differed between groups. All patient groups
were significantly impaired compared to controls, although no differences were found
between controls and any unaffected relative group. Schizophrenic subjects performed
less well than their well relatives and bipolar subjects also did les well than their well
relatives. However, no significant differences were found between bipolar subjects from
mixed families and their well relatives. Differences between affected or unaffected
groups showed no diagnostic or familial specificity.
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Figure 5.9.1: Means and crude 95% confidence intervals for DSST test
(number of correct substitutions made in 90 sec), simple and choice
reaction times
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The marginal distributions of each component of executive function were first
inspected. Hayling Sentence Completion Test (HSCT) summary scores were found to be
negatively skewed and were transformed to an approximately normal distribution by
squaring each raw value. Using a mixed model MANCOVA, executive function (verbal
fluency, transformed Hayling Sentence Completion Test, Stockings of Cambridge) did
not differ significantly between
groups (F20,196.6= 1.29, p=0.19). Similarly, mixed effects 1-way ANOVAs did not
differentiate the groups in terms of either measure of HSCT performance, whether
corrected for current 1Q or not. However, Stockings of Cambridge Test mean scores
differed between the groups in the non-IQ corrected (F6,62=3.53, p=0.005) but not in the
1Q corrected analysis. Verbal fluency also differed between the groups in the non-IQ
corrected analysis (F6,64=2.98, p=0.013), but not once 1Q had been added to the model
(F6,62:=2, p<0.08).
Since the null hypothesis of no difference could not be rejected (the overall
MANOVA was not significant), pairwise comparisons for each test were estimated as a
means of data exploration rather than as a hypothesis test. Estimates are presented with
and without WASI FSIQ as a covariate.
Table 5.10: Executive function summary statistics
FAS Total SOC Total HSCT TSS HSCT TES
Control Mean 44.5 9.2 325.6 37.0
SD 10.4 2.3 86.4 13.9
Scz from Scz family Mean 31.9 6.8 241.4 24.2
SD 11.6 2.2 96.5 13.3
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OK from Scz family Mean 42.0 7.6 273.5 29.2
SD 10.4 2.3 98.6 14.1
BPD from BPD family Mean 37.0 7.6 266.4 28.6
SD 10.7 2.3 95.4 14.0
OK from BPD family Mean 38.8 8.1 320.4 36.1
SD 8.5 1.9 95.1 15.9
BPD from mixed family Mean 34.8 6.8 262.2 28.2
SD 11.5 1.9 104.9 15.6
OK from mixed family Mean 41.6 7.5 315.6 34.4
SD 14.0 2.7 73.3 10.7
FAS- verbal fluency, SOC- Stockings of Cambridge, HSCT - Hayling Sentence
Completion Test. TSS- transformed (X") total score, TES- transformed (X2) scaled error
score
Verbal fluency (FAS) was lower in each patient group compared to controls
(non-IQ adjusted). No significant differences were found for any unaffected groups
compared to controls. Schizophrenic patients and bipolar patients were significantly
more impaired than their well relatives. No difference was found between patients from
mixed families and their well relatives. There was no evidence that differences were
specific to diagnosis or familial history. After controlling for WASI FSIQ only two
differences remained significant: schizophrenic subjects remained more impaired than
their well relatives (difference=7.5, 95%CI 0.9 to 14.1) and bipolars from bipolar
families performed significantly better than their well relatives (difference=10.0 95%CI
3.7 to 16.3). In addition, unaffected subjects from schizophrenic families performed
significantly better than unaffected subjects from bipolar families (difference=7.2,
95%CI 0.7 to 13.8) and showed a tendency to perform better than controls
(difference=4.8, 95%CI -0.7 to 10.3).
Hayling sentence completion tests (overall scaled scores) were significantly
lower in unaffected subjects from schizophrenic families than in controls. This was the
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only significant finding, although there was a tendency for schizophrenic subjects to also
have lower scores than controls. After covarying for WASI FSIQ none of these
differences remained significant and no new significant findings emerged. A similar
pattern of results was also observed for the Hayling total scaled error scores.
The Stockings of Cambridge Test (number of trials completed in minimum
number of moves) was significantly different between groups. All patient groups
performed significantly worse than healthy controls with bipolars from bipolar families
showing the smallest degree of impairment (difference=1.4, 95%CI 0.14 to 2.6).
Similarly, unaffected subjects from schizophrenic and mixed families also performed
significantly worse than controls. No significant difference was found between
unaffected subjects from bipolar families and controls. Patient groups did not differ
significantly from each other, or their healthy relatives. There was a tendency for
bipolars from bipolar families to do better than those from mixed families, although this
was not statistically significant (difference=1.2, 95%CI -0.18 to 2.6). After adjusting for
IQ, only two significant findings remained. Bipolar subjects and healthy relatives from
mixed families both did significantly worse than healthy controls. None of the other
pairwise differences remained significant.
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Figure 5.10: Means and crude 95% confidence intervals for total verbal
fluency score (FAS & animals)
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5.11 Medication and substance effects on neuropsychological function
The mixed-effects analyses of variance quoted above (sections 5.7 to 5.10) did
not include medication as a covariate for symptom effects are likely to be more
important than medication effects. This is partly for reasons of simplicity but also
because medication has been shown to have an ameliorating as well as deleterious effect
on cognition in some studies (see chapter 2). However, to check the validity of the
models chosen, the unstandardised residuals (unexplained variation) from each analysis
were plotted against current conventional antipsychotic dose (chlorpromazine
equivalents), lithium dose and weekly alcohol intake. Antimuscarinic medication and
benzodiazepines were not prescribed in sufficient numbers to make the equivalent
analyses possible and no bioequivalent dose information is available for antimuscarinic,
antidepressant or anticonvulsant medications. However, the influence of these
medications was investigated by labelling plots of fitted versus observed values by
whether these medications had been prescribed at all and detecting any observed
patterns graphically.
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5.12 Relationship of neuropsychology to genetic liability
5.12.1 Genetic liability to schizophrenia and general intelligence
NART and WASI full scale IQ, WASI verbal IQ and WASI performance IQ
were all reduced in schizophrenics and their healthy relatives. In addition, bipolars from
mixed families and their unaffected relatives also performed less well than controls.
These findings suggested that general intelligence might be related to the genetic
liability to schizophrenia. In order to further investigate this relationship, Pearson
product-moment correlation coefficients were computed between each measure of
intelligence and the continuous measure of genetic liability to schizophrenia.
Within schizophrenic subjects themselves, genetic liability to schizophrenia was
inversely related to NART FSIQ (r=-0.49, p=0.01), WASI FSIQ (r=-0.33, p=0.1, trend
only) and WASI verbal IQ (-0.55, p=0.004) but not WASI performance IQ (r=-0.01,
p=0.94). However, within the healthy relatives of schizophrenic subjects, genetic
liability to schizophrenia was positively related to WASI performance IQ (r=0.45,
p=0.03) and WASI FSIQ (r=0.36, p=0.08, trend only). No relationship was found
between NART FSIQ (r=0.31, p=0.13) or WASI verbal IQ and genetic liability (r=0.06,
p=0.78).
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Figure 5.12.1a: Relationship between genetic liability to schizophrenia and
verbal IQ in patients with schizophrenia
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Figure 5.12.1b: Relationship between genetic liability to schizophrenia and










Genetic liability for schizophrenia
Within bipolar subjects from mixed families there were no significant
relationships between genetic liability to schizophrenia and measures of intelligence, and
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no suggestion of any trends. Within unaffected subjects from mixed families however,
genetic liability was negatively related to WASI FSIQ (r=-0.33, p=0.09, trend only) and
WASI verbal IQ (r=-0.39, p=0.05). Genetic liability was not related to WASI
performance IQ orNART FSIQ.
5.12.2 Genetic liability to schizophrenia and memory
There was no evidence of a relationship between genetic liability to
schizophrenia and scores on the Rivermead Behavioural Memory Test within any group.
5.12.3 Genetic liability to bipolar disorder and general intelligence
There was no evidence of a relationship between genetic liability to bipolar
disorder and any measure of general intelligence within bipolar subjects from bipolar
families, their well relatives or bipolar subjects from mixed families. However,
unaffected subjects from mixed families showed negative associations between genetic
liability to bipolar disorder and WASI FSIQ (r=-0.50, p=0.009), WASI verbal IQ (r=-
0.47, p=0.01), WASI performance IQ (r=-0.40, p=0.04) but not NART FSIQ.
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Figure 5.12.3: Relationship between genetic liability to bipolar disorder
and WASI full-scale IQ in unaffected subjects from mixed families
Genetic liability for bipolar diorder
5.12.4 Genetic liability to bipolar disorder and memory
There was no evidence of a relationship between genetic liability to bipolar
disorder and scores on the Rivermead behavioural memory test within any group.
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5.13 Discussion
Two-hundred patients were successfully recruited for the current study, in
accordance with the pre-stated aims. Fifty controls, 74 affected patients and 76
unaffected relatives were recruited in approximately the proportions required. Slightly
fewer bipolar patients from 'mixed' families with histories of both schizophrenia and
bipolar disorder were recruited (20). Most subjects provided complete
neuropsychological data and no subjects failed to complete more than 2 tests.
Demographically, the groups were reasonably close in terms of age, gender,
paternal social class and weekly alcohol consumption. Patients with schizophrenia and
bipolar patients from mixed families were more often unmarried than the other groups
and patients with schizophrenia had higher levels of cigarette use than all of the other
groups. Past cannabis use was common in all groups, but was most common in
unaffected people from schizophrenic families and lowest in unaffected families with a
history of bipolar disorder only. Height, weight and body mass index were also
reasonably similar across all groups. Unaffected people from schizophrenic families had
a slightly smaller proportion of people with a right handed preference for writing. An
educational history of compulsory education or less was more common both in patients
with schizophrenia and their well relatives than in the other 5 groups.
Medication status differed across all 7 groups, although no controls were
receiving medication at the time of the study. Antidepressant, benzodiazepine and
antipsychotic use was recorded in all patient groups. A few relatives also received an
antidepressant (4), benzodiazepines (1), or an antipsychotic (1). However, none suffered
from a major affective disorder or schizophrenia. Two unaffected relatives had recent
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bereavements, an additional unaffected relative was prescribed a low-dose antipsychotic
as a hypnotic agent and one further subject was prescribed an antidepressant for
symptoms of anxiety. Medicated relatives or controls were deliberately not excluded
from the analysis since prescription of many of these medications is common in the
general population and to exclude them would have limited the study's generalisability.
All groups generally had low scores in terms of the HDRS, Y-MRS and
PANSS subscales. However, none of the groups were symptom free and many
individuals from each group had partially or full psychotic symptoms on the Present
State Examination. It is perhaps regrettable that control subjects were not also rated
using the PSE. This would have led to a more meaningful comparison of the groups in
terms of psychotic and other symptoms. Patients with schizophrenia had the largest
median HDRS and PANSS scores compared to the other groups. However, bipolar
patients from mixed families had higher scores on the YMRS than the other groups.
Some unaffected relatives and controls also had several symptoms rated from the HDRS.
Fewer symptoms were recorded using the other two scales (PANSS positive and Y-
MRS). As anticipated, scores on the three symptom scales used differed between
amongst the groups. In order to correct between group differences for the effects of
symptoms, these measures were used as covariates in the subsequent analyses.
Studies have examined neuropsychological function in symptom free patients.
However, positive and affective symptoms in bipolar and schizophrenic patients are both
common and enduring in studies of discharged patients and their exclusion would have
decreased the study's generalisability in terms of its overall characteristics. Symptoms
detected using the PSE would often not be detected during a routine clinical examination
301
and may reflect the tendency of people with psychotic diagnosis to have chronic positive
symptoms between episodes about which they do not complain.
Patients with Bipolar Disorder I only were included since Bipolar II disorder is a
generally milder condition of less certain nosological status which may be more closely
related to depression (Angst and Mameros 2001). If patients with Bipolar II disorder had
been included in the current study then the groups may have differed more in terms of
past psychiatric histories and illness severity and could have further confounded the
results. The number of previous psychiatric admissions was not recorded on the basis
that patients from several areas were recruited each of which differed widely in terms of
community provision limiting the use of 'number/duration of inpatient admissions' as an
index of severity. However, case note information was also insufficiently complete to
make this calculation possible, as many patients were known to have been admitted to
other hospitals, although no record of this could be found in the current case notes.
Patients with bipolar disorder from mixed families were intermediate between
patients with schizophrenia and bipolar patients from bipolar families on several
measures (e.g. memory, IQ, educational history, current socio-economic status). This is
possibly consistent with a spectrum of continuous phenotypic variation from
schizophrenia to bipolar disorder through intermediate forms. The finding is consistent
with data from other sources that finds evidence of continuous variation in patients with
functional psychosis (van Os et al. 1999;McIntosh et al. 2001).
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5.13.1 Measurement of genetic liability
Genetic liability was measured using a continuous measure devised by Pak Sham
at the Institute of Psychiatry in London (Lawrie et al. 2001). It provides a continuous
score of genetic loading which increases according to the number and proximity of
affected relatives in a family. It has been criticised on the grounds that everybody
exceeding the threshold liability is assumed to develop the target disorder. Some have
suggested a probit model would be more appropriate as it allows risk to increase with
genetic loading, but not to a stage where disease is ever inevitable. Secondly, the
calculation of the loading score is dependent upon the quality of family information
available. In many cases, family members who were interviewed could remember
several generations of extended family history. However, the families questioned are
likely to differ in their openness towards mental illness, the area in which affected
relatives were treated and the recommended classification system of the time. These
differences in recall of familial data may be random, although it is possible that the
diagnosis of the affected probands may be associated with possible bias. For example,
patients with schizophrenia (and their relatives) may perceive more stigma and have
greater memory impairments than patients with bipolar disorder. This may lead them to
recall less family members with psychiatric disorder or, alternatively make false
recollections about the nature of particular psychiatric symptoms. These difficulties
might have been overcome if family data had been limited to first and second degree
relatives only or if family data was only accepted as true where it could be confirmed in
all cases by the corroborative oral account of close relatives and from written case-note
information. However, although case note information on family background was
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typically sparse, collaborative information from a relative was available in all patients.
The diagnosis of relatively distant family members was not always possible to confirm
from case records using operationalised criteria, although the diagnosis of at least one
family member (other than the participant themselves) was conformed in all cases.
Nevertheless, these methodological factors limit the validity of the continuous measure
of genetic liability used.
5.13.2 Neuropsychological findings
5.13.3 General intellectual ability (IQ)
Schizophrenic patients had lower NART FSIQ, WASI FSIQ, performance and
verbal IQ than control subjects. Bipolar patients from bipolar families differed from
controls in terms of performance IQ only, having on average a lower performance IQ by
about 10 points. Bipolar subjects from mixed families had significantly lower WASI
FSIQ and performance IQs than controls, and NART IQ and verbal IQ impairments
were greater than found in the bipolar subjects suggesting that the genetic liability to
schizophrenia conferred an additional intellectual disadvantage to these patients.
Unaffected subjects with schizophrenic relatives only were also reduced in terms
of NART IQ, WASI FSIQ, performance and verbal IQ compared to controls. Unaffected
subjects with mixed family histories were also reduced in terms of NART IQ, WASI
FSIQ, performance IQ but not verbal IQ, although the difference was suggestive of a
non-significant reduction compared to controls. In contrast however, unaffected subjects
with bipolar relatives only, showed no overall differences in any measure of intellectual
ability compared to controls.
304
These results suggest that a broad pattern of intellectual impairments is
characteristic of a genetic liability to schizophrenia only. A genetic liability to bipolar
disorder appears to have no independent effect on any intellectual measure, with the
exception of performance IQ in affected patients. It has been suggested that any
pathological process affecting the brain will have a tendency to affect performance
rather than verbal IQ, and the verbal-performance IQ deficit has been taken as a measure
suggestive of organic brain dysfunction in some studies (Max et al. 1998). The measure
of cognitive decline used in this study was the NART-FSIQ deficit, and this deficit was
present (and positive) in all patient groups. However, only the well subjects with
schizophrenic relatives only showed a difference in NART versus current IQ. These
results also suggest that all patients and the well relatives of people with schizophrenia
may have operated at a higher intellectual level previously than they did at interview.
The reason for the difference in well relatives of schizophrenic patients was not clear,
but the possibility that some relatives may become ill in the course of time is one which
must be considered. Furthermore, in prospective studies of people at high risk of
schizophrenia, intellectual disadvantage has been shown to be a risk factor which
precedes the onset of symptoms.
5.13.4 Memory
Total Rivermead Memory scores (E-RBMT) were reduced in all patients and
relatives compared to controls, whether or not these results were corrected for current
IQ. The differences were greatest in affected patients, although unaffected subjects with
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schizophrenic relatives only, showed larger impairments compared to the other
unaffected groups.
Therefore there was little evidence for disease specificity for memory
impairments in functional psychoses or in their well relatives. This is perhaps
unsurprising since studies of schizophrenic patients (Aleman et al. 1999) and bipolars
(Quraishi and Frangou 2002) have show a reduction in memory function compared to
controls. However, this study found that these differences did not appear to differ in
magnitude according to either diagnosis or family history, although relatives were
generally less severely impaired than patients.
The RBMT measures primarily episodic memory and is designed so that its
component tasks reflect everyday memory tasks. This study found that everyday
memory tasks are impaired in both relatives and affected patients with psychosis and
that these results persisted after correction for differences in current IQ and prescribed
medication.
5.13.5 Executive function
The mean vector consisting of executive function test scores did not differ
significantly between groups using MANOVA. Therefore the chosen hypothesis test did
not reveal differences between the groups in terms of the pattern of executive function.
However, mean vectors may fail to differentiate groups when differences are present
between only one or two groups, or only on one measure of executive function, but not
others. For this reason, mixed model ANOVAs were conducted to compare the mean
score between groups on each measure of executive function individually.
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For the HSCT, no differences were observed between any groups and controls
for overall scaled score or error score, whether or not FSIQ was included on the model
as a covariate. Therefore, although pair-wise differences have been presented for
exploratory reasons, there appears to be a finding of 'no difference' for this measure.
This finding is in contrast to several others, including one from the Edinburgh High Risk
Study of (Byrne et al. 2003). Patients in the current study are on average about 15 years
older than those in the EHRS, and other studies. The unaffected subjects may therefore
include fewer people likely to develop psychosis in future and the older patients
identified in this study may be those with better functional outcomes than identified in
prospective studies. However, neither of these explanations are very satisfactory and the
failure to find a difference may simply be due to insufficient sample sizes.
In contrast however, the Stockings of Cambridge (SOC) test scores clearly
differed between the groups when the model did not include current IQ. All patient
groups performed significantly worse than controls. However, only the unaffected
relatives with at least one schizophrenic relative performed significantly worse than
controls, whether or not other family members had a history of bipolar disorder. Once
current FSIQ was taken into account, bipolar patients from bipolar and mixed families
performed significantly worse than controls in post-hoc tests, and all other pair-wise
differences disappeared.
Verbal fluency test scores also differed significantly between groups, with all
patient groups showing impairments compared to controls. Unaffected relatives from all
groups did not differ significantly in terms of performance from controls and to the
appropriate unaffected relative group, although schizophrenic patients did significantly
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worse than unaffected relatives with the same family history. Once the results had been
corrected for current FSIQ, all of the between-groups differences became non¬
significant.
5.13.6 Attention and psychomotor performance
Psychomotor performance was reduced compared to controls in all patient
groups compared to controls. Patients had lower digit-symbol substitution scores and
longer simple and choice reaction times, although choice reaction in bipolars from
mixed family was non-significantly reduced compared to controls, but was in the
expected direction. Schizophrenic subjects performed relatively worse than other patient
groups in terms of digit-symbol scores, although these differences were not statistically
significant. Bipolars from mixed families performed significantly worse than bipolar
subjects from bipolar families but were not significantly different from patients with
schizophrenia. Unaffected relatives from each group showed no differences in either
simple or choice reaction time compared to controls. However, unaffected subjects with
schizophrenic relatives only had significantly lower scores on the DSST than controls.
These results suggest that psychomotor impairments are a consequence of illness,
but not a genetic liability to illness. The exception to this is a finding of DSST
impairments in relatives of patients with schizophrenia. Deficits in cognitive tasks with a
high attentional component have been found before in the relatives of patients with
schizophrenia (Pogue-Geile et al. 1991;Franke et al. 1993). In fact, these deficits have
been measured in a number of ways, including using psychophysiological methods.
Their presence has suggested to some that attentional deficits may be a mechanism by
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which schizophrenia may develop although few have proposed a similar mechanism in
bipolar disorder. The finding of an attentional deficit in unaffected subjects with
schizophrenic relatives only supports the view that attentional disorders may reflect a
vulnerability to schizophrenia. However, their presence in all affected subjects suggests
that once the disease is apparent, attentional deficits show no diagnostic specificity and
may possibly act to maintain psychiatric symptoms regardless of the factors which led to
their development.
5.13.6 Relationship to genetic liability
Associations with genetic liability were examined by estimating the correlation
coefficient between genetic liability for each disorder and measures of
neuropsychological function. Only IQ (NART FSIQ, WASI FSIQ, PIQ, and VBIQ) and
memory were considered as they differed across each group. A significant negative
association was found between genetic liability for schizophrenia and WASI verbal IQ
in patients affected by schizophrenia, but not those with bipolar disorder from mixed
families. In contrast, unaffected subjects from schizophrenic families showed a positive
association between genetic liability and performance IQ. This finding in schizophrenic
subjects is consistent with a growing body of evidence showing that premorbid IQ is
reduced many years before the onset of schizophrenia (see chapter 2). This relationship
in relatives is in the opposite direction to that expected since the group as a whole
performed worse on this measure than controls with no family history of mental
disorder. The finding could be interpreted as evidence that genes for schizophrenia carry
an advantage for those who do not express the full-blown syndrome. Although this
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finding could be a false positive, it is possible that within the unaffected group with
schizophrenic relatives, a subgroup of people with schizophrenia spectrum disorders
accounted for the lower mean IQ, whereas in those patients without these spectrum
disorders, the effect of genes for schizophrenia was to convey an intellectual advantage.
This hypothesis is speculative, and since no measure of schizotypy was used in this
study, we were unable to test this hypothesis. The finding is not without some support
from studies of obligate carriers of schizophrenia who have been shown to have superior
intellectual performance in one study (Steel et al. 2002), in spite of relatively high
genetic liability. Others have also suggested that the ability of schizophrenia to persist,
despite the fact that affected individuals typically reproduce less compared to the general
population, suggests that the genes for schizophrenia must confer an advantage in at
least some of those who carry them.
Genetic loading for bipolar disorder had no effect in patients where the disorder
'bred true'. However, in families where there was a mixed history of both schizophrenia
and bipolar disorder and schizophrenia, three associations were found. In unaffected
relatives, genetic liability was negatively associated with WASI full-scale, verbal and
performance IQ, but not NART IQ. These differences were not expected since the group
as a whole showed non significant reductions in these measures compared to controls.
However, the presence of a subgroup of patients with schizophrenia or bipolar spectrum
disorders might clarify or explain this finding, although data was not collected which
would have allowed us to explore this further.
5.14 Strengths and limitations
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Patients and controls participating in research projects may be atypical of the
populations they are chosen to represent. Consenting patients are likely to have better
neuropsychological, social and clinical function than those who decline the offer of
participation and observed effect sizes from case-control studies may therefore be
underestimated. The current study may also been subject to this general limitation,
although the inclusion of some detained patients may have reduced this effect to a
degree. Similar concerns could also be expressed about the sample of healthy controls.
For example, controls may be unrepresentative of the general population when they are
drawn from socially advantaged backgrounds, such as from the clinical staff of an
associated research institution. The control subjects for the current study were drawn,
where possible, from the non-genetic relatives and social networks of the patients
themselves. This was in an attempt to draw controls from a similar population as the
other groups, differing only in terms of genetic background and diagnosis. However, it is
uncertain whether this can ever be accomplished in case-control studies. Furthermore,
control subjects from the current study had higher intellectual functioning than that
expected from a mean population IQ of 100. It is possible therefore that some pairwise
comparisons with controls may have been overestimated in this study, although other
comparisons are less likely to have been affected. Furthermore, many analyses were
adjusted for current IQ so that differences in neuropsychological performance were
probably not due to differences in general intellectual function alone.
The measurement of IQ using the WASI is well validated in normal populations
and the level of agreement with the full WAIS-R is known to be high (see product
manual). Similarly, the other neuropsychological measures used were chosen because of
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previous use in psychiatric populations and because they have yielded differences
between psychotic patients and controls in other studies (Byrne et al. 2003). However,
although the NART is repeatedly used in studies of psychiatric patients, it maybe be
more unreliable (Heinrichs and Zakzanis 1998) and show a tendency to overestimate
premorbid IQ in affected patients (David et al. 1997).
The results of this study were corrected for current symptoms (PANSS positive,
Y-MRS, HDRS) in all cases. However, the possibility of confounding by motivation or
general health (amongst others) is possible. Sex and, where appropriate, age were also
included as covariates. A role for age and sex in neuropsychological test performance
has been suggested by several authors, necessitating their inclusion as covariates. Age of
onset, number of previous episodes and duration of illness were not included as
covariates, although it is possible that they too may affect neuropsychological test
performance. Age of onset and duration of illness in years were relatively similar in the
three patient groups which may have reduced any potential confounding. An interaction
between number of episodes and diagnosis has been suggested by some authors,
although this was not systematically investigated in the current study. It is however
possible that neuropsychological impairment in bipolar subjects is associated with
cumulative episodes of illness and hypercortisolaemia (Rush et al. 1996), whereas in
schizophrenia this relationship may be absent. Other potential confounds were
deliberately not-adjusted for in the analysis. For example, current intellectual
performance and socio-economic status may deteriorate after the first episode of illness.
By matching on these variables, it is possible that socially and intellectually
disadvantaged controls would have been selected.
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Finally, many of the neuropsychological differences observed between groups
may have affected recall of episodic and autobiographical events. This may have led to a
biased assessment of genetic liability between groups making any adjustment for genetic
liability between groups difficult. For example, differences between schizophrenic
patients and their relatives could be taken as an index of neuropsychological impairment
contingent upon phenotypic expression of illness. However, the calculation of genetic
liability assumes that subjects become ill primarily because they are at increased genetic
liability and affected subjects always have higher genetic loading scores that their
unaffected relatives. However, there is some evidence (covered in more detail in the next
chapter) that genetic liability is not the major determinant of phenotypic expression in
multiply affected families, and that affected and unaffected family members are
probably more closely matched on this measure that the results shown earlier in this
chapter would suggest.
Although several differences were observed between the groups used in this
study, it is impossible to be certain whether they preceded or followed the expression of
illness in affected subjects. It is also likely that those impairments also found in close
relatives (e.g. memory impairments) were present before illness onset. However, the
possibility that these differences are magnified or confounded by the brain's adaptation
to the effects of medication, psychotic symptoms or other aspect of the disease process
cannot be excluded. The meaning of these differences in terms of the neurotransmitter or
physiological pathways affected is also unclear. Although memory performance (for
example) is associated with changes in the hippocampus in healthy subjects, the
mechanism of impairments in those affected by psychosis or at increased genetic
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liability may not necessarily involve the same mechanism. The interpretation of IQ in
terms of brain physiology or structure is particularly difficult and may involve the
coordination of several interconnected regions (Posthuma et al. 2003).
Future studies of neuropsychological performance in subjects with, or at
increased liability to, psychosis could make several improvements in terms of study
methodology. Firstly, unaffected subjects could be followed prospectively, preferably
before illness onset such that performance could be ascertained before any physiological
adaptation to illness or medication had the potential to confound the results. Once some
subjects had become unwell, repeated assessments could continue in order to measure
any progressive features of the illness. Large study numbers would be required, even if
the study included only those at very high risk. Brain physiology could also be examined
during test performance, to further elucidate the mechanisms underlying cognitive
impairments.
Although the current study examined groups of people with 'functional
psychosis' it is unclear whether the differences observed relate only to diagnosis, or
whether they relate to psychotic symptoms (hallucinations or delusions). Most people
included in the current study had psychotic symptoms, although the numbers involved
do not allow enough statistical power to perform sensitivity analyses. It has also been
suggested that dimensions of psychotic symptoms found in affected subjects represent
the extremes of a range of variation within the population as a whole. Brian anatomy and
physiology may be more closely related to these dimensions than to diagnosis. A future
study could usefully re-examine symptom dimensions a broad spectrum of functional
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psychotic illness and relate these findings to neuropsychological test performance, brain
structure and perhaps function.
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Chapter 6: Imaging Results
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6.1 Summary of patient groups and contrasts performed
The purpose of collecting neuropsychological and imaging data on patients with
psychosis and their well relatives was so that the role of genetic liability alone could be
separated from environmental effects and effects which are dependent upon disease
expression. Since environmental effects were not actually measured in this study, effects
contingent upon disease expression or environmental exposure could not be separated.
Figure 6.1 summarises the main genetic and phenotypic effects in each group. Gs
refers to a genetic liability to schizophrenia, Gb refers to a genetic liability to bipolar
disorder and Ps and Pb refer to the phenotypic associations of schizophrenia and bipolar
disorder respectively. Gsxb refers to a possible interaction between genetic liability for
schizophrenia and bipolar disorder. Genetic and phenotypic/environmental effects are
assumed to be additive in the diagram and lead to the brain structure observed in
affected patients. The effects observed in relatives are assumed to reflect only the
changes contingent upon genetic liability alone. Assuming a standard threshold-liability
model, these assumptions may not be valid as differences between affected family
members and their well relatives are likely to represent differences in genetic liability as
well as environmental/phenotypic effects. However evidence from the Edinburgh High
Risk Study (Johnstone et al. 2004) and from studies of identical twins (Cardno and
Gottesman 2000;Sullivan et al. 2003) suggests that this may not be the case. In the
EHRS, high-risk subjects who became unwell were similar to those who remained
healthy in terms of the continuous measure of genetic liability used. Evidence from a
meta-analysis of twin studies suggests that shared environmental factors are important
for the development of schizophrenia in people matched in terms of their genetic
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liability farther suggesting that, at least in schizophrenic twins matched in terms of
liability, that environmental influences may determine who becomes unwell. In general
terms, these data are consistent with a two hit model with genes determining the
presence of an extended schizophrenic phenotype (including schizotypal and other
disorders) and environmental influences determining in the majority of cases who
becomes unwell. This model could be criticised on a number of grounds including the
fact that many people with psychosis show no personality or social impairments before
they become unwell. However, it is not clear that a more suitable model is available and
this relatively simple model is convenient for the purposes of the current study as long as
its limitations are bome in mind. The figure is meant to act as a visual aid to the
contrasts described on the following page and as an aid to the interpretation of results.
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Contrasts performed (grey matter)
(2-tailed unless otherwise stated)
Group 1: Patients versus controls
Two-tailed contrasts in this group were performed between each patient group
and controls. This was in order to ascertain the additive genetic and
environmental/phenotypic effects acting upon the subjects within each group.
Differences between schizophrenics (SCZ) and controls are assumed to reflect the
additive genetic and environmental/phenotypic influences acting in that group. The
control versus bipolars from mixed families (MIX) contrast is assumed to represent the
phenotypic/environmental effects of a bipolar phenotype plus the genetic liability to both
bipolar disorder and schizophrenia. Finally, the differences between bipolars from
bipolar families (BPD) and controls are assumed to reflect the phenotypic/environmental
effects of having bipolar disorder plus the genetic liability to that disorder.
Contrasts performed in group 1
la: SCZ versus controls: (Gs + Ps - 0)
lb: MIX versus controls: Gs+Gb+Gbxs+Pb
lc: BPD versus controls: Gb+Pb
Group 2: Between patient group contrasts
Contrasts were performed between patient groups to assess the magnitude and
specificity of control versus patient differences found previously. Schizophrenic patients
were compared with bipolar patients from both mixed and bipolar pedigrees in order to
ascertain which control versus SCZ findings was specific to this contrast. Differences
between schizophrenic subjects and bipolars from mixed families may also reflect
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environmental/phenotypic effects contingent upon having bipolar disorder. Differences
between bipolar subjects from mixed families and bipolars from bipolar families may
also reflect differences contingent upon a genetic liability to schizophrenia.
Contrasts performed in group 2
2a: SCZ versus MIX: (Gs+PsMGs+Gb+GBxs+Pb)
2b: SCZ versus BPD: (Gs+Ps)-(Gb+Pb)
2c: MIX versus BPD: (Gs+GB+GBxS+PB)-(GB+PB)
Group 3: Masked contrasts
On the basis of the results of contrasts from group 3, two further masked
contrasts were performed. Both were used to address the specificity of grey matter
reductions in schizophrenic subjects compared to controls. The first contrast examined
which reductions did not occur in the MIX versus control contrast (lb).The second
examined which reductions did not occur in the BPD versus control contrast (lc).
Contrasts performed in group 3
3a: Contrast la masked by contrast lb: (Gs+Ps) NOT (Gs+Gb+Gbxs+Pb)
3b: Contrast la masked by contrast lc: (Gs+Ps) NOT (Gb+Pb)
Group 4: Patient versus unaffected relative contrasts
In order to assess the specific environmental/phenotypic effects in affected
patients, three contrasts were made between affected patients and unaffected family
members from the same family background. The first contrast compared schizophrenic
patients to well family members and is assumed to reflect grey matter changes
contingent upon the phenotypic effects of schizophrenia only. This may reflect the
additional environmental or phenotypic effects in that group. The two bipolar groups
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were also compared to family members from the same pedigrees. In both of these
contrasts the environmental/phenotypic influences upon people with bipolar disorder
were estimated. Differences between the results of these contrasts may also reflect the
interaction of phenotypic/environmental effects with the effects of a genetic liability to
schizophrenia.
Contrasts performed in group 4
4a: SCZ versus uSCZ: (Gs+Ps)-(Gs)
4b: MIX versus uMIX: (Gs+Gb+Gbxs+Pb)-( Gs+Gb+Gbxs)
4c: BPD versus uBPD: (Gb+Pb)-(Gb)
Group 5: Unaffected subjects versus controls
Unaffected relatives of affected subjects from all groups were compared to
controls. These contrasts were assumed to reflect the effect of genes for either
schizophrenia or bipolar disorder or their sum. The actual contrasts computed are shown
below.
Contrasts performed in group 5
5a: uSCZ versus controls: Gs
5b: uMIXversus controls: Gs+Gb+Gbxs
5c: uMIX versus controls: Gb
Group 6: Exploratory contrasts
Finally six exploratory contrasts were performed. The first calculated the
schizophrenic versus relatives of schizophrenic patients contrast (SCZ vs. uSCZ, 1-
tailed), masking it with the bipolar versus unaffected relatives of bipolar patients contras
(BPDvs. uBPD, 1-tailed). This contrast may be taken to infer the effect of a phenotypic
expression of schizophrenia that is not present in bipolar disorder. Secondly, the SCZ vs.
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uSCZ contrast was masked with the MIX-uMIX contrast providing information on
changes contingent upon phenotypic but not genotypic effects in patients affected by
schizophrenia. Thirdly and fourthly, patients versus relatives contrasts were calculated
for both bipolar groups and were masked by the schizophrenic versus unaffected family
members form schizophrenic families contrast (SCZ vs. uSCZ, 1-tailed). These contrasts
enabled grey matter differences contingent upon a phenotype of bipolar disorder to be
calculated in both cases. In bipolar patients from bipolar families, this was assumed to
reflect differences which were not present in schizophrenic patients. The second analysis
was assumed to reflect phenotypic but not environmental influences upon a diagnosis of
bipolar disorder.
Contrasts/analyses performed in group 6
6a: uSCZ-SCZ masked by uBPD-BPD: (PS) NOT (PB)
6b: uSCZ-SCZ (~PS) masked by uMIX-MIX (~GS): (PS) NOT (GS)
6c: uMIX-MIX(-PB) masked by uSCZ-SCZ (~PS): PB NOT PS
6d: uBPD-BPD (~PB) masked by uSCZ-SCZ (~PS): PB NOT PS
6e: uMIX-MIX (~PB) masked by control-uBPD (~GB): PB NOT GB
Contrasts performed (white matter)
Only contrasts from group 1, 3 and 5 were conducted based upon the results of
the grey matter analyse, for the reasons which are outlined in the forthcoming pages.




Seven people out of 200 (3.5%) declined to have an MRI scan of the brain. Of
the remaining 193 scans, one further scan was lost from the 'bipolar from bipolar
families' group at the reporting stage when a 'large cyst of presumed
neurodevelopmental origin' was found on the scan by the reporting neuroradiologist.
Therefore 192 people (96%) provided useable data and no scans were lost due to
movement artefact. The proportion of each group providing useable data is summarised
in table 6.1.
Table 6.1: Proportion from each group who received an MR scan
Had a scan?(n/%) Total
Group No Yes n
Control 1 (2) 49 (98) 50
Scz from Scz family 1 (3.7) 26 (96.3) 27
OK from Scz family 1 (4) 24 (96) 25
BPD from BPD family* 0 27(100) 27
OK from BPD family 2 (8.3) 22 (91.7) 24
BPD from mixed family 1 (5) 19 (95) 20
OK from mixed family 1 (3.7) 26 (96.3) 27
Total 7 (3.5) 193 (96.5) 200
*A scan was lost at the reporting stage because of a large undiagnosed temporal lobe
cyst
6.3 Characteristics of patients receiving an MRI scan
The proportions of people from each group expressing a right-handed preference
for writing were similar. Patients with schizophrenia and their close unaffected relatives
had the lowest proportions (88.5% and 83.3% respectively). The proportion of males
from each group was less balanced between groups, ranging from a minimum of 14/26
(36.8%) in bipolar patients from mixed families to 14/26 (53.9%) in their close relatives
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and in bipolar patients from bipolar families. Mean height was similar across all groups
(maximum 1.72m in controls, minimum 1.67m in the relatives of schizophrenic
subjects) with approximately equal variance. Mean age showed less balance across the
groups ranging from a maximum of 40.5 years in bipolar subjects from bipolar families
to a minimum of 34.2 years in unaffected people from mixed families. Since
handedness, sex, height and age may all potentially confound between group differences
in regional brain volumes, they were included as nuisance covariates in the VBM
analyses.











Control 49 46 (93.9) 23 (46.9) 1.72 (0.10) 35.27(11.12)
SCZ from SCZ 26 23 (88.5) 13 (50) 1.70 (0.08) 36.85 (13.70)
OK from SCZ 24 20 (83.3) 11 (45.8) 1.67 (0.07) 38.92 (12.87)
BPD from BPD 26 24 (92.3) 14 (53.9) 1.70 (0.11) 40.5 (12.07)
OK from BPD 22 21 (95.5) 9 (40.9) 1.70 (0.10) 34.73 (12.60)
BPD from MIX 19 19(100) 7 (36.8) 1.69 (0.08) 39.74 (9.22)
OK from MIX 26 24 (92.3) 14 (53.9) 1.71 (0.11) 34.12 (12.98)
Total 192 177 (92.2) 91 (47.4) 1.70 (0.10) 36.87 (12.15)
Voxel based tests were conducted in three broad categories stated previously in
the methods chapter. Each analysis used the same covariates stated above. Grey matter
analyses included the number of grey matter voxels extracted from each scan as a
covariate, extracted using the get_globals.m MATLAB script. Similarly total white
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matter voxel number was used as a covariate in the white matter analyses. In both cases,
voxels were extracted from brains in native (untransformed) space.
6.4 Differences between patients and controls
Pairwise differences between patients and controls were computed using t-
contrasts. Results are presented in the form of tables and in the form of statistical
parametric maps overlaid on transverse slices through the study specific T1 template.
Parametric maps were thresholded at a significance of p=0.01. Differences with a voxel-
wise significance level of p<0.1 (corrected) are reported in the tables at the voxel of
maximum difference.
Differences between schizophrenic subjects and controls were found in several
areas, particularly the left middle and inferior frontal gyri and also in Broca's area (BA
44). A trend was also found for reductions in left parahippocampal grey matter density
in schizophrenic patients compared to controls. Significant differences were also found
in the medial-dorsal and anterior thalamus using the small volume correction (SVC)
image. Although the differences in cortical volumes are right-sided, the contrast image
suggests that corresponding areas of left-sided reduction may also be present which
failed to reach voxel-wise significance.
Patients with bipolar disorder from mixed families showed reductions in grey
matter density in the right inferior frontal gyrus, right insula and right pre-central gyrus
(non-significant trend). The qualitative appearance of the contrast image is similar to
that for the schizophrenic versus control comparison (thresholded at p<0.01) and the
significant right sided critical differences found appear to also have left sided
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counterparts which did not reach voxel-wise significance. However, no differences were
found in thalamus, amygdala or hippocampal grey matter density using the SVC,
although areas of possible difference can be seen on the contrast image at the anterior
pole of the thalamus which failed to reach voxel-wise significance.
Bipolar patients from bipolar families showed none of the frontal grey matter
reductions found in schizophrenic patients or bipolar patients from mixed families. Even
frontal grey matter differences thresholded at p<0.01 (uncorrected) were sparse and did
not appear to form confluent areas. However, bipolar patients from bipolar families
differed significantly in terms of anterior thalamic density bilaterally compared to
controls. The voxel of maximal difference was situated immediately anterior to the
anterior thalamus and the map of uncorrected voxels with which it was contiguous
clearly included the anterior thalamus. However, a small part of the caudate nucleus was
also included in the region of difference (overlaid on the contrast image and thresholded
at p<0.01).
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Figure 6.4.1 and Table 6.4.1: Differences in grey matter density between
schizophrenic subjects and controls
Voxel x, y, z (mm)
P corrected Talairach coordinates
Region of difference
Results for whole brain
0.002 -41 12 48 Middle frontal gyrus, BA6
0.004 -34 31 40 Middle frontal gyrus, BA 8
0.046 -50 11 21 Inferior frontal gyrus, BA 44
0.075 -31 -48 -5 Parahippocampal gyrus, BA 19
Small volume correction thalamus and amygdala-hippocampus
0.004 1 -16 7 Thalamus (medial dorsal nucleus)
0.006 0 -1 9 Thalamus (anterior nucleus)
0.017 5 -21 6 Thalamus (medial dorsal nucleus)
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Figure 6.4.2 and Table 6.4.2: Differences in grey matter density between
bipolar subjects from mixed families and controls
Voxel x, y, z (mm) Region of difference
P corrected Talairach coordinates
Results for whole brain
0.004 55 5 25 Inferior frontal gyrus, BA 9
0.021 41 11 12 Insula, BA 13
0.089 50 -1 44 Pre-central gyrus, BA 4
Small volume correction thalamus and amygdala-hippocampus:
No differences
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Figure 6.4.3 and Table 6.4.3: Differences in grey matter density between
bipolar subjects from bipolar families and controls
Voxel x, y, z (mm) Region of difference
P corrected Talairach coordinates
Results for whole brain
0.075 51 -7 46 Pre-central gyrus (BA 4)
Small volume correction thalamus and amygdala-hippocampus
0.005 -4 -1 11 Thalamus (anterior nucleus) and body of
caudate nucleus
0.01 2 -3 13 Thalamus (anterior nucleus) and body of
caudate nucleus
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6.5 Pairwise differences between patients with psychosis
Pairwise contrasts between each affected patient group were conducted. No
significant differences were found for any region. A single trend to significance was
found between schizophrenic subjects and bipolars from mixed families. Schizophrenic
subjects had a single area of decreased density in the left superior temporal gyrus
compared to bipolars from mixed families (Talairach coordinates -53, -31, 11;
pcorrected=0.059) although the voxel of maximum difference was approximately 3mm
from the superior temporal gyrus itself. No other significant differences were found.
Since considerable differences were found for each control-patient comparison,
between patient differences required further clarification. Since most subjects were in
the control group, contrasts including this group will have had the greatest statistical
power. Furthermore, within patients with a given diagnosis there may be considerable
heterogeneity in terms of symptoms, cognitive deficits and previous risk factor
exposures (e.g. obstetric, drug and alcohol, stressful life events). A given diagnosis may
therefore reflect a single endpoint of a number of different aetiological pathways each of
which may have different effects on brain structure. Therefore, grey and white matter
density may show greater variance within affected patients than within control subjects,
further reducing the power to detect any real differences between groups. For these
practical and theoretical reasons, pairwise differences between patient groups were
investigated by computing the contrast image between schizophrenic subjects and
controls and masking the differences with each bipolar versus control contrast images.
Each mask was thresholded at p<0.05 (uncorrected) so that any differences between
bipolar subjects and controls significant at this level would be removed from the
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schizophrenic versus control comparison. This analysis effectively yields differences in
grey matter density between schizophrenics and controls (for example) which are not
found between bipolars and controls (the masking images).
Table 6.4: VBM analysis of schizophrenia versus bipolar patients from
mixed families
Voxel x, y, z (mm) Region of difference
P corrected Talairach coordinates
Results for whole brain
0.059 -53 -31 11 Superior temporal gyrus, BA 41
Small volume correction thalamus and amygdala-hippocampus:
No differences
6.6 Masked contrasts
In order to overcome these potential problems of direct patient group
comparisons, two further analyses were conducted. Firstly, the control versus
schizophrenia contrast was masked with the control versus bipolars from mixed families
contrast. This contrast removed any significant regions of differences in both groups
from further consideration and therefore tested whether any reductions were exclusive to
schizophrenia, or were also found in bipolar patients with a family history of
schizophrenia. Secondly, the control versus schizophrenia contrast was masked with the
controls versus bipolar from bipolar families contrast. Again, this removed any regions
of common difference from further consideration, and tested for differences which were
not present in bipolars from bipolar families.
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Masked contrast 1: schizophrenia versus controls contrast masked with bipolars from
mixed families versus controls contrast
The first contrast examined which reductions in grey matter density found
between schizophrenics and controls were not found in bipolars from mixed families
compared to controls. The resulting analysis found that reductions in middle and inferior
frontal gyrus and dorsomedial thalamus remained after masking with the control-bipolar
from mixed families contrast image. This suggests that these reductions are greater in
schizophrenia and are possibly specific to this group. An area close to the anterior
thalamus also emerged as significant. However, by inspecting the contrast image itself,
this voxel appears to be contiguous with an area of medial and midline difference
suggesting medial rather than anterior thalamic differences.
Masked contrast 2: schizophrenia versus controls contrast masked with bipolars from
bipolar families versus controls contrast
The second contrast examined which reductions in grey matter density found
between schizophrenics and controls were not found in bipolars from bipolar families
compared to controls. Middle frontal gyrus grey matter density reductions were found
which were not removed by the masking image. However, all inferior frontal gyral
reductions were removed after the mask was applied (BA 9 and 44). Dorsomedial
thalamic grey matter reductions remained significant suggesting they were either greater
in schizophrenic subjects or specific to them.
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Figure and table 6.6.1: Differences in grey matter density between
schizophrenic subjects and controls (exclusively masked by control
versus bipolars from mixed families contrast)
Voxel x, y, z (mm)
P corrected Talairach coordinates
Region of difference
Results for whole brain
0.004 -34 31 40 Middle frontal gyrus, BA 8
0.040 -40 13 46 Middle frontal gyrus, BA 6
0.046 -50 11 22 Inferior frontal gyrus, BA 44
0.08 -31 -48 -6 Parahippocampal gyrus, BA 19
Small volume correction thalamus and amygdala-hippocampus
0.004 0 -16 7 Thalamus (medial dorsal nucleus)
0.013 -1 -2 7 Thalamus
0.016 5 -21 6 Thalamus (medical dorsal nucleus)
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Figure and table 6.6.2: Differences in grey matter density between
schizophrenic subjects and controls (exclusively masked by control-
bipolar from bipolar families contrast)
Voxel x, y, z (mm) Region of difference
P corrected Talairach coordinates
Results for whole brain
0.003 -40 13 50 Middle frontal gyrus, BA 6
0.004 -34 31 40 Middle frontal gyrus, BA 8
Small volume correction thalamus and amygdala-hippocampus
0.02 -4 -19 6 Thalamus, mediodorsal nucleus
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6.7 Differences between patients and unaffected relatives
To detect differences contingent upon the expression of illness, pairwise
comparisons were made between patients and unaffected subjects from the same
types of family.
Differences between schizophrenic subjects and their well relatives were the
most extensive, and qualitatively similar in many regards to the differences between
schizophrenic subjects and controls. Significant differences in grey matter density
were found in the left superior and middle temporal gyri and left pre-central gyrus.
Using the small volume correction, reductions were also found in right amygdala.
Examination of the contrast image itself, with differences of significance p<0.01
uncorrected superimposed, did not suggest the presence of lateralised differences.
No significant differences were found between bipolar subjects from bipolar
families and their well relatives or between bipolars from mixed families and their
well relatives.
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Figure and Table 6.7.1: VBM analysis of schizophrenics versus healthy
subjects from schizophrenic families
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results for whole brain
0.006 -58 -39 20 Superior temporal gyrus, BA 22
0.009 -58 -33 5 Middle temporal gyrus, BA 22
0.012 -53 -15 36 Pre-central gyrus, BA 4
Small volume correction thalamus and amygdala-hippocampus
0.033 30 1 -20 Amygdala
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6.8 Differences between unaffected relatives and controls
No significant differences were found between unaffected subjects from
schizophrenic families and controls. Unaffected relatives from bipolar families had
reduced grey matter density maximal immediately anterior to the thalamus and
posterior to the caudate nucleus. The area of contiguous voxels (thresholded at
p<0.01 uncorrected) extended into both caudate and anterior thalamus, although were
much more extensively distributed in the latter structure. A trend to significance was
also found in a similar region, but in the right hemisphere. The area of contiguous
voxels (thresholded at p<0.01 uncorrected) also extended into both caudate and
anterior thalamus.
Unaffected relatives from mixed families differed from healthy controls in
left and right anterior thalamic nuclear density. The region of contiguous voxels
extended into the body of the caudate bilaterally, although the anterior thalamus was
more closely associated with this region of significant difference.
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Figure and table 6.8.1: Differences in grey matter density between
unaffected subjects from bipolar families and controls
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results for whole brain:
No differences
Small volume correction thalamus and amygdala-hippocampus
0.026 -5 -1 12 Thalamus (anterior nucleus) and body of
caudate
0.092 3 -1 13 Thalamus (anterior nucleus)
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Figure and table 6.8.2: Differences in grey matter density between
unaffected subjects from mixed families and controls
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results for whole brain:
No differences
Small volume correction thalamus and amygdala-hippocampus
0.026 15 -4 16 Thalamus (anterior nucleus) and body of
caudate
0.092 -10 1 13 Thalamus (anterior nucleus) and body of
caudate
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6.9 Thalamic densities across groups
Evidence for a reduction in anterior thalamic grey matter density was found
in schizophrenic and bipolar subjects compared to controls, regardless of the family
history. Reductions in bipolars from mixed families compared to controls were
indirectly inferred from the contrast image, which showed reductions in anterior
nucleus grey matter (p<0.01 uncorrected) and from the masking contrasts. In
addition, significant differences were also found between unaffected relatives from
bipolar families and controls and between unaffected subjects from mixed families
and controls. Therefore, anterior thalamic grey matter density was reduced
significantly for control versus patient and control versus relative comparisons apart
from the 'unaffected relatives from schizophrenic families versus controls'
comparison.
Schizophrenic patients had an additional region of dorsomedial thalamic grey
matter reduction compared to controls, which was not evident in other comparisons.
This area of dorsomedial thalamic reduction remained after the contrast was masked
with the control versus bipolar contrast but was removed when masked by the control
versus bipolars from mixed families contrast. No significant differences were found
between unaffected people from schizophrenic families and controls in terms of
anterior or dorsomedial thalamic grey matter density.
Anterior thalamic density reductions appeared to show no disease specificity,
and were present in two of the three relatives groups compared to controls. Since the
groups sizes were relatively small, it was not safe to conclude that there was no
difference in anterior thalamic density between controls and unaffected people from
schizophrenic families without first examining the effect size in that group. Three
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further post-hoc contrasts were performed comparing 1) controls to all groups 2)
controls to all patients and 3) controls to all relatives. In each case, reductions in
anterior thalamic density were found in all contrasts. The maximum difference was
found at a voxel anterior to the anterior thalamus in all cases, but the region of
difference (contiguous voxels thresholded at p<0.01 uncorrected) extended into the
body of the anterior nucleus in all cases, and was present bilaterally. The controls
versus all groups contrast also showed significant differences in anterior thalamic
grey matter density. Two further seeds were placed at the anterior pole of the anterior
thalamic nuclei using the study-specific template [MNI ±7, -5, 12]. The grey matter
density at each voxel are plotted in the two following figures and reveal differences
in grey matter density across all groups, with the smallest difference in density being
between controls and unaffected relatives of schizophrenic patients. Although the
95% confidence intervals for all patients and controls showed considerable overlap
with one another, none of the patient or relative groups' confidence intervals
overlapped with that of the control group suggesting that the differences in grey
matter density were likely to be present across all patient and control groups, and
were not disease specific.












Figure 6.8.2: Grey matter density in right anterior thalamus
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6.10 Exploratory contrasts
Analyses 6a-f were conducted as planned. Analyses 6a and 6b were the only
ones to yield differences which were significant at p<0.1 (corrected). The negative
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contrasts were all intended as 4 separate tests of the specificity of changes occurring
in those with bipolar disorder or as a consequence of a genetic liability to the
disorder. Contrasts 6c (uMIX-MX masked by uSCZ-SCZ) and 6d (uBPD-BPD
masked by uSCZ-SCZ) were both measures of grey matter reduction occurring as a
consequence of the bipolar phenotype that were not present as a consequence of a the
schizophrenic phenotype. Analysis 6e (UMIX-MIX masked by control-uBPD) was
intended as a measure of the phenotypic consequences of bipolar disorder which
could not be attributed to genetic liability to bipolar disorder. This result was also
non-significant.
Analyses 6a (uSCZ-SCZ masked by uBPD-BPD) and 6b (uSCZ-SCZ masked
by uMIX-MIX) were intended as a measure of the consequences of the schizophrenic
phenotype, that were not also common to the bipolar phenotype. The results of both
analyses are identical to those given in the comparison between schizophrenic
subjects and their well relatives. These results both indicate a grey matter density
loss in superior temporal gyrus, pre-central gyrus and, using the thalamus/amygdala-
hippocampal SVC, amygdala.
6.9 White matter analysis
White matter density was contrasted between each patient and relative group
and controls. This was not originally part of the analysis plan and so hypotheses were
generated on the basis of the other imaging results and were deliberately limited in
number. Analyses were restricted to two specific regions chosen on the basis of the
grey matter analysis. Firstly, two spherical volumes of subgyral prefrontal white
matter were chosen on the basis they were likely to contain white matter tracts from
344
many regions of the brain to several prefrontal cortical areas. These spheres were
located at (±22, 40, 6) and were both of 11mm radius. Secondly, two spheres of
tissue were also placed in the left and right limb of the anterior internal capsule. The
spheres were located at (±18, 12, 6) [MNI] and were also of 11mm radius. This was
chosen because the anterior limb of the internal capsule contains thalamo-preffontal
fibres originating from the anterior thalamic nucleus. This area has been shown to
have reduced white matter density in schizophrenic subjects compared to controls
(Suzuki et al. 2002), although no study has yet examined this region in bipolar
patients. Since the results suggested reductions in anterior thalamic density across all
patient and relative groups, the efferent projections from this area to the prefrontal
cortex appeared worthy of further investigation. Secondly, projections from the
anterior thalamus are thought to project principally to the anterior cingulate cortex.
Since this area has been implicated in both schizophrenia and bipolar affective
disorder, white matter density reductions and/or increases might form a physical
substrate for functional deficits observed in several other studies. All spheres were
added to a single SVC image and used in all subsequent analyses. Together, the SVC
image consisted of 6.7 RESELS. All analyses were conducted using the SVC since
these regions of interest were the only ones suggested by the previous analyses, with
the possible exception of projections from dorsomedial thalamus to amygdala.
However, although frontal grey matter and thalamus (anterior and dorsomedial
nuclei) were reduced in density, this study found no evidence of amygdala grey
matter density reduction in any of the patient or relative groups compared to controls,
although some evidence of reduced density was found in schizophrenic subjects
compared to their unaffected relatives. Hence only those white matter pathways
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connecting regions shown to be reduced in grey matter density in this sample were
examined.
6.9.1 Contrasts between patients and controls
Patients with schizophrenia showed reductions in subgyral white-matter
(bilaterally) and also in left anterior internal capsule white matter. Additionally, a
region of white matter density reduction was found in the left anterior cingulate.
Although significant reductions in anterior internal capsule white matter were found
only in the left hemisphere, inspection of the contrast image (thresholded at p<0.01
uncorrected) suggested the presence of a non-significant white matter reduction in
the right anterior internal capsule also.
Patients with bipolar disorder from mixed families showed no significant
differences in white matter density compared to controls. Examination of the contrast
image (thresholded at p<0.01 uncorrected) suggested no trends to statistical
significance. Patients with bipolar disorder from bipolar families showed white
matter density reductions in left anterior internal capsule but not in subgyral white
matter, although there was a suggestion of a non-significant trend in left subgyral
white matter. The significant reduction in left-sided anterior internal capsule white
matter was matched by a non-significant right-sided reduction on the contrast image,
suggesting that this deficit was not lateralised.
Patient groups were compared by masking the control-patients contrast with
another patient-control contrast image. This method of analysis was chosen because
of the grey matter findings and because white matter densities have greater variances
than grey matter. Power issues are therefore likely to be at least as pertinent for white
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matter as they are for grey. Therefore by keeping the control group in each analysis
the number of subjects included in each comparison was maximised.
Masked contrast 1: schizophrenia versus controls contrast masked with bipolars from
mixed families versus controls contrast
Once control versus schizophrenic white matter differences were masked
with the control versus bipolars from mixed families contrast image, no significant
differences remained. This suggests that similar white matter reductions may be
found in bipolars from mixed families that did not reach voxel-wise significance.
Masked contrast 2: schizophrenia versus controls contrast masked with bipolars from
mixed families versus controls contrast
Once control versus schizophrenic white matter differences were masked
with the control versus bipolars from mixed families contrast image, significant
differences in prefrontal subgyral white matter density remained (bilaterally). This
suggests that the anterior internal capsule white matter reductions are also found in
bipolars from bipolar families, but that frontal subgyral differences are either much
greater in schizophrenia or absent in bipolar patients without schizophrenic relatives.
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Figure 6.9.1: Differences in white matter density between schizophrenic
subjects and controls
Table : White matter differences between schizophrenics and controls
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results after frontal white matter small volume correction
0.01 -25 35 15 Left subgyral frontal white matter1
0.011 -12 37 4 Left anterior cingulate
0.012 31 44 6 Right subgyral frontal white matter2
0.045 -15 4 7 Left anterior internal capsule
Nearest grey matter BA 9, nearest grey matter BA 10
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Figure 6.9.2: Differences in white matter density between bipolar
subjects from mixed families and controls
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results after frontal white matter small volume correction
No significant differences
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Figure 6.9.3: Differences in white matter density between bipolar
subjects from bipolar families and controls
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results after frontal white matter small volume correction
0.036 -8 8 5.1 Left anterior internal capsule
0.069 -22 38 9 Left subgyral frontal white matter
Nearest grey matter BA 32
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Figure 6.9.4: Differences in white matter density between schizophrenic
subjects and controls (masked exclusively with controls versus
bipolars from mixed families contrast)
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results after frontal white matter small volume correction
No significant differences
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Figure and table 6.9.5: Differences in white matter density between
schizophrenic subjects and controls (masked exclusively with control
versus bipolars from bipolar families contrast)
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results after frontal white matter small volume correction
0.012 31 4 6 Right middle frontal gyral white matter
0.033 25 42 -5 Right middle frontal gyral white matter
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6.9.2 Contrasts between unaffected relatives and controls
No significant differences were found between unaffected subjects from
either schizophrenic or bipolar families and controls. Unaffected relatives from
mixed families showed two areas of significant difference compared to controls. The
first region of difference was found in right superior frontal gyrus white matter and
the second in right medial frontal gyrus white matter. These were unexpected being
present in neither relatives of schizophrenics nor relatives of bipolars subjects
compared to controls.
Table 6.9.2: Differences in white matter density between bipolar
subjects from mixed families and controls
Voxel X, y, z (mm) Region of difference
P corrected Talairach coordinates
Results after frontal white matter small volume correction
0.02 30 43 9 Right superior frontal gyral white matter
0.049 16 47 0 Right medial frontal gyral white matter
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6.10 Discussion
6.10.1 Main findings: prefrontal cortex
Prefrontal cortical grey matter reductions were most extensive in the
schizophrenic group with reductions in Brodmann's areas 6, 8 and 44. Differences
were also found in bipolar subjects from mixed families in BA 9 (dorsolateral
prefrontal cortex). However, when patient groups were compared directly, no
significant pairwise differences in frontal lobe grey matter density remained.
Similarly, when reductions in schizophrenics compared to controls were 'masked' by
the other patient-control contrasts, only the reduction in middle frontal gyrus (BA 6
and 8) in schizophrenic subjects remained. These results show that there are
widespread reductions in prefrontal grey matter density in schizophrenic subjects
compared to controls, which are greater than in either bipolar group. There is
insufficient evidence to conclude that such differences are absent in bipolar disorder,
since the mixed group were smallest in number of all groups. The smaller number of
subjects in this group is likely to have left fewer significant voxels (thresholded at
p<0.05 uncorrected) in the masking image and therefore more control versus
schizophrenic differences will have remained. Furthermore, two differences between
schizophrenics and controls were removed by the application of the bipolar from
bipolar families versus controls mask suggesting that a trend to significant difference
between bipolars and controls in BA 9 and 44 is likely.
The frontal lobe regions implicated in this study include BA 6, 8, 9 and 44
(see figure 6.10.1). All of these areas form a contiguous region situated mostly on the
dorsal and lateral aspect of the prefrontal cortex.
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Figure 6.10.1: Brodmann's areas. Reproduced from
www.clarkson.edu/~rcarlson with the permission of the author
Brodmann's area's 9 and 44 are sometimes both included in the definition of
dorsolateral prefrontal cortex (DLPFC). Reductions were found in both
schizophrenic subjects and bipolar subjects from mixed families compared to
controls but not between unaffected relatives and controls. This suggests either that
these differences are the expression of quantitative trait (e.g. mood incongruent
features), the expression of a certain threshold of liability to schizophrenia or a
general liability to schizophrenia. However, for the third possibility to be tenable, the
failure to find differences between unaffected relatives of schizophrenic subjects and
controls would need to be explained (e.g. perhaps by low statistical power). The
possibility that the similarity between schizophrenics and bipolars from mixed
families is a quantitative trait has support from several strands of evidence. Firstly,
some evidence suggests that the presence of a personal or family history of affective
disorder conveys a prognostic advantage to people with schizophrenia (Vaillant
1964). Secondly, there is evidence from several factor analysis studies that
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continuous variation in symptoms and course can be observed in a broad spectrum of
people with unselected functional psychotic illness (van Os et al. 1999) and that
these may be associated with patterns of brain volume reduction (Mcintosh et al.
2001). Broca's area is also located in BA 44. The finding of reduced grey matter
density in this area in schizophrenic patients compared to controls is of interest since
this area has been implicated previously in functional imaging studies of
hallucinating patients (McGuire et al. 1993;Cleghorn et al. 1990).
Brodmann's areas 6 and 8 were reduced in grey matter density in
schizophrenic subjects compared to controls, but were not reduced in the other
groups compared to controls. Area 6 is often activated during working memory tasks,
especially where the stimulus is verbal or numeric (Coull et al. 1996). Area 8 is
thought to be involved in eye movements and in attention for visual stimuli.
Perfusion of area 8 has also been related to the perception of hedonic odours
(Fulbright et al. 1998) and the severity of delusional ideation in subjects with
Alzheimer's Disease (Sultzer et al. 2003). The precise functional role of both
structures is as yet unclear.
6.10.2 Main findings: thalamus
Anterior thalamic density reductions were apparent across all patient and
relative groups, although relatives from schizophrenic families only demonstrated
this reduction on a post-hoc comparison. In addition, the schizophrenic patients, but
not their relatives demonstrated reductions in dorsomedial thalamic grey matter
density that were not found in any of the other groups. These results suggest that the
anterior thalamic reductions may be one expression of a general liability to
356
psychosis, irrespective of the phenotype. In contrast, dorsomedial thalamic
reductions appear specific to schizophrenia being absent in all other control versus
patient or relative contrasts.
Thalamic reductions in schizophrenic patients are well described in several
region-of-interest studies and have led some investigators (e.g. the Iowa group,
Andreasen et al. 1999) to propose a central role for this structure in schizophrenia.
The role of the thalamus as a filter of sensory information has also been proposed to
account for the symptoms of schizophrenia (Vollenweider and Geyer 2001). The
thalamus is a diverse collection of nuclei each having a unique pattern of cortical and
subcortical projections. Since most studies combine these nuclei in a single
volumetric measure, few will be able to attribute overall differences to a specific
region or function.
A few ROI studies have examined specific nuclei. Two MRI studies from the
same research group have found results suggestive of anterior thalamic nucleus
volume reductions in one study of schizophrenic subjects (Kemether et al. 2003) and
mediodorsal nuclear volume reductions in another two (Byne et al. 2001;Kemether et
al. 2003). The former study also found evidence of thalamic shape differences and
dorsomedial under perfusion in schizophrenic subjects. Further support for these
findings can be found in several post-mortem studies from several groups which
have found evidence of reduced mediodorsal (Dom et al. 1981;Pakkenberg
1990;1992;1993a;Popken et al. 2000;Byne et al. 2002;Danos et al. 2003) and anterior
nuclear volumes (Danos et al. 1998;Young et al. 2000).
Studies of total thalamic volume in bipolar disorder tend to suggest that
thalamic volume is neither increased nor decreased compared to controls or subjects
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with schizophrenia (see chapter 3). However, there is considerable between study
heterogeneity and studies exist which find effects in both directions (Strakowski et
al. 1999;Getz et al. 2002). MRI studies of specific nuclei in bipolar patients are yet to
be performed and no post-mortem studies of the thalamus could be found.
Reductions of anterior thalamic density in schizophrenia and bipolar disorder are
however of some interest because of its connection with the anterior cingulate cortex.
Abnormalities of the anterior cingulate have been implicated in many
neuropathological (see Knable et al. 2002;Eastwood and Harrison 2001 for a review),
structural (Lopez-Larson et al. 2002) and functional neuroimaging (Blumberg et al.
2000;Rubinsztein et al. 2001) studies of bipolar disorder. Studies of schizophrenic
subjects versus controls also implicate this region (Goldstein et al. 1999;Job et al.
2002). Since the anterior thalamic nucleus is a major afferent input to this structure,
its structure and function are also likely to be important to the aetiology of bipolar
disorder and schizophrenia.
The anterior thalamic nucleus is situated at the anterior pole of the thalamic
nuclear complex. It sends efferent connections to anterior cingulate cortex and
hippocampus and receives its major input from the hippocampal complex and
mammillary bodies. It was initially thought that the anterior thalamus was part of a
circuit ('Papez Circuit') thought to serve emotional experience and expression
(Papez 1937). More recently the Papez Circuit has been implicated in mnemonic
functions, the theta rhythm of electrical activity found on EEG tracings and is also
associated with fear and avoidance conditioning in rats (Vertes et al. 2001). It is
thought that the anterior thalamus may also have a role in working memory function
and with motivation via its connections with anterior cingulate. For instance there is
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some evidence from fMRI that the anterior thalamus and cingulate become activated
when alcoholics are exposed to alcohol related cues (George et al. 2001). There is
also some unpublished evidence (personal communication with Professor W Deakin
at 2004 Schizophrenia Winter Workshop) that the anterior thalamus and Papez
circuit may be activated during emotionally salient tasks (e.g. hearing a child cry).
Such tasks are likely to clarify a role for this nucleus in normal subjects and explain
why volumetric reductions in psychosis may be a risk factor or consequence of
illness. However, functional studies of the thalamus are rare and a precise function
role for this area has yet to be found. Future functional imaging studies might design
or discover tasks which activate this region and help clarify its connectivity and role.




The mediodorsal nucleus of the thalamus has extensive efferent projections to
prefrontal cortex, and has reciprocal connections with amygdala and other medial
temporal areas (Nolte 1988). It is thought to control emotional and motivational
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responses to sensory stimuli perhaps mediated by its connections with orbitofrontal
cortex. It is also involved in two fronto-subcortical loops linking areas of the
prefrontal cortex and basal ganglia (Alexander et al. 1990). The first loop links the
dorsolateral and lateral orbitofrontal cortex with the internal globus pallidus and
substantial nigra. Since dorsolateral prefrontal cortex is thought to be involved in
both animal and human working memory, this loop is also thought to play a role in
the manipulation of several items in memory. Lesions of the dorsomedial thalamus
are associated with global amnesia and with Korskoff s syndrome (Joseph 1996).
Figure 6.10.2.2: Alexander's prefrontal circuit
Mediodorsal thalamus is also implicated in Alexander's limbic loop. This loop
involves orbitofrontal cortex, anterior cingulate, ventral pallidum and ventral
striatum. This circuit is thought to be over-activated during pain, depression and in
patients with obsessive compulsive disorder. There is some functional imaging
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literature to support these hypotheses (see Ebmeier and Reid 1998 for a review) and
also to implicate this circuit in the aetiology of abnormal emotion and social function
found in schizophrenic patients (Taylor et al. 2002;Chemerinski et al. 2002).
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Figure 6.10.2.3: Alexander's limbic circuit
6.10.3 Other findings
Parahippocampal volumes were also decreased in schizophrenics compared
to both controls and unaffected relatives, although the masked control versus
schizophrenia differences were not statistically significant. This region is almost
certainly reduced in volume in schizophrenia (Wright et al. 2000). Reduced volume
has also been associated with poor memory performance on some tasks (e.g. verbal
fluency- recall task). However, the precise role of this brain area is probably
unknown although it receives afferent inputs from the cingulate gyrus with which it
is in anatomical continuity with around the splenium of the corpus callosum
(Crossman and Neary 1988).
Grey matter density reductions in the body of the caudate nucleus were found
in the unaffected relatives of both bipolar groups and in bipolar subjects from bipolar
families compared to controls. These changes were not found in bipolar patients from
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mixed families, but since this group was smaller in number than any of the other
groups, this may simply reflect a lower statistical power for this contrast. In each
case the region of difference extended into anterior thalamus and was in fact more
closely associated with this structure than the caudate nucleus. The failure to
distinguish these structures may reflect their close anatomical proximity and the use
of an 8mm smoothing kernel. This would have smeared grey matter voxels from the
edges of both structures and may have made their delineation more difficult. No ROI
or VBM studies reporting volumetric reductions in caudate volume and/or density
could be located (see chapter 3). Functional studies reporting a state-dependent
hyper-perfusion of the caudate nucleus have been reported previously (Blumberg et
al. 2000;Caligiuri et al. 2003) and may point to an underlying dysfunction of this
nucleus. Lesion studies, usually following vascular accidents, also suggest that the
caudate nucleus has a role in the production of manic symptoms, apathy and
catatonia (Joseph 1996). The caudate nucleus is continuous with the putamen and
these two structures are sometimes collectively referred to as neostriatum. This
region is important in the control of movement and is rich in dopamine containing
neurones. Functional and effective connectivity between caudate, dorsolateral
prefrontal cortex and thalamus is also enhanced by the dopamine antagonist sulpiride
(Honey et al. 2003). This provides a possible mechanism to explain the efficacy of
antipsychotic medication in mania and is further evidence of its potential importance
in bipolar disorder.
The white matter findings were complimentary to those for grey matter in
affected patients. Schizophrenic patients had reductions in frontal subgyral white
matter which were complementary to the results for grey matter in that they included
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association and projection fibres to those areas. Bipolar patients from bipolar
families and schizophrenic subjects also had reductions in anterior internal capsule
white matter, carrying white matter tracts from anterior thalamus to cingulate cortex.
No differences were found between bipolar subjects from mixed families and
controls. Relatives of schizophrenic and bipolar subjects showed no white matter
differences compared to controls. Unaffected subjects from mixed families showed
reductions in subgyral white matter which were unexpected. This may be attributable
to a gene-gene interaction in this group, a greater propensity to develop mental
illness at a later age, a false positive finding or an additive effect of genes for both
disorders.
The finding of amygdala density reduction in schizophrenic patients
compared to their relatives also has some support from previous studies. It is perhaps
surprising that this difference was unobserved in the schizophrenia versus controls
comparison. By observing the differences between schizophrenic patients and
controls overlaid on coronal sections of the study-specific template, evidence of
reduced areas of amygdala density can be found. The fact that these are non¬
significant might reflect sampling error or reduced variance in either the relative or
schizophrenics group (although this seams unlikely). A further possibility is that
amygdala grey matter density was increased in relatives of schizophrenic subjects,
although I am aware of no supportive studies to substantiate that possibility.
6.11 Methodological limitations
The current study included 192 subjects (49 controls and 143
patients/relatives) making it comparatively large and therefore able to estimate the
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error (sampling) variation comparatively accurately. The issues of whether the
patients, relatives and controls were representative of the populations from which
they drawn has been addressed in the previous chapter, as has the potential
confounding effects of medication. Several people declined the offer of an MRI scan
and this may have led to patients who were less severely ill remaining in the
experiment, if the numbers had been large and unbalanced. The fact that only 8 from
200 failed to complete the imaging stage is not likely to have introduced any further
bias.
Relatives of affected subjects were chosen because of their common genetic
liability to schizophrenia. By studying relatives it was hope that brain changes
contingent upon either disease expression or genetic variation could be separated.
However, the threshold-liability model adopted in the calculation of genetic liability
used earlier assumes that it is those subjects with greatest liability who will become
unwell. Therefore, relatives and affected subjects were probably unequal in terms of
genetic liability which probably confounded any comparisons made. The
methodological difficulties involved in the calculation of genetic liability were
outlined in the previous chapter. These made any attempt to correct analyses for
genetic liability difficult and dependent of several assumptions. For example, the
calculation of genetic liability in mixed pedigrees would have to quantify the extra
genetic liability contingent upon having a family member with schizophrenia (and
vice versa). I am aware of no methods by which this calculation can be made.
Voxel based morphometry (VBM) as implemented in SPM99 is also a
relatively new technique for the study of grey matter differences between groups.
Although it shows a large degree of agreement with conventional ROI studies,
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differences remain and until these are better understood, region of interest studies
will probably be regarded as providing more robust data than those reliant solely on
VBM (Kubicki et al. 2002b). In contrast to ROI analysis, VBM can measure grey
matter density in an objective manner and find differences in very small structures. It
is much less time consuming and practical problems (such as employing several
image analysers over the time course of a study) are effectively avoided.
The validity of VBM is dependent on accurate image registration and
normalisation both of which were performed using established methods employed by
other researchers in Edinburgh (Job et al. 2002) and elsewhere (Maguire et al. 2000).
This study used the grey and white matter optimised techniques employed by other
researchers which might have led to better image normalisation (Good et al. 2001).
However, further refinements have been made to SPM recently which might have
provided for a better fit between source images and template. For instance, SPM2
now performs normalisation by Bayesian methods which it claims, on its website,
achieves better a match for individual cortical gyri. Other software, designed
specifically for structural image analysis, is also available (Suckling et al. 1999) but
it is unclear whether this software would have led to the same results being obtained.
At the current time, there appears to be no image analysis software which can take
into account the non-independence of observations from members of the same
family.
The template generation was based on an MNI template based on 152 normal
brain scans (Evans et al. 1993). Although a custom template was subsequently used,
unusual or outlying voxel densities in any of the MNI scans might have led to an
inaccurate template. In fact the MNI template is known to differ structurally from the
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Talairach brain atlas and 3D transformations have had to be developed in order to
make the 'brains' more compatible. An alternative method of brain analysis might
have taken into account variation in normal brain structure and used this in the
statistical models fitted. However, normal brain structure appears to have been
characterised too poorly for an analysis of this sort to take place and in fact no
software is currently available which provides this sort of analysis, so far as I am
aware. VBM also makes the additional assumption that errors are normally
distributed. Whilst this may have been the case, it is difficult to check. Even in
analyses where error terms are non-normally distributed, violation of normality is
often not very important unless the data are very skewed and the number of
observations relatively small. White matter density however, has a large variance
with most values around 0 (not white) or 1 (white). This generates a bimodal
distribution which is markedly non-normal. Using a small volume correction meant
that these results could not be confirmed using a permutation test and should
therefore be interpreted cautiously.
Finally, areas of peak difference between groups sometimes occurred outwith
the region with which they were contiguous. This may be explained by the fact that
differences in brain structures occurring across groups are most likely at the edges
(where presumably variation in grey matter density/volume is the greatest). The
region of maximum difference may then be displaced from its location in native
space by the smoothing process. A related phenomenon may occur when two
separate regions situated closely together show reductions in grey matter volume
(e.g. caudate and anterior thalamus). Because the grey matter voxel values are
smoothed, the point of maximum difference between groups may occur at a point
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intermediate between the two structures, particularly when those areas are separated
by a distance less than the width of the smoothing kernel at half maximum.
All analyses in the current study were checked and the areas of difference
(thresholded at p<0.01) were overlaid on the custom template constructed from the
study's source images. By checking the analysis in this way, in addition to using the
Talairach Daemon, areas of difference were inspected to ensure that they lay within
the regions of interest quoted. Problems with the registration of normalised images
also have the potential to give misleading results. These registration errors can occur
as a consequence of an abnormal brain structure in affected patients and the attempt
to normalise these images to a template constructed from 'healthy' brains. Non-linear
functions have the ability to compress or stretch regions from abnormal brain images
so that the images contours more closely fit the template image. Around brain areas
of abnormal shape or structure, such as the third ventricle, differences in grey matter
density found between groups may reflect abnormal shape or volume of the third
ventricle. Whilst the thalamic reductions found in the current study could be due to
mis-registration of images, the use of a grey matter optimised template makes this
less likely since CSF and white matter voxels are not used in the normalisation
process. Furthermore, whilst anterior thalamic density differed across all groups,
third ventricular enlargement has been demonstrated convincingly only in
schizophrenia and in some (but not all) studies of close relatives (Wright
2000;Sharma 1998). Bipolar patients and their relatives do not consistently show
ventricular enlargement compared to controls (see chapter 3).
6.12 Summary
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One hundred and ninety-two patients completed the scanning stage of the
study. Image analysis revealed grey matter differences between schizophrenic
subjects and controls which may be relatively specific to schizophrenia. Principally
these areas included BA 6 and 8, BA9 (dorsolateral prefrontal cortex) and BA44
(Broca's area and dorsolateral prefrontal cortex) and dorsomedial thalamus. All
patients and relatives, regardless of diagnosis, showed evidence of a reduction in
anterior thalamic grey matter density compared to controls. This suggests that the
reduction is either a marker of genetic liability to psychosis in general, or an
adaptation to it. Bipolar patients from mixed families showed a single area of frontal
grey matter reduction suggesting that affected patients from that group may be
intermediate between the other two patient groups. Unaffected relatives of each
patient group showed no differences in addition to their anterior thalamic grey matter
reductions. These observations are consistent with variation in prefrontal grey matter
across a continuous phenotype.
White matter reductions generally complimented grey matter findings in
affected patients. Groups with frontal grey matter reductions had complimentary
frontal subgyral white matter reductions in addition. Anterior thalamic grey matter
reductions were complimented by reductions in anterior internal capsule white
matter, although these were not present in unaffected relatives. Unaffected relatives
ofmixed families, in contrast, showed reductions in frontal white matter compared to
controls. This may have been because white matter analyses are more difficult to
model in SPM, or because genes raising the likelihood of both disorders interact to
give rise to these areas of difference.
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The current study was relatively complex in terms of the number of groups
examined, although the total number of participants was relatively large. However,
repeating the current study with larger numbers would be a useful development
which would improve the power of the study and reduce the possibility of false
positive findings. Because the current study was a case-control design and could not
determine whether grey/white matter density reductions were risk factor or a
consequence of illness or its treatment, this study should be followed-up using a
prospective study of schizophrenic and bipolar subjects from before the illness has
become manifest. The practical difficulties involved in such research are likely to
mean that any prospective study will follow a cohort of unaffected people at
enhanced risk for the disorder. Information collected on life events and early
development could also potentially clarify the role of environmental influences.
The current study examined white matter density using Voxel Based
Morphometry of white matter from Tl-weighted images. This technique has largely
been superseded by diffusion-weighted imaging (DWI) which can examine white
matter integrity and directionality. It is possible that DWI would have shown
differences in white matter integrity which were not apparent using analysis of T1
weighted images. There remains some controversy surrounding the use of VBM
(Bookstein 2001) and it is possible that the combination of VBM and ROI analysis
will help resolve the areas of disagreement.
Whilst structural analysis can yield volumetric differences associated with
broadly defined phenotypes and genetic liability, it does not necessarily bridge the
gap between abnormal structure and clinical symptoms or course. A future study
might usefully combine functional and structural imaging to demonstrate altered
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cerebral physiology during a suitable task. In the current study, memory performance
and executive tasks would have been of some interest because memory showed no
disease specificity whilst executive function appeared to be reduced in the
schizophrenic patients.
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Chapter 7: Brain Mapping and the Future of Attempts
to Separate 'Functional' Psychotic Disorders
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7.1 Introduction
Although schizophrenia and bipolar disorder have remained 'legitimate'
diagnoses for almost a century, they are relatively poor predictors of treatment response
and outcome. This has led some to question the division of 'functional psychoses' into
schizophrenia, depression, bipolar disorder and intermediate forms. There is no concrete
evidence to either confirm or refute these entities on biological grounds. Nevertheless,
these diagnoses continue to be used in day to day practice presumably because they
provide some, if rather limited, useful information for both patients and clinicians.
Diagnoses based on aetiology are likely to be the most useful, as in other medical
disorders prognosis and rational treatments generally follow from an understanding of
the biological basis for the disorder. Unfortunately, psychiatric disorders have been slow
to reveal their aetiology and schizophrenia and bipolar disorder continue to be
syndromes rather than diagnoses which may be confirmed or refuted by laboratory or
radiological investigation.
At the present time, the confirmation, refutation or reformulation of existing
diagnostic categories is best based on evidence of strong causal factors. Where this is not
possible, a division based on experimental function, structural imaging or pathology is
probably better than relying on the symptoms alone. A sine qua non of this approach is
that patients with both disorders should be optimally studied within the same
experiment, otherwise observed differences inferred from indirect comparisons may be
due to methodological differences between studies which have nothing to do with true
differences in phenotype. Until now bipolar disorder has been rarely directly compared
to schizophrenia and subsequently research in bipolar disorder has proceeded at a very
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slow pace in comparison (Clement et al. 2003b), despite the fact that it affects about as
many people.
7.2 Causation and psychosis
The causation of psychosis could be investigated using several methods.
Epidemiological research of large representative samples has provided many positive
results and obstetric complications, maternal influenza and, more recently, urbanicity
have all been linked to a later diagnosis of schizophrenia. Epidemiological research
often uses routinely collected data which was not collected for the purpose of research,
and the quality of such data is sometimes uncertain. However, the recruitment of large,
representative cohorts of people make this a particularly useful form of research which
may suggest public health level interventions aimed at reducing disease incidence.
Although evidence based on epidemiological studies has provided several possible risk
factors, some of which have been replicated, the proportion of cases in a population
attributable to these environmental factors is small (Murray et al. 2003) and most risk
factors for schizophrenia also confer additional risk for bipolar disorder (Gattaz and
Hafner 2004;van Os and Verdoux 2003).
Genetic factors have been shown to account for the majority of risk to psychosis
and are probably the area of aetiological research which has the greatest possible
potential in the longer term. However, as discussed in chapter 1, there is evidence that
these factors also show little diagnostic specificity. Recently, replicated reports of
individual gene loci thought to raise the probability of schizophrenia or bipolar disorder
have begun to emerge. Although these may be non-specific, they provide an important
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means by which individual gene effects on the risk of psychosis can be investigated. The
discovery of genes of major and minor effect is certainly advancing but has still not
accounted for the majority of genetic risk in the population as a whole, although the
explained risk in specific populations may be somewhat higher.
The relative paucity of specific genes for schizophrenia or bipolar disorder has
also contributed to a lack of animal models in this area. Several animal models exist for
chronic diseases such as Parkinson's Disease and Alzheimer's Dementia (Lythgoe et al.
2003). These models have enhanced our understanding of these conditions and are
beginning to suggest novel treatments (e.g. stem cell research, gene replacement).
Animal models may also be based on a physiological mechanism, such as the reduced
sensorimotor gating found in schizophrenia (Braff et al. 1995). Animal models have
been developed which mimic this dysfunction by artificially inducing these gating
abnormalities using psychostimulants (Ellenbroek 2003). However, although these
models are helping to describe the brain pathways involved in sensorimotor gating and
habituation, the proximity of these animal models to patients with positive psychotic or
affective symptoms remains debateable.
In light of the shortcomings of epidemiological and genetic research, evidence
from neuropathology, neuroanatomy, structural imaging and experimental function must
be considered. Neuropathology has the potential to identify 'causes' by searching for
macroscopic and molecular lesions, but may also lead to the discovery of a chain of
events leading to the disease in question. However, there are many methodological
limitations to this research (please refer to chapter 2) and the current political climate is
making this type of research somewhat difficult. The fact that brain structure and
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function may also be investigated in vivo using a variety of neurophysiologic,
neuropsychological and imaging techniques is arguably the strongest method of
assessing pathophysiology.
Prior to 1976. there was no accepted 'macroscopic pathology' of functional
psychosis. Positive pneumoencephalographic and neuropathological studies had been
conducted previously but were generally dismissed as the secondary effects of
institutionalisation or treatment. Following Johnstone's 1976 study, it was gradually
accepted that structural abnormalities were to be found in the brains of patients with
schizophrenia. Subsequent studies showed that these changes were present at first-
episode and could not be attributed to medication or institutionalisation. It was hoped
that with better imaging techniques the neuropathology of schizophrenia might be
elucidated but, in spite of numerous methodological advances, brain imaging has not yet
led to the discovery of a cause and rarely provides information which guides the clinical
care of affected patients.
The apparent failure of imaging and related methods to provide a cause could be
attributed to several factors. There are certainly a number of methodological problems
with current research (see following section), but this may not be the only or even the
main reason for an apparent lack of success in this area. For other neurological diseases
(e.g. multiple sclerosis, Parkinson's disease, stroke, certain dementias) in which imaging
has been important in the understanding of causation/pathology, the lesions are much
less subtle than anything found so far in schizophrenia or bipolar disorder. Although it is
possible that a given set of brain/functional measures will account for each case of
schizophrenia or bipolar disorder in time, there is no reason to guarantee that this will be
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the case. The contribution of neuroimaging and studies of experimental function to
knowledge of causation is, in my view, likely to be through the discovery of the
mechanisms by which genetic and environmental factors lead to brain changes,
neuropsychological deficits and finally the clinical syndrome.
7.3 Issues of study design and analysis in imaging research
Subjects willing to participate in research tend to have less severe illnesses than
those who do not and controls have a tendency to be recruited from relatively
advantaged backgrounds or be members of health professions. Even, where differences
between cases and controls are minimised, the groups are likely to differ in many
respects limiting the number of inferences which can reliably be made from this type of
research. These differences can be tackled by matching on important confounds which
are associated with both disease and exposure, but by definition do not lie on the causal
pathway. Age and height may be examples of confounds, but limited knowledge of the
precise mechanisms leading to psychosis means that true confounds are somewhat
difficult to identify.
Random sampling from a geographically defined population might lead to more
representative cohorts being obtained. However, such an approach is unlikely to receive
ethical permission and because subjects would still have to 'opt-in', socioeconomic
differences between patients and controls may still emerge. Even if representative
cohorts were recruited, it would be difficult to distinguish those biological factors (e.g.
brain anatomy, neuropsychology) which are risk factors from those which are an
adaptation to the illness or its treatment.
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The relatively low lifetime risk for psychosis means that prospective study of
healthy individuals before they become unwell is virtually impossible for practical
reasons alone. However, the paradox is that without it, it will be impossible to
distinguish changes which are 'causal' from those which reflect adaptive/tertiary
processes or the effects of medication. Technological advances occurring during the
execution of the study are also likely to render the methods obsolete many years before
it can be completed. For these reasons, studies of unaffected cohorts at increased risk of
the disorder seem to be the only realistic alternative. Several high risk studies of
schizophrenia are underway and one has been completed (Mednick 1966). Only a few
have obtained prospective imaging data and one of these, the Edinburgh High Risk
Study, will shortly begin publishing the final results for those subjects who have
developed schizophrenia. No study has yet been published which has followed patients
at high risk of bipolar disorder. Few areas of the country have sufficiently stable
populations to make this practical and, using conventional criteria, a high risk individual
who develops depression could not yet be considered to have bipolar disorder until a
second manic episode of illness had occurred, perhaps many years later. There are also
uncertainties within the concept of bipolar disorders as to whether Bipolar Disorder I
and II should be separated from one another and whether bipolar disorder should be
separated from unipolar affective disorders. However, providing sufficient numbers
could be recruited, most of these practical problems could be overcome.
Much of the neuroimaging literature is internally inconsistent. This is due in part
to clinical heterogeneity and to the relatively small sample sizes typical of imaging
research. A possible solution to the problem is to combine the results of several studies
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together in a meta-analysis. However, the summary effect sizes of such analyses are
often heterogeneous and the overall result is often misleading unless the causes for
statistical heterogeneity are explained in some detail. A meta-analysis of the results from
several studies are a relatively inefficient way of examining the role of effect modifiers
or confounders which are often better examined within the subjects of an individual
study, or using individual patient data from several studies combined. However,
investigators are likely to restrict their analyses to a limited number of hypotheses and
outcome measures and studies frequently cannot be combined because compatible data
from several studies are not comprehensively published, even if they were actually
collected at the time. Collaborative re-analysis and meta-analysis using individual
patient data are alternative approaches to the problem but require the presence of large
data repositories with detailed meta-data available across wide geographical networks.
7.4 Developments in image acquisition
Studying the neuropsychology of a disorder can be justified on the basis that it
provides additional clinical information helpful to patients or clinicians, or provides data
on aetiology. Neuropsychological data ideally provides an indirect examination of brain
integrity, but is influenced by effort, motivation, the confounding effects of positive
symptoms and general intelligence. Unfortunately, it is difficult to control for many of
these factors. However, where neuropsychological functions can be localised to specific
brain regions or networks, the findings in affected subjects may be closer to the
fundamental biology of illness than symptoms alone, which are arguably influenced to a
relatively greater extent by life events and personality.
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Neuropsychological and psychophysiological associations of psychiatric
disorders, single symptoms and symptom dimensions may reveal the mechanisms
underlying symptom/syndrome generation more fruitfully than MRI imaging alone,
acting as an intermediate level between the syndrome and the structure and function of
individual neurones. Psychophysiological experiments have proved very popular in
schizophrenia, and have the added advantage that robust animal models exist. This
enables the pathways and mechanisms to be studied in animals in a way which would
never be possible in human volunteers. Psychophysiological experiments in bipolar
subjects are however particularly rare.
Functional MRI is a relatively recent development in imaging research designed to
measure changes in cerebral blood flow/oxygenation. It is based on the property that the
iron in deoxygenated haemoglobin has paramagnetic properties which cause local
magnetic field gradients around blood vessels. The resultant gradient inhomogeneity
interferes with the spin-spin relaxation properties in a concentration dependent manner
and accelerates the dephasing of proton nuclei resulting in a shortening of the T2*
relaxation constant. As neural activity in a brain region increases, the flow of
diamagnetic oxygenated haemoglobin will increase and the ratio of deoxygenated to
oxygenated haemoglobin will decrease, extending T2* relaxation times in the
circumscribed area of increased activity. This change in T2* weighted signal is referred
to as the blood oxygen level dependent (BOLD) signal. BOLD signal changes can be
detected using sequences with short repetition times which are sensitive to short term
changes in local signal strength (commonly FLASH or echo-planar imaging sequences).
There are however, a large number of variations on experimental designs (Aguirre and
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D'Esposito 2000) and an extensive list of methodological limitations (Kim and Ugurbil
1997).
A number of experimental designs can be combined with fMRI in order to
observe specific neurovascular responses contingent upon a subject's experience or task
performance. Commonly experiments are 'blocked', 'parametric' or 'event -related'.
Block-design experiments typically involve the repeated presentation of an active and
rest condition alternately over many identical trials. The difference in BOLD signal
between tasks, represent a subtraction in the cognitive processes involved in both tasks,
although this is an oversimplification.
Parametric designs are essentially similar but involve the variation of a single
task over the course of an experiment by altering one of its parameters continuously
between trials. The study design assumes that as a task becomes more difficult blood
flow to a specific region will increase or decrease.
Event-related designs involve the presentation of a single stimulus during which
the temporal pattern of BOLD response is determined in detail. Involving often only one
stimulus presentation, they generally have less statistical power compared to other sorts
of design, although the assumptions upon which the other study designs are based may
be more frequently violated.
The major advantage of fMRI is that it is able to provide relatively high-
resolution data on neural function whilst subjects perform a specific task or are
presented with a specific stimulus. This technique has been useful in determining the
neural consequences of neuropsychological test performance, providing more direct
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evidence of the differences in neural activation which underlie differences in task
performance.
Functional MRJ has also enabled a reformulation of many of the problems of
contemporary psychiatry. For instance, a study of auditory hallucinations using a novel
sampling strategy (Silbersweig and Stem 1996;Shergill et al. 2000) has revealed
differences in the hallucinating versus non-hallucinating state which do not appear to be
specific to any given phenotype and suggest a defective monitoring of inner speech. It is
also possible to meaningfully reformulate psychiatric problems in terms of disturbances
in normal neurocognitive systems (Bullmore and Fletcher 2003) and to examine
functional and effective fronto-temporal connectivity in schizophrenic subjects and
controls. These studies have revealed a pattern of dysconnectivity in schizophrenic
subjects which may be due to a defect in an existing neurocognitive mechanism.
In spite of its obvious advantages, fMRI has not quite been able to bridge the gap
between neural function and neuropsychological/psychophysiological performance or
symptoms. This is partly due to the fact that the temporal resolution is poorer than, for
example, the EEG and, the spatial resolution is unlikely to be sufficient to image
individual cells. However, resolution is continuously improving and recently researchers
at the University of Minnesota have used high-field MRI to provide functional imaging
data on the visual cortex. This technique is able to image neuronal activity in individual
populations of neurones in single ocular dominance columns on a sub-millimetre scale
(Yacoub et al. 2003).
A newer form of imaging, diffusion tensor imaging (DTI) has also been
developed which can view white matter integrity by examining the constrained motion
382
of free water molecules across membranes. This technique can provide a scalar measure
of white matter integrity as well as a vector based measure enabling the directionality
and integrity (see figure 7.4) of individual white matter tracts to be examined in vivo
(Behrens et al. 2003). The techniques for assessing the directionality and connectivity of
white matter tracts are still in their infancy (Behrens et al. 2003) but have the potential to
provide a structural substrate for dysconnectivity found in functional imaging studies.
DTI has been used in schizophrenic patients to examine the integrity of fronto-
temporal white matter tracts. Results have so far shown a 'structural dysconnectivity' in
white matter integrity between frontal and temporal lobe which may represent a physical
substrate for fronto-temporal dysconnectivity found in fMRI studies. However, this is
only one example of how differing imaging modalities can be integrated to provide
additional information about neural activity, pharmacology, connectivity and task
performance. Concurrent DTI examination of subjects in the current study might have
revealed which white matter tracts, if any, were compromised in terms of their integrity
instead of the rather exploratory and indirect examination actually made.
Figure 7.4: Tractography of a single subject using DTI
(image provided by Dr M Bastin, Edinburgh University)
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Information provided by multiple structural (sMRI, DTI) and functional (e.g.
fMRI, MRS, EEG) imaging techniques could be combined fruitfully with clinical data
allowing the integration of information on clinical presentation, brain structure and
function and neuropsychology/psychophysiology which may improve our understanding
of how these 'fundamental' deficits translate into the clinical features.
7.5 Imaging analysis
Over the last 25 years there has been a large shift in the methods employed for
the analysis of medical images. Studies initially measured ventricle to brain ratio,
conflating two anatomical measures in one statistic. These studies were often positive
and gradually, as better image acquisition methods became available, investigators
began to measure individual structures firstly by hand, and subsequently using (semi)
automated methods assisted by operationalised definitions and detailed brain atlases to
define regions of interest (ROIs). However, even these methods may be subjective
and/or unreliable for small structures, even when such structures are traced in three
dimensions simultaneously. The results for many brain regions (e.g. thalamus, prefrontal
cortex) often ignore the anatomical sub divisions of these structures and their diverse
functional associations.
Over the last 10 years, fully automated methods have become available which
involve no manual tracing of brain regions, are highly reliable, and involve few
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subjective judgements. These techniques, exemplified by statistical parametric mapping
(SPM), generally register all brains from an experiment in standard anatomical space,
smooth the images to provide voxel intensities with randomly distributed errors, and
compare average voxel intensities across each group. These analyses are a major
advance over the preceding semi-automated techniques, although their results sometimes
conflict with those of conventional ROI analyses and may be more difficult to interpret.
Potential limitations of such analyses include the imperfect registration and
normalisation of images and the assumption of normally-distributed random errors.
Conventional analysis of biometric data commonly involves the parametric
assumptions of equality of variance, independence of observation and normally
distributed errors. It is not clear whether these assumptions are met in all VBM or
functional studies and there is uncertainty as to how such data should best be analysed.
Often, non-parametric randomisation tests are conducted to confirm the results of a
parametric analysis. These analyses involve the empirical estimation of a kernel density
and examine the probability with which the actual data would have been observed by
chance alone. They are based on conventional hypothesis testing and incorporate no
prior information into the analysis, only the sample images themselves. They have the
advantage of being distribution free tests but are likely to have a lower statistical power
than the corresponding parametric analysis.
Methods for the analysis of non-normally distributed, autocorrelated data,
without equality of variance, have been available for some time. Several programs allow
distribution free tests to be conducted using rank transformed data or by repeated re¬
sampling or simulation (e.g. randomisation, bootstrapping and Monte Carlo analysis).
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An exciting development, outwith the neuroimaging literature, is the ability to combine
re-sampling techniques with prior information about the distribution and values of the
parameters estimated. An example of such a program is BUGS (Bayesian inference
Using Gibbs Sampling). BUGS can incorporate prior distributional assumptions about
population parameters and can resample the data to provide posterior distributions of
each parameter involved using Markov chain Monte Carlo methods.
Although I am aware of no fully-Bayesian realisation of such a technique in the
imaging analysis literature, a Bayesian framework is now used for the normalisation of
images in SPM2 and some authors are clearly beginning to appreciate the potential of
such techniques (Friston et al. 2002). Such models could incorporate information about
the distribution of grey/write matter density in a normal population and model the role of
confounds and potential biases (Spiegelhalter et al. 2004). It is of course desirable that
normal brain structure be modelled using informative priors based on well characterised
and representative populations. This would require a much greater characterisation of
normal brain structure, and its correlates, than is currently available at the present time.
Some advantages and disadvantages of Bayesian versus conventional (ffequentist) are
shown in table 7.5.
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Table 7.5: Comparison of Bayesian and conventional analysis
Classical Based on classical 'Popperian' hypothesis testing in which null
inference hypotheses are tested and, in the absence of evidence, rejected.
P-values represent the problem of obtaining the observed data in the
absence of an effect, not he likelihood of the effect being present.
Although the p-value reflects evidence against the null hypothesis, it
is often arbitrarily interpreted as <0.05 significant, >0.05 significant
The p-value can never reject the presence of an effect (HA), just the
provide evidence against H0
Given enough observations, almost all differences or relationships
(no matter how small) can become 'significant'.
P-values are dependent on the number of comparisons/search
volume. However, the likelihood that such an effect is present is
independent of these considerations
Bayesian Uses prior information about the distribution of the
inference parameters/effects which can be found from previous studies or
sample information. Priors can be uncertain/non-informative and
assume no prior knowledge about the parameters studies or
increasing degrees of knowledge. Sample information is then
collected in order to provide a posterior probability distribution for
the parameters/effects given the sample information.
The posterior distribution of parameters can be stated in terms of a
credible interval (usually 95%) which gives the most likely estimate
and an upper and lower bound.
Avoids many of the problems of multiple hypothesis testing and
arbitrarily defined p-values
Bayesian analyses are usually more computationally intensive and
have been criticised widely in the past on the basis that the prior
information provided is somewhat arbitrary, largely determines the
results, and is subjective/unscientific
7.6 Clinical associations and exploratory factor analysis
Within the current diagnoses of schizophrenia and bipolar disorder there is a
great deal of clinical heterogeneity. It is possible that certain clinical symptoms or
historical variables (e.g. drug history) may themselves be associated with particular
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patterns of brain structure and anatomical function and if, as suggested, the current
categories are imperfectly defined, much clinical and historical information is being
sacrificed at the expense of making a diagnostic decision.
Novel clusters of individual patients, defined on the basis of clinical difference
(usually Euclidian or 'statistical' distance) could be extracted from clinical and historical
data in an atheoretical way using multivariate techniques such as cluster and latent class
analysis. Unfortunately, this might have the effect of replacing an arbitrary classification
which most people 'understand' with another which is not. The problem of information
loss would not be solved by this approach. However, investigating the clinical correlates
of single clinical and historical variables might be somewhat more fruitful (e.g.
symptoms, age of onset, course and prognosis) and has already yielded some positive
results (e.g. though disorder and STG volumes in schizophrenia, Shenton et al.
1992;Rajarethinam et al. 2000). Investigation of co-occurring symptoms and clinical
variables using the technique of factor analysis might also be useful since the effect of a
single misreported symptom or variable might be minimised and the redundancy in the
data caused by multi-colinearity would be avoided. This technique has also showed
some promise in the neuroimaging and neuropsychological literature, both in
schizophrenia alone (Liddle et al. 1992;Chua et al. 1997) and within a spectrum of
individuals with a number of functional psychotic diagnoses (Mcintosh et al. 2001).
Epidemiological research concerning dimensional representations of psychosis is
also providing interesting results. The distribution of psychotic and quasi-symptoms in
representative populations has the potential to clarify whether diagnoses represent the
upper tail of a normal distribution of symptoms, whether such symptoms are bimodal, or
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whether the distribution is half normal (i.e. most people have no symptoms), van Os and
Verdoux (2003) have suggested the distribution of symptom dimensions in the general
population has the potential to reveal whether risk factors are specific for one dimension
or diagnosis and also whether they act alone (are of major effect) or co-participate with
other factors. The combination of large scale epidemiological and neuroimaging
research is an attractive prospect which would require considerable resources, but such
research could be more generalisable and help to overcome the sampling difficulties
inherent in many existing imaging studies.
7.7 Conclusions
Neuroimaging research in the 'functional' psychoses has made considerable
progress over the last twenty-five years. Disorders once regarded as the consequence of
bad parenting are now firmly within the remit of the 'cognitive neuroscientist and brain
imager'. However, progress has been slower than expected and maybe due to
inadequately powered and inappropriately designed experiments rather than a failure to
acquire new technology.
With the advent of the internet and broadband data connectivity, the technical
resources to share large quantities of data across multiple centres are now becoming
possible. A recent publication in Nature suggests that centres in the USA are already
sharing large amounts of neuroimaging data across networks (Chicurel 2000). A recent
call for e-science proposals to the MRC in the UK suggests that at least some researchers
have had the same idea this side of the Atlantic. However, there has so far been no
decision on what to include in these databases and technical obstacles relating to data
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collection and relational databases have still to be overcome. Even if such obstacles are
overcome, it remains to be seen how well researchers will collaborate with other centres
they may previously have viewed as competitors.
Recent innovations in imaging technology and statistical analysis and the
possibility of multimodal imaging make the prospects for understanding the mechanism
of mental disorder better than ever before. Although the international diagnostic
concepts currently used clinically may be imperfectly defined, there is good reason to
suppose that reformulation of the problems in terms of correlated symptoms or in terms
of disrupted normal neurocognitive processes are likely to lead to rationally defined
syndromes or dimensions which will confirm, modify or totally reformulate our current
classification of functional psychotic illness.
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